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ABSTRACT 
 
Pharmaceuticals represent important and indispensable elements in modern society and 
their usage is considerable. Post consumption and body-elimination, pharmaceuticals are 
not completely removed in sewage treatment works (STWs) and as such, have been 
detected at low levels in STW effluents, surface waters, seawaters, ground waters and 
some drinking waters. Accordingly, pharmaceutical toxicity has been detected in several 
aquatic organisms. To date, environmental risk assessments (ERA) examine for toxicity 
using a series of chronic toxicity assays that examine for standard physiological 
responses in algae, Daphnia and fish and do not address pharmaceutical mode of action. 
Therefore, using the fathead minnow (Pimephales promelas) and the β-blocking 
pharmaceutical propranolol as the test-species and test-drug, respectively, the aim of this 
study was to establish an intelligent targeted 4-phased ERA using molecular, in vivo 
exposure, metabolomic and quantitative expression analytical techniques. The first phase 
established that the fathead minnow expressed the β3bi-adrenergic receptor (AR), which is 
a target receptor for propranolol in humans. The in vivo pair-breeding assay suggested 
that at 1mgL
-1
 and 10mgL
-1
, propranolol levels in fish blood plasma exceeded the human 
therapeutic concentration and caused 80% and 100% mortality, respectively. The most 
likely causes of mortality were liver failure and central nervous system toxicity. It was 
not possible to identify a robust biomarker of propranolol exposure using proton nuclear 
magnetic resonance (
1
H NMR) as there was considerable metabolic variation between 
male liver tissues within the same treatment groups. β3bi-AR expression was significantly 
lower at 1mgL
-1
 in the brain and liver, which was most likely the result of desensitisation 
in response to elevated levels of epinephrine and cortisol. β3bi-AR expression was 
significantly increased in the heart at the environmentally relevant concentration of 
0.001mgL
-1
, however it was not possible to link β3bi-AR expression to a toxic response. 
Propranolol is unlikely to pose a threat to the aquatic environment as the concentrations 
measured in the environment are approximately 1000-fold lower than those that induced 
a toxic response. The proposed ERA represents a marked improvement over the existing 
ERA as it addresses pharmaceutical mode of action and both subtle and physiological 
toxicity responses, however it still requires further validation studies to address both 
metabolomic and gene expression variation. 
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 2 
1.0 Pharmaceuticals in the environment 
The United States Food and Drug Administration (USFDA) and European Union (EU) 
define a pharmaceutical drug as a substance intended to affect the structure or any 
“function of the body” for the purpose of cure, mitigation, treatment or prevention of a 
disease (Williams, 2006). Unsurprisingly, pharmaceuticals represent important and 
indispensable elements of modern life. They are employed in a variety of disciplines 
including human and veterinary medicine, agriculture and aquaculture. In 2002, the UK 
pharmaceutical industry alone contributed 0.6% of the total U.K gross domestic product 
(GDP) and accounted for 3% of world sales (£8.5 billion). It has been estimated that over 
3000 active substances are licensed for use in the U.K and that usage exceeds 10 tonnes 
per annum for all of the top 25 compounds and 100 tonnes per annum for the top three 
compounds (paracetamol, metformin hydrochloride and ibuprofen) (Ayscough et al, 
2000; Ernst & Young, 2003; Bound & Voulvoulis, 2004). These figures only represent 
prescription drug usage and do not include drugs sold over-the-counter, and and so actual 
usage could be considerably higher (Fent et al, 2006). 
 
Coupled with their large volume production, pharmaceuticals are biologically active 
compounds that are designed to have a specific mode of action in the body. Furthermore, 
pharmaceuticals are usually lipophilic and often have a low biodegradability. These 
intrinsic properties pose potential for bioaccumulation and persistence in the environment 
(Christensen, 1998; Fent et al, 2006). 
 
1.1 Routes of exposure 
The potential sources of pharmaceuticals into the aquatic environment, excluding non-
routine events such as potential transport accident, include release from pharmaceutical 
manufacturers, disposal of pharmaceutical from the supply chain (prior to distribution to 
patients), disposal of unused pharmaceuticals by patients or health care facilities in 
wastewater and patient excretion of an active pharmaceutical ingredient (Williams et al, 
2006).  The manufacture of pharmaceuticals in the UK is controlled by the Good 
Manufacturing Practice (GMP) regulations. Furthermore, sites are regularly inspected by 
the Medicines Control Agency (MCA) to ensure the quality and safety of products. 
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Therefore wastage from manufacturing sites is kept to a minimum due to the careful 
handling and packaging of the expensive pharmaceutical products (Ayscough et al, 
2000). This therefore leaves use and disposal as key routes of pharmaceutical entry into 
the aquatic environment. 
 
After consumption, most pharmaceuticals undergo complete or extensive Phase I and 
Phase II hepatic metabolism. Phase I reactions consist of oxidation, reduction and/or 
hydrolysis, whilst Phase II involves conjugation (e.g. the addition of glucuronic acid, 
sulphate, acetic acid or amino acid). These processes yield polar metabolites excreted in 
the urine, which normally exhibit insignificant pharmacological activity. However, in 
some instances, the parent-pharmaceutical-compound can be resistant to hepatic 
metabolism and can be excreted in its pure, biologically active, form (Ternes, 1998; 
Hirsch et al, 1999). Sewage is taken to sewage treatment works (STWs) where the 
majority of drugs are removed by either mineralisation by micro-organisms to carbon 
dioxide and water or adsorption to suspended solid sludge particles. Adsorption is 
dependent on both the hydrophobic and electrostatic interactions of the pharmaceutical 
with particulate matter. Acidic pharmaceuticals such as the non-steroidal anti-
inflammatory drug (NSAID) acetylsalicylic acid do not adsorb readily to sludge and so 
elimination via mineralisation is most common (Ternes et al, 2004). STW elimination 
rates vary depending on the nature of the pharmaceutical, STW treatment technology and 
performance, temperature and weather (Vieno et al, 2007; Fent et al, 2006). 
Consequently, pharmaceutical elimination efficiencies range from 7 – 99%; for example, 
the elimination efficiency rate for carbamazepine was 7 to 8% whilst it was 99% for 
salicylic acid (Ternes, 1998; Heberer, 2002). Accordingly, a proportion of a 
pharmaceutical enters the aquatic environment via sewage effluent. In some cases STWs 
can activate pharmaceutical potency. There is evidence to suggest that conjugated 
pharmaceutical metabolites entering the STW may be hydrolysed to the parent drug 
through bacteria hydrolases, therefore reaching the environment in their active form 
(Panter et al, 1999; Jessica et al, 2007). For example metabolites of the pharmaceutical 
clofibric acid have been found to hydrolyse back to their parent compound (Daughton & 
Ternes, 1999). STWs represent the main route of pharmaceutical entry into the aquatic 
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environment; moreover they represent a constant source of pharmaceutical entry (Barceló 
& Petrovic, 2007). 
 
Additional routes of entry include via veterinary medical applications. Unlike human 
pharmaceuticals, veterinary pharmaceuticals do not pass through STWs and so may enter 
the aquatic environment in their pure active state. Livestock manure, which may contain 
active pharmaceutical ingredients, is used as agricultural fertiliser and there is the 
potential for pharmaceuticals to enter the aquatic environment via leaching and run-off. 
STW sludge is also used as a soil conditioner and so human pharmaceuticals may enter 
the aquatic environment by similar means (Ternes, 1998; Jørgensen & Halling-Sørensen, 
2000).  
 
1.2 Pharmaceutical fate in the environment 
The fate and transport behaviour of a pharmaceutical in a river/stream/water body very 
much depends on its physicochemical properties. For example the acid dissociation 
constant (pKa) value will determine how much the pharmaceutical will dissociate at 
different environmental pH values, whilst the octanol and water partition coefficient 
(Kow) values determines the likelihood of a pharmaceutical moving from a polar, water-
soluble form into a non-polar fat-soluble form. A pharmaceutical with a high Kow value is 
hydrophobic or lipophilic and is therefore more likely to accumulate in animal or plant 
tissues. Also, the organic carbon-normalised distribution coefficient (Koc) value 
determines whether a pharmaceutical will interact and adsorb onto organic particle 
molecules during STW removal. Interactions with the environment will also determine 
the likely fate of a pharmaceutical. For example, the abiotic transformation of a 
pharmaceutical in surface waters may occur by hydrolysis and photolysis. Since 
pharmaceuticals are usually resistant to hydrolysis, the extent of this event is usually 
negligible. The photolysis rate (kphoto) value for a pharmaceutical determines the 
likelihood of transformation and degradation in the presence of sunlight (both ultraviolet 
(UV) and visible light) (Kümmerer et al, 2006). Direct photolysis of a compound is 
caused by direct absorption of solar light whereas indirect photolysis involves natural 
photosensitisers such as nitrate and humic acids. Pharmaceutical degradation due to both 
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direct and indirect photolysis has been experimentally demonstrated (Nikolaou et al, 
2007). Therefore, the potency of the same pharmaceutical can differ hugely between 
different aquatic environments. There is also the potential for pharmaceuticals with a 
high degree of degradation resistance to accumulate in the aquatic environment. 
 
1.3 Pharmaceutical concentrations in the aquatic environment 
Arguably, our progressive understanding of pharmaceutical toxicity in the aquatic 
environment is driven by improvements and developments in water chemistry analysis 
(Sacher et al, 2001; Fent et al, 2006). To date, more than 50 pharmaceutical compounds 
have been detected in sewage, surface and ground waters throughout the U.K., Western 
and Eastern Europe, Asia and North and South America and Australasia. Table 1 
provides a representative list of pharmaceuticals that have been detected in wastewater 
effluents and, in some cases, surface waters. This is not by any means a comprehensive 
list of all pharmaceuticals that have been identified, nor are the pharmaceuticals solely 
present at the identified locations.  
 
In order to obtain a high degree of selectivity, which is extremely important when the 
water sample may contain a large number of closely-related compounds, chromatography 
followed by mass spectrometry allows for many pharmaceutical compounds to be 
identified and quantified with a high degree of accuracy (Ternes, 1998). This analytical 
and identification process has improved dramatically over the past decade, giving rise to 
several techniques. In some instances, load figures for the same pharmaceutical (e.g. the 
antibiotic trimethoprim) varied between different studies, which can either be the result 
of using different techniques (e.g. liquid chromatography followed by mass spectrometry 
[LC/MS] compared with gas chromatography followed by mass spectrometry [GC/MS]) 
or due to internal factors such as water matrix effects, which in turn can lead to either 
suppressed or enhanced measurements (Terzic et al, 2008). An additional source of 
variation between chemical measurements of drugs is unregulated drug prescriptions. For 
example levels can be higher in countries where prescription drugs can be purchased over 
the counter. Accordingly, the figures in table 1 merely provide an indication/estimation of 
pharmaceutical loads in the environment. 
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Unsurprisingly, the concentration of analgesics and anti-inflammatory drugs were 
relatively high compared with other pharmaceutical classes as would be expected for 
non-prescription over-the-counter drugs where use is considerably higher than 
prescription drugs (Reemtsma et al, 2006). Coupled with the fact that it is poorly 
metabolised and has a high Kow value, ibuprofen in particular was found at considerably 
high levels (Ashton et al, 2004; Thomas & Hilton, 2004; Gros et al, 2006; Peng et al, 
2008). Larsson and colleagues (2007) measured ciprofloxacin at 31mgL
-1
. This was 
unusually high compared to other pharmaceuticals; however Larsson and colleagues 
noted that over 90 pharmaceutical companies discharged into a single Indian STW, from 
which effluent was measured. 
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Country Class Pharmaceutical 
Concentration 
range (ngL
-1
) Reference  
U.K., Spain, 
Germany, South 
China 
Analgesics and 
anti-inflammatory Ibuprofen <8 - 27,256* 
Ashton et al (2004);  
Thomas & Hilton (2004); 
Gros et al (2006); Ternes 
(1998) 
Spain   Ketoprofen <28 - 1520 Gros et al (2006) 
Spain, 
Germany, South 
China   Naproxen <9 - 1550 
Gros et al (2006); Ternes 
(1998); Peng et al (2008) 
Spain   Indomethacine <7 - 240 Gros et al (2006) 
Spain, 
Germany, U.K.   Diclofenac 50 – 4200* 
Gros et al (2006); Ternes 
(1998) Ashton et al (2004);  
Thomas & Hilton (2004) 
Spain, U.K.   Mefenamic acid <3 – 1440* 
Gros et al (2006); Ashton et 
al (2004);  
Thomas & Hilton (2004) 
U.K.   Dextropropoxyphene <8 - 682* 
Ashton et al (2004);  
Thomas & Hilton (2004) 
Spain   Propyphenazone <7 - 461 Gros et al (2006) 
South China, 
Canada   Salicylic acid 24 – 35,000 
Peng et al (2008); Brun et al 
(2006) 
Spain Psychiatric Carbamazepine 120 - 1550 Gros et al (2006) 
Spain   Fluoxetine 35 Gros et al (2006) 
Spain   Paroxetine 6 Gros et al (2006) 
Croatia, U.K.  Antibiotic Trimethoprim 35 – 2550* 
Senta et al (2005); Ashton et 
al (2004); Thomas & Hilton 
(2004) 
U.K.   Sulfamethoxazole <50 - 132* Ashton et al (2004) 
U.K. Anti-cancer Tamoxifen <4 - 71 Thomas & Hilton (2004) 
Croatia Sulfonamide Sulfadiazine <1 - 132 Senta et al (2005) 
Croatia   Sulfapyridine <4 - 931 Senta et al (2005) 
Croatia   Sulfamethoxazole 19 - 11600 Senta et al (2005) 
Croatia, U.K.  Fluoroquinolone Erythromycin 24 – 1842* 
Senta et al (2005); Ashton et 
al (2004) 
Croatia   Azithromycin 6 - 1140 Senta et al (2005) 
Croatia   Josamycin <8 - 16 Senta et al (2005) 
Croatia   Roxithromycin <1 - 50 Senta et al (2005) 
 
Table 1. Pharmaceuticals measured in effluent and (*) surface waters.  denotes unusually high quantity; Larsson et al (2007) 
reported that over 90 pharmaceutical companies discharged into a single STW. 
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Croatia Fluoroquinolone Norfloxacin 16 - 2940 Senta et al (2005) 
Croatia, India   Ciprofloxacin 
<7 – 
31,000,000 
Senta et al (2005); Larsson et 
al (2007) 
Croatia   Enrofloxacin <2 - 18 Senta et al (2005) 
Spain, Canada Beta-blocker Atenolol <42 - 7560 
Gros et al (2006); Lee et al 
(2007) 
Spain, Canada   Sotalol <29 - 1080 
Gros et al (2006); Lee et al 
(2007) 
Spain, 
Germany, 
Canada, U.S.A,    Metoprolol <12 - 4680 
Gros et al (2006), Ternes 
(1998); Lee et al (2007); 
Huggett et al (2003) 
Spain, U.K., 
Germany, 
Canada, U.S.A   Propranolol <12 - 255 
Gros et al (2006) Ashton et al 
(2004); Thomas & Hilton 
(2004) Ternes (1998); Lee et 
al (2007); Huggett et al 
(2003a) 
Canada   Acebutolol <10 - 1090 
Andreozzi et al (2003);  Lee 
et al (2007) 
Canada   Labetalol 64 - 279 Lee et al (2007) 
Canada   Bisoprolol 20 - 74 Lee et al (2007) 
Canada   Timolol <7 - 7 Lee et al (2007) 
Canada, U.S.A   Nadolol 26-360 
Lee et al (2007); Huggett et al 
(2003a) 
Canada   Salbutamol <6 - 17 Lee et al (2007) 
Spain Anti-ulcer Lansoprazole 14 Gross et al (2006) 
Spain 
Histamine H1 and 
H2  Loratidine 4 Gross et al (2006) 
Spain receptor agonist Famotidine <12 - 120 Gross et al (2006) 
Spain   Ranitidine <24 - 758 Gross et al (2006) 
Spain, Germany 
Lipid regulator 
and cholesterol Gemfibrozil <3 -1700 
Gross et al (2006); Ternes 
(1998) 
Spain, Germany lowering drug  Bezafibrate 9-350 
Gros et al (2006); Ternes 
(1998) 
Spain   Pravastatin <60 - 1170 Gross et al (2006) 
U.K., Germany, 
South China   Clofibric acid <20 - 248 
Thomas & Hilton (2004); 
Ternes (1998); Peng et al 
(2008);  
Germany   Fenofibric acid 45 Ternes (1998) 
South China Synthetic steroid 17 α-ethinyloestradiol 1 - 2 Peng et al (2008) 
U.K.  (EE2) 13.6 - 24 
Johnson et al (1999); Aherne 
& Briggs (1989) 
Germany & 
Russia   15  
Rathner & Sonneborn (1979); 
Ternes et al  (1999) 
Canada   42 Ternes et al (1999) 
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1.4 Pharmaceutical effects on the aquatic environment 
 
1.4.1 Mode of Action 
Pharmaceuticals achieve their medical application via binding with a drug target, such as 
a receptor or an enzyme and initiating a response. Drug targets have been classified into 4 
major groups: receptors, ion channels, enzymes and transporters (see figure 1) (Rang et 
al, 2003). In general, there are three requirements for a pharmaceutical to elicit a 
response in a body. The first is that the drug structure is bioactive, the second is that the 
organism has the necessary drug target (or site of action), and the third is that there must 
be a link between the drug target and a response mechanism (Williams, 2006). All 
commercially available pharmaceuticals meet these requirements in humans. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Advances in DNA sequencing and subsequent bioinformatics and mathematical 
modelling have led to the elucidation of full genomic sequences, and subsequent 
functional understanding (albeit limited compared to humans), for several test-species 
(e.g. beta-blockers, 17α-ethinylestradiol (e.g. aspirin, ketoconazole) 
(e.g. local anaesthetics, cypermethrin) 
(e.g. imipramine, omeprazole) 
e.g. β-blockers, 17α-ethinyloestradiol e.g. asprin, ketaconazole 
e.g. imipramine omeprazole 
e.g. local anaesthetic, cypermethrin 
Figure 1. The four major groups of drug targets. Figure taken from Rang et al, 2003. 
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including fish. A limited review of fish receptors and enzyme systems by Huggett et al 
(2003b) indicated that overall receptor and enzyme identities were 31 – 88% similar to 
mammalian targets. Therefore, it is possible that the therapeutic targets in humans may 
also be present in fish and, as such, pharmaceuticals present in the aquatic environment 
could interact with their target receptors and elicit a pharmacological response. 
Furthermore, some aquatic invertebrate taxa such as molluscs appear to contain many of 
the same enzyme and receptor systems expressed in mammals, however their 
pharmacological function is still poorly defined (Huggett et al, 2006). 
 
There is also evidence to suggest that fish and aquatic invertebrates may express 
receptors in tissues different to that in humans, indicating that pharmacodynamic 
activities of certain drugs may also be very different (Nickerson et al, 2003; Laville et al, 
2004). Furthermore, one cannot rule out potential cross-talk, where a drug designed to 
interact with a specific receptor in a human interacts with a structurally similar, but 
functionally very different, receptor in an aquatic organism. Finally, another interesting 
avenue to explore is whether a pharmaceutical present at the same pharmaceutical dose in 
the aquatic environment as administered in humans will elicit the same response in 
aquatic organisms. Currently, there is very little data available to answer that question. 
 
1.4.2 Measurable effects  
The first measurable effects of pharmaceuticals in the aquatic environment were observed 
over twenty years ago in the U.K. Male gonochoristic fish living downstream of STWs in 
the River Lea catchment (South-East England) were showing signs of intersex, or 
hermaphroditism. Further studies suggested that the principal component in the female 
contraceptive pill, α-ethinyloestradiol (EE2), was present in STW effluent and was 
responsible for the feminisation of fish (Tyler & Routledge, 1998). Interestingly, 
although EE2 has been measured in the aquatic environment (see table 1), it has not been 
found at considerably higher levels than other pharmaceuticals. However, EE2 is highly 
lipophilic (log Kow = 4.48) and so it is extremely likely to move from water into tissues 
and bioaccumulate. Although much attention has focused on the effects of EE2, 
ecotoxicological studies have also examined the effects of other pharmaceuticals on 
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wildlife. Most notably, a population decline of >95% in the Oriental white backed 
vulture, Gyps bengalensis, was linked to the non-steroidal anti-inflammatory drug 
diclofenac (Oaks et al, 2004). By eating the carcasses of cattle treated with the drug, the 
vultures ingested diclofenac and subsequently suffered from renal failure and visceral 
gut. These two case studies alone have provided enough cause for concern to further 
examine pharmaceutical toxicity in the environment. 
 
The possible effects of aquatic environmental exposure to pharmaceuticals can be 
classified into three groups, the first is a standard acute toxic response, the second is 
antibiotic resistance and third is endocrine disruption (or hormone mimicking) (Jørgensen 
& Halling-Sørensen, 2000). 
 
1.4.2.1 Acute toxicity 
The impact of a pharmaceutical can be on any level of biological hierarchy: cells-organs-
organisms-population-ecosystems-ecosphere. At least 24 pharmaceuticals have been 
examined for their acute toxicity on aquatic wildlife (Ayscough et al, 2000). Measurable 
physiological effects include mortality, decreased heart rate and inhibition of growth for 
vertebrate fish (Henschel et al, 1997; Huggett et al, 2002; Larsson et al, 2006); growth 
inhibition, immobilisation and mortality for the invertebrate Daphnia magna water flea 
and mysid shrimp (Mysidopsis bahia) (Lilius et al, 1995; Henschel et al, 1997; Huggett et 
al, 2002); and growth inhibition, inhibition of luminescence and mortality for algae and 
bacteria (Sanyal et al, 1993; Kümmerer et al, 2000; Stuer-Lauridsen et al, 2000); and 
morphological changes in the cnidarian Hydra attenuata (Quinn et al, 2008). This list is 
by no means comprehensive, but it does give an indication as to the acute toxic effects 
observed in aquatic species exposed to environmentally relevant concentrations of 
pharmaceuticals.  
 
1.4.2.2 Antibiotic resistance 
The mechanism of action for antibiotics is very different from other pharmaceuticals 
because bacteria are the target organisms. The increased use of antibiotics over recent 
years has caused a genetic selection of more harmful bacteria that have become resistant 
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to antibiotics. The genetic pool of microorganisms within the aquatic environment has 
changed significantly, and one of the catalysts for this change is the introduction of 
xenobiotics. The development of antibiotic-resistance in aquatic ecosystems is favoured 
by low concentrations of antibiotics (Petersen et al, 1997) and therefore the surviving 
bacteria may be particularly harmful to other wildlife (Jørgensen & Halling-Sørensen, 
2000; Williams, 2006). Antibiotic resistance as a result of pharmaceutical exposure is still 
poorly understood. 
 
1.4.2.3 Endocrine disruption 
To date, much attention has focused on this effects group because of the observed 
significant physiological impact. Following on from the initial work conducted by Tyler 
and Routledge (1998), hermaphrodite fish have also been observed in rivers below STW 
outlets in a number of countries including the U.K. (Purdom et al, 1994; Harries et al, 
1997; Jobling et al, 1998) and the U.S.A (Folmar et al, 1996); there is a strong positive 
correlation between incidence and severity of feminisation of male fish and proportion of 
treated sewage effluent in receiving waters (Gross-Sorokin et al, 2006). Fish feminisation 
has also been measured in marine populations of flounder (Platichthys flesus) (Jobling et 
al, 2002) dab (Limanda limanda) (Scott et al, 2007) and cod (Scott et al, 2006). In recent 
years, there has been a surge of government- and academia-led activity in researching the 
effects of oestrogenic compounds on aquatic life and it has been demonstrated that EE2 
can inhibit fish growth and reproduction and can induce a female yolk protein, 
vitellogenin, in male livers, which has subsequently been used as a marker of oestrogenic 
exposure in male fish (Purdom et al, 1994; Jobling et al, 1996; Tyler & Routledge, 1998). 
Furthermore, it has been demonstrated that long-term exposure to EE2 can cause 
mortality at the embryo, juvenile fry and adult stages (Schweinfurth et al, 1996). 
Consequent effects on reproductive hierarchies, sexual selection and group spawning 
have also been found to be influenced by exposure to EE2 (Coe et al, 2008).  
 
1.5 β-blockers in the aquatic environment 
β-blockers are prescribed to patients to treat migraines, essential tremors, stress, 
glaucoma and asthma and work by targeting β1, β2 and β3-adrenergic receptors (β1-ARs, 
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β2-ARs and β3-ARs, respectively). Because of their extensive use, β-blockers are in the 
top 200 prescribed medications in the U.S.A (Hernando et al, 2004). β-blockers oppose 
the excitatory effects of the neurotransmitters adrenaline and noradrenaline released from 
sympathetic nerve endings at β-ARs. There are at least 15 different beta-blockers 
available on the commercial market and they can be divided into two groups: specific and 
non-specific. β-blockers with a specific mode of action block one type of receptor, for 
example atenolol is a β1-blocker and is prescribed to treat patients with hypertension-
related illnesses. Non-specific beta-blockers, such as propranolol, interact with all three 
β-ARs (Gros et al, 2008). 
 
The elimination of β-blockers after human consumption occurs via hepatic metabolism in 
the liver. Lipophilic β-blockers, such as propranolol (figure 2a) that has a logKow value of 
3.78, are extensively metabolised and eliminated after glucuronidation, whilst the more 
hydrophilic β-blockers, such as atenolol (figure 2b) that has a log Kow of 0.16, are almost 
exclusively excreted unchanged in urine (Lee et al, 2007). Due to their prevalence of use, 
β-blockers have been measured in environmental samples. As shown in table 2, at least 
10 different β-blockers have been detected surface waters. It can be seen that β-blocker 
concentrations range from the ngL
-1
 to µgL
-1
 level, depending on both individual drug 
usage and STW removal efficiency rates; for example the removal rate of propranolol in 
a STW has been found to range from <10% (Roberts & Thomas, 2006) to 96% (Ternes, 
1998), hence its presence in surface waters varies considerably. Regardless, β-blockers 
enter the aquatic environment and therefore there is the potential for β-blockers to 
directly interact with aquatic species and eliciting a toxicological effect. 
 
 
 
 
 
 
 
Figure 2. The chemical structure of propranolol (A) and atenolol (B). 
A B 
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1.5.1 Effects of β-blockers on aquatic organisms 
Acute invertebrate toxicity studies have found that exposure to environmentally-relevant 
concentrations of β-blockers can inhibit algal (Desmodesmus subspicatus, Cyclotella 
meneghiniana and Synechococcus leopolensis) and Lemna (duckweed) growth and 
induce mortality and immobilize Daphnia water-flea (Cleuvers, 2004, Ferrari et al, 
2004). However, of all the β-blockers, propranolol seems to pose the biggest threat to 
aquatic organisms. Propranolol is not found at the highest concentration compared to 
other β-blockers in the aquatic environment; however it has the highest log Kow value and 
is therefore more likely to bioaccumulate in organism tissues. Furthermore, its Predicted 
Environmental Concentration/Predicted No Effect Concentration ratio (see section 1.6 for 
more details) is far higher than other β-blockers, suggesting it can elicit a toxic effect at 
much lower concentrations than other β-blockers (Cleuvers, 2004). Further fish-based 
studies have examined the effects of acute and chronic waterborne exposure to 
propranolol and have observed mortality (LC50 = 24.3mgL
-1
), inhibition of
 
growth 
Compound Surface water 
concentration (ngL
-1
) 
Reference 
Acebutolol 3 - 14 Vieno et al (2007) 
Atenolol 3.44 - 859 Calamari et al (2003); Andreozzi et al (2003) 
Betaxolol 28 Ternes, (1998) 
Bisoprolol 2,900 Ternes, (1998) 
Carazolol 110 Ternes, (1998) 
Metoprolol <3.8 - 2,200 Ternes (1998); Vieno et al (2006) 
Propranolol <10 - 590 Ashton et al (2004); Ternes, (1998) 
Salbutamol 35 Ternes (1998) 
Sotalol <3.9-52 Vieno et al (2006) 
Timolol 10 Ternes (1998) 
Table 2. Minimum and maximum concentrations of β-blockers found in surface water samples throughout 
the world. 
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(0.5mgL
-1
) and reproduction (<0.5mgL
-1
) and a decrease in heart rate (1.5mgL
1
 via 
intravenous injection) (Huggett et al, 2002; Larsson et al, 2006). 
 
1.5.2 β-blocker mode of action 
In eukaryotes, communication between cells occurs via the release and synthesis of a 
signalling molecule and subsequent binding to a cell receptor. In mammals, the „flight or 
fight‟ syndrome, or response to stress, is regulated by the catecholamines epinephrine 
(adrenaline) and norepinephrine (noradrenaline) (see figure 3). Norepinephrine is the 
major neurotransmitter in the peripheral nervous system, whereas epinephrine is the 
primary hormone secreted by the adrenal medulla in mammals. Both catecholamines are 
produced by chromaffin cells via the Blashko pathway from the amino acid precursor 
tyrosine (Reid et al, 1998). In times of stress (including exercise and trauma) secretion of 
these hormones is stimulated by acetylcholine release from preganglionic sympathetic 
fibres innervating the adrenal medulla. Following secretion into blood, the 
catecholamines bind loosely to, and are carried by, albumin and other serum proteins 
throughout the body to target tissues (Reid et al, 1998). Both catecholamines 
characteristically contain a catechol moiety and therefore their sudden presence in blood 
in response to a stress stimulus allows for a rapid response (Lodish et al, 2000). Both 
epinephrine and norepinephrine are involved in regulating a host of physiological 
functions such as peripheral excitation or inhibition of certain types of smooth muscles in 
different tissues and organs. Epinephrine is particularly important in mediating the body‟s 
response to stress, when all tissues have an increased requirement for glucose and fatty 
acids. Epinephrine triggers the breakdown of glycogen in the liver (glyocogenolysis) and 
triacylglycerol in the adipose tissues (lipolysis) and these principal metabolic fuels are 
rapidly supplied to the blood (Schwartz, 1996; Weaver, 2002). 
   
 
 
 
 
 
 Norepinephrine 
   Epinephrine 
Figure 3. Chemical structures of epinephrine and norepinephrine. Image taken from www.biopsychiatry.com. 
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Catecholamines are unable to pass through cell plasma membranes and therefore, to 
initiate their action, bind to specific protein receptors, termed adrenergic receptors, 
located on the surface of cell membranes. Adrenergic receptors belong to the large family 
of integral membrane proteins termed the G-protein-coupled receptors (GPCRs). GPCRs 
are membrane receptors that are coupled to intracellular effector (response) systems via a 
Guanine-binding protein. Using large-scale phylogenetic analysis, GPCRs have been 
divided into 5 distinct families in the human genome: (G) Glutamate, (R) Rhodopsin, (A) 
Adhesion, (F) Frizzled/Taste2 and (S) Secretin, which has been aptly named the GRAFS 
classification system (Schiöth & Fredriksson, 2005). Adrenergic receptors belong to the 
largest Rhodopsin family. Subsequent studies examining agonist and antagonist binding 
have further divided the adrenergic receptors into two principal groups: α and β 
(Fredriksson et al, 2003). In mammals, nine different subtypes exist; α1A, α1B, α1D, α2A, 
α2B, α2C and β1, β2, and β3.  Each subtype carries out a particular function and has been 
identified as a separate subtype based on the receptor‟s pharmacology, location and 
relative binding affinity for adrenaline and noradrenaline (Owen et al, 2007).   
 
GPCRs are membrane-bound serpentine receptors and consist of a single polypeptide 
chain of up to 1100bp; their characteristic structure, as shown in figure 4, comprises 
seven hydrophobic transmembrane domain (TMD) α-helices which span the membrane 
in an anti-clockwise manner with an extracellular amino terminus (N-terminal domain) of 
varying length and an intracellular C-terminal domain that contains several sites for 
phosphorylation by protein kinase A and β-adrenoceptor kinase (Strosberg, 1993). There 
are over 800 different human GPCRs, all of which share this 7 TMD characteristic 
arrangement (Lodish et al, 2000; Schwartz, 1996; Warne et al, 2008). These 
transmembrane regions are crucially involved in the binding of ligands (Lefkowitz & 
Caron, 1988). The β-ARs are not fixed in a linear fashion within the membrane; instead 
through a series of amino-acid bonds between TMDs, they exist as a complex cylindrical 
3-dimensional (3D) structure. The 3D structure produces a “pocket”, which enables 
ligand binding. For example in the β3-AR, bonding between TMDs 3, 5 and 7 and 
between TMDs 4, 5 and 6 produces an adrenaline-binding pocket (Blin et al, 1993; 
Strosberg & Pietri-Rouxel, 1996). 
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G-proteins represent the level of middle management, intervening between the receptors 
and the effector enzyme or ion channel gate (Weaver, 2002). These proteins are so called 
G-proteins because of their interaction with the guanine nucleotides guanine tri-
phosphate (GTP) and di-phosphate (GDP(ii)). The G-protein consists of three subunits α, 
β and γ and is freely diffusible in the membrane plane. The Gα-subunit is a GTPase 
switch protein that alternates between an active (on) state with bound GTP and an 
inactive (off) state with bound GDP(ii). The Gα-subunit has three different subtypes: Gαq, 
to stimulate phospholipase C and Gαs- and Gαi- to stimulate or inhibit adenylyl cyclase, 
respectively (Lodish et al, 2000). Figure 5 illustrates the response of the Gα-subunit to 
receptor binding to a ligand. In a „resting state‟, (stage 1), the G-protein exists as an 
unattached αβγ-trimer, with GDP(ii) occupying the site on the α-subunit. Upon 
stimulation by a ligand, (stage 2), a conformational change occurs in the cytoplasmic 
domain of the receptor causing it to acquire higher affinity for the αβγ-trimer. 
Association of the αβγ-trimer with the receptor causes the bound GDP(ii) to dissociate 
and be replaced with GTP, which in turn causes dissociation of the G-protein trimer, 
releasing α-GTP and βγ-subunits. The α-GTP subsequently binds to and activates the 
effector, (stage 3), which in the case of β1 and β2-ARs, and sometimes in β3-ARs 
(depending on the tissue) is the enzyme adenylyl cyclase (Lodish et al, 2000). Once 
Figure 4. Three dimensional structure of a typical GPCR with noted TMD regions within the membrane 
lipid bilayer, external N-terminus and internal C-terminus. Image taken from Strosberg & Nahmias (2007). 
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activated, adenylyl cyclase catalyses the synthesis of the second messenger, cyclic3‟5‟-
adenosine monophosphate (cAMP). cAMP is a nucleotide that regulates many aspects of 
cellular functioning including enzymes involved in energy metabolism, cell division and 
cell differentiation, ion transport, ion channels and the contractile proteins in smooth 
muscle. These varied effects are brought about by the activation of protein kinase A by 
cAMP. Protein kinases regulate the function of different cellular proteins by catalysing 
the phosphorylation of serine and threonine residues, using ATP as a source of 
phosphate. The binding of epinephrine to β-ARs induces a rise in cAMP production, 
which in turn activates enzymes involved in glycogen and fat metabolism in liver, fat and 
muscle cells. The overall result is a coordinated response to noradrenalin/adrenaline in 
which stored energy in the form of glycogen and fat is made available as glucose to fuel 
muscle contraction and enable the individual to respond to the stress-stimulus (Alberts, 
1994; Watson & Arkinstall, 1994). The activation process is terminated when the 
hydrolysis of GTP to GDP(ii) occurs through the GTPase activity of the α-subunit. The 
resulting α-GDP(ii) then dissociates from the effector enzyme and reunites with the β-
complex, (1) (Watson & Arkinstall, 1994; Lodish et al, 2000).  
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adenyl cyclase 
(inactive) 
STAGE 1 
STAGE 2 
STAGE 3 
Figure 5. Schematic illustration of the response of the Gα-subunit to receptor binding to a ligand. Stage 
1 refers to the receptor complex in a “resting state”; stage 2 illustrates ligand binding to the GPCR; and 
the replacement of α-GDP with α-GTP and stage 3 shows how α-GTP displaces from the βγ-subunit 
and moves to the effector. Image amended from Becker et al (2008).   
OUTSIDE  
OF CELL 
INSIDE  
OF CELL 
Adenyl cyclase (inactive) 
Adenyl cyclase (active) 
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High intracellular concentrations of cAMP ranging from tens of thousands to millions of 
molecules per cell are required to initiate a cellular response. However, approximately 
only a thousand β-ARs are present on the outer membrane of a cell. Therefore, the 
hormone signal is amplified in order to generate sufficient numbers of cAMP. This is 
achieved by two methods, the first is by „signal amplification‟ where a single GPCR 
complex can activate up to 100 inactive Gαs-molecules, and the second is by the synthesis 
of several hundred cAMP molecules by adenylyl cyclase before the receptor-complex 
dissociates (Lodish et al, 2000).  
 
Beta-blockers, also referred to as β-AR antagonists, bind to the β-AR complex without 
initiating a G-protein response, which firstly minimises adrenaline and noradrenaline 
binding, and secondly reduces the usual physiological activity of the hormones (Lodish et 
al, 2000).  
 
1.5.3 β-AR subtype locations and pharmacology 
The three β-AR subtypes in humans have been classified according to their location and 
binding affinities with adrenergic ligands. β1- and β2-ARs are generally located in the 
cardiovascular system; β1-ARs are primarily located in cardiac muscle and are 
responsible for inducing heart rate and contractility and subsequently blood flow when 
activated by adrenergic ligand catecholamines, whilst β2-ARs are present in smooth 
muscle cells lining the bronchial passage, and when active enable the relaxation of 
smooth muscle, allowing the bronchioles to open (Lodish et al., 2000). Diseases related 
to elevated levels of adrenaline and noradrenaline and subsequent activation of β1- and 
β2-ARs include hypertension, angina, pectoris, hypertrophy, arrhythmia, bradycardia, 
tachycardia and heart failure (Watson & Arkinstall, 1994). Therefore, the majority of 
non-specific β-blockers (such as propranolol) are primarily designed to interact with both 
β1- and β2-ARs as to modulate heart function; selective β1-AR blockers (such as atenolol) 
are also available and may be preferentially used by patients where there are fewer side 
effects, such as bronchial constriction, which may occur as a result of β2-AR blocker 
activity in the lung (Warne et al, 2008).  
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In humans, the β3-AR has been identified in a variety of tissues. They have been found to 
inhibit contractile activity of the ileum and colon (Manara & Bianchetti, 1990), modulate 
neuronal bronchomotor inducing relaxation of airway smooth muscle, produce peripheral 
vasodilation which is predominant in skin, reduce contractile force in human ventricular 
muscle, stimulate L-type calcium current in human atrial myocytes and regulate 
vasodilation in the human internal mammary artery (Krief et al, 1993; Skeberdis, 2004; 
Rozec et al, 2005). The β3-AR mRNA is also expressed in the human brain, especially in 
very young infants; the role of this, however, has not yet been confirmed (Rodriguez et 
al, 1995). However, the β3-AR has been found to be most highly expressed in the brown 
and white adipose tissues (BAT and WAT, respectively) where it is likely to regulate 
norepinephrine-induced changes in energy metabolism and thermogenesis and thus play 
an important role in obesity and type II diabetes (Muzzin et al, 1991; Krief et al, 1993). 
The ratio of β1, β2 and β3-AR expression in the BAT and WAT is 3:1:150, respectively 
(Collins et al, 1994). The essential features of BAT and WAT is their capacity to 
stimulate the mobilisation of lipids from the white fat cells, oxidise fat and produce heat 
without synthesising ATP from ADP (Arch, 1989; Collins et al, 1994; Arner & Hoffstedt, 
1999). 
 
There is still some debate as to whether the β3-AR is a separate β-AR subtype or is 
actually a sub-species of a β1-AR. Pharmacological analysis suggests that the human β1-
AR and β3-AR a more similar to each other across the transmembrane domains (76%) 
than to the β2-AR (71% and 68% for the β1- and β3-AR, respectively) (Machida et al, 
1990; Skeberdis, 2004; Owen et al, 2007). Additionally, the most potent catecholamine 
for both β1-AR and β3-AR is noradrenaline, whilst it is adrenaline for the β2-AR 
(Strosberg & Pietri-Rouxel, 1996). However, there are some notable differences between 
the β1- and β3-AR. Firstly, it has been suggested that the β3-AR has either three exons and 
two introns in its sequence (as in humans) or two exons and one intron (as found in dogs 
and monkeys) (Bensaid et al, 1993; Watson et al, 1997); whereas there are no introns in 
the β1-AR. Secondly, there is data to suggest that unlike the β1- and β2-AR which only 
interact with the Gαs-proteins, the β3-AR interacts with a multitude of proteins, as shown 
in figure 6. In adipocytes, the β3-AR is coupled to the two heterotrimeric proteins Gαs- 
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and Gαi (Soeder et al, 1999). This dual coupling permits two parallel signaling pathways 
to be activated: (i) cAMP generation and camp-dependent protein kinase activation 
(PKA), and (ii) cellular tyrosine kinase (Src) recruitment to the receptor and activation of 
extracellular signal-related kinase (ERK). In the first case (A), stimulation of the β3-AR 
leads to the sequential stimulation of adenylyl cyclase and cAMP and PKA, which in turn 
activates a specific protein kinase cascade culminating in the activation of p38 mitogen-
activated protein kinase (p38 MAPK) and activation of a subset of transcription factors 
including activating transcription factor 2 (ATF2), peroxisome proliferator-activated 
receptor-gamma (PPARγ) and –gamma coactivator 1 alpha (PGC-1α). These events 
allow for a sustained thermogenic response by increasing uncoupling protein 1 (UCP1) 
expression. In the second case, the PKA and ERK pathways can also lead to the 
phosphorylation of hormone-sensitive lipase (HSL), which mediates lipolysis (Robidoux 
et al, 2006). The β3-AR-mediated signalling pathways in the human atrial myocytes (B) 
are very different to those in the adipocytes. Activation of the β3-AR leads to the 
phosphorylation of calcium channels and an increase in Ica. β3-AR agonists exert a 
negative inotropic effect (weakens the force of muscular contractions) on human 
ventricular muscles and this is related to the activation of inhibitory Gαi-proteins 
(Skeberdis, 2004). The stimulation of Gαi does not induce cAMP but instead activates the 
nitric oxide (NO) pathway via the activation of endothelial constitutive NO synthase 
(eNOS). The production of NO causes an increase in intracellular cyclic guanosine 
monophosphate (cGMP) and subsequent activation of cGMP-dependent protein kinase 
(PKG) and possible inhibition of phosphodiesterase 3 (PDE 3) and/or activation of 
phosphodiesterase 2 (PDE 2), which can reduce the contraction force usually stimulated 
through the cAMP pathway (Skeberdise, 2004). In contrast to the heart that uses calcium 
channels, the β3-AR mediated relaxation effect on the rat aorta involves several 
potassium channels (C), whilst in the portal vein myocytes (D), the activation of β3-AR 
stimulates L-type calcium channels through a Gα/s-induced stimulation of the cAMP/PKA 
pathway leading to the subsequent phosphorylation of the those channels (Rautureau et 
al, 2002). Therefore, considering their different modes of activation, it is more likely that 
the β3-AR as an individual β-AR subtype, rather than a β1-AR subtype. 
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1.5.4 β-ARs in fish 
Similarly to humans and higher vertebrates, fish respond to environmental or 
physiological stress via the secretions of the catecholamines adrenaline and 
noradrenaline. Like humans, fish also possess α and β adrenergic receptors and the 
Figure 6. Signaling pathway of β3-AR in adipocytes, cardiomyocytes and blood vessels. In adipocytes (A), the 
β3-AR is coupled to both Gs and Gi leading to the activation of PKA and ERK 1/2 pathways, respectively. 
PKA subsequently activates p38 MAPK, which in turn activates ATF2, PPARγ and PGC-1α which control for 
prolonged thermogenesis, whilst ERK 1/2 and PKA activate HSL, which controls for lipolysis. (B) β3-AR is 
not coupled to the Gs protein but only to Gi, which leads to the activation of eNOS. The downstream 
production of NO activates the soluble GC isoform leading to an increase in cGMP concentration, which in 
turn activates PKG. (C) β3-AR mediates relaxation through activation of a NO synthase pathway and 
subsequent increase in cGMP concentration. (D) Activation of β3-AR stimulates L-type calcium channels. Gs 
= stimulatory G-protein; Gi/o = Gi/o protein; AC = adenylyl cyclase; cAMP = cyclic adenosine monophosphate; 
cGMP = cyclic guanosine monophosphate; PKA = cAMP-dependent protein kinase; HSL = hormone-sensitive 
lipase; PGC-1α = peroxisome proliferator-activated receptor; PPARγ = peroxisome proliferator-activated 
receptor-gamma coactivator-1; UCP1 = uncoupling protein 1; ERK = extracellular signal-related kinase; p38 
MAPK = p38 mitogen-activated protein kinase; eNOS = endothelial nitric oxide synthase; GTP = guanosine 
triphosphate; GC = guanylyl cyclase; NO = nitric oxide; Ca2+ = calcium; K+ = potassium. Figure taken from 
Ursino et al (2009). 
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transduction pathway of GPCR interaction and subsequent cAMP activation is the same 
(Randall & Perry, 1992). However unlike humans, adrenaline, like noradrenaline, is 
synthesized in both adrenergic neurons and chromaffin cells and thus both 
catecholamines can act as neurotransmitters. Additionally in fish, the chromaffin tissue is 
located within the anterior or head kidney, often associated with the walls of the posterior 
cardinal veins (Nilsson, 1983). Furthermore, levels of adrenaline and noradrenaline in the 
chromaffin tissue vary between teleost (bony) and elasmobranch (cartilaginous) fish 
species (Hathaway & Epple, 1989). Catecholamine activation in fish leads to numerous 
physiological responses, both direct and indirect, all of which either increase or maintain 
energy turnover via glyogenolysis or gluconeogensis and oxygen supply under adverse 
conditions (Randall & Perry, 1992).  
 
To date, the β1- and β2-ARs have been characterised in a handful of aquatic species 
including the African clawed frog Xenopus laevis, where the β1-AR mRNA was 
expressed in the mature oocytes and embryos (Devic et al, 1997); the channel catfish 
Ictalurus punctatus, where both β1- and β2-AR were identified in membranes isolated 
from the head kidney and spleen leukocytes (Finkenbine et al, 2002) and the rainbow 
trout Oncorhynchus mykiss, where the β2-AR was identified in the spleen, white muscle, 
red muscle, liver and kidney of adult rainbow trout (Nickerson et al, 2001). It has been 
proposed that the β1-AR is involved in maintaining the immunostatus of carp, however its 
function in other fish and aquatic organisms is unknown (Jozefowski & Plytycz, 1998; 
Owen et al, 2007). Meanwhile, the function of the liver β2-AR in rainbow trout and other 
species of teleosts has been found to be involved with the mobilisation of hepatic 
glycogen (Nickerson et al, 2001).  
 
The complete β3-AR has been solely characterised in the rainbow trout, Oncorhynchus 
mykiss (Nickerson et al, 2003). Two β3-AR subtypes were identified as β3a- and β3b-AR. 
The β3a-AR was found in the heart and gills of adult rainbow trout, whilst the β3b-AR was 
found in the red blood cells (RBC). Interestingly, neither subtype was found in the 
adipose tissue; fish are poikilothermic and do not regulate their own body temperature 
and are therefore not likely to require a thermogenic response mechanism. Nickerson and 
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colleagues suggested that the catecholamines were able to augment haemoglobin/oxygen-
binding affinity by increasing RBC intracellular pH through β3-AR signalling. Activation 
of the trout the β3-AR leads to accumulation of cAMP and activation of PKA that in turn 
activates the β Na+/H+ (β-NHE) exchange system. Once activated the β-NHE extrudes H+ 
from the RBC in exchange for Na
+
, resulting in alkalisation of the cytoplasm. This 
increase in RBC intracellular pH enhances the affinity of haemoglobin for O2 and allows 
for the increased oxygen transport by the blood. This suggests the roles of both β3a- and 
β3b-AR are interestingly novel in the trout and possibly fish. Maximum likelihood 
analysis of aligned vertebrate β-AR sequences placed the trout β3a- and β3b-AR in the 
mammalian/avian β3-AR group with strong statistical support (97%) and further ligand 
binding assays revealed both β3-ARs had a stronger affinity for norepinephrine than for 
epinephrine, matching the preferential catecholamine affinity identified in human β3-
ARs. 
 
A partial β3b-AR sequence has also been identified in the black bullhead (Ameiurus 
melas) (Dugan et al, 2008). Along with identifying the β2-AR, Dugan and colleagues 
identified a β-AR sequence that was phylogenetically most similar to other vertebrate β3-
ARs and spanned from TMD4 to TMD7. The proposed β3b-AR sequence was identified 
in the liver, however its function is not known and one cannot rule out the possibility that 
the β3b-AR mRNA detected was a result of residual blood in the hepatic tissues. 
 
Fish and humans both express β-adrenergic receptors, albeit in different tissues and their 
exact functions in fish still unknown or unconfirmed. Fish and humans are separated by 
approximately 450 million years of evolution, though they both belong to the same 
vertebrate lineage and therefore share important developmental pathways, such as the 
evolution of adrenergic receptors (Froschauer et al, 2006). It has been suggested that two 
genome duplications occurred at the origin of vertebrates 500-800 million years ago, 
termed the 2R hypothesis (Ohno, 1970), hence explaining why humans are diploid.  
However, further fish-specific genome duplications have occurred leading to most ray-
finned fish being tetraploid (4R) (Froschauer et al, 2006). More recent tetraploidisation 
(and even octoploidisation) events have occurred independently through different 
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mechanisms in several lineages of teleost fish and it is these events that are responsible 
for the huge species diversity observed in this group (Ruuskanen et al, 2005). Duplicated 
genes can also lead to functional divergence, where one duplicate might acquire a novel, 
positively selected function (termed neofunctionalisation) and it is therefore possible that 
through neofunctionalisation, the location and subsequent roles of β-ARs in fish have 
become different to humans (Froschauer et al, 2006). Therefore, in response to 
environmental β-blocker exposure, fish may show an unanticipated toxic reaction tha 
could not be predicted from mammalian studies. 
 
1.6 Pharmaceutical Environmental Risk Assessments (ERAs) 
The realisation that pharmaceuticals in the environment can cause sometimes severe 
toxicological effects has led to the enforcement of environmental risk assessments 
(ERAs). As stipulated by the committee for medicinal products for human use (CHMP) 
within the European medicines agency (EMEA), an ERA is required for all new 
marketing authorisation applications for a medicinal product through standardised 
procedure. Vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates and 
lipids are exempted because they are unlikely to result in a significant risk to the 
environment. 
 
According to the guideline on the environmental risk assessment of medicinal products 
for human use (EMEA/CHMP/SWP/4447/00 [2006]), the assessment procedure is a step-
wise, phased procedure, consisting of two phases (see table 3). The first phase (Phase I) 
estimates the exposure of the environment to the pharmaceutical, the second phase (Phase 
II) assesses the fate and potential effects in the environment. 
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In Phase I, the estimation of load into the environment is based on the drug substance, 
irrespective of its route of administration, pharmaceutical form, metabolism and 
excretion. Any substance with a log Kow >4.5 is screened in Phase II regardless of its load 
into the aquatic environment as it has a high bioconcentration factor (BCF) and so is 
likely to exert an effect on aquatic organisms (Cleuvers, 2004). 
 
The predicted environmental concentration (PEC) is calculated for a pharmaceutical 
based on its usage and assumes that the predicted amount used per year is evenly 
distributed over the year and throughout the geographic area, STW effluent is the main 
route of entry, there is no biodegradation and metabolites in the patient are not taken into 
account. The PEC in the surface water (PECsurfacewater) is calculated using the following 
equation: 
 
PECsurfacewater = Maximum daily dose consumed per inhabitant x Percentage of market use 
              Amount of waste per inhabitant per day x dilution factor 
 
If the PECsurfacewater exceeds 10ngL
-1
, the pharmaceutical is required for Phase II 
screening. PEC levels are usually over-estimated, which decreases the likelihood of 
Stage in 
regulatory 
evaluation 
Stage in risk 
assessment 
Objective Method Test/Data requirement 
Phase I Pre-screening Estimation of 
exposure 
Action limit Consumption data, logKow; 
PEC 
Phase II 
Tier A 
Screening Initial prediction of 
risk 
Risk 
assessment 
Base set aquatic toxicology 
and fate; PEC/PNEC 
Phase II 
Tier B 
Extended 
screening 
Substance and 
compartment-
specific refinement 
and risk assessment 
Risk 
assessment 
Extended data set on 
emission, fate and effects 
Table 3. The phased approach in the ERA (taken from EMEA/CHMP/SWP/4447/00). 
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getting false-negative errors in the phase II assessments. Arguably, it is better to have 
more false-positive pharmaceuticals that require further testing than underestimate the 
pharmaceutical loads into the environment (Ferrari et al, 2004). Phase II Tier A assesses 
the fate and effects of a pharmaceutical in the environment according to test protocols 
issued by the European commission, Organisation for economic co-operation and 
development (OECD) or the International organisation for standardisation (ISO). A 
predicted no-effect concentration (PNEC), at which no adverse effect on the aquatic 
environment function is to be expected is calculated by dividing the lowest 50%-effect 
concentration from standard long-term toxicity tests using three aquatic test-species, one 
plant (algal growth inhibition test), one invertebrate (Daphnia reproduction test), and one 
fish vertebrate (fish early life stage test). In addition to standard toxicity tests, data on the 
physical-chemical structural properties, such as quantitative structure-activity 
relationships (QSARs), primary and secondary pharmacodynamics, toxicology, 
metabolism, excretion, degradability and persistence of the drug substance and/or its 
metabolites are also taken into account when calculating the PNEC (Cleuvers, 2004).  A 
risk quotient PEC/PNEC is then calculated. If this ratio equals or exceeds 1, an ecological 
risk is suspected and further evaluation on the fate of the drug and/or its metabolites in 
the aquatic environment is conducted in Phase II Tier B. This ERA represents a marked 
improvement over previous risk assessments, which in the past have determined the 
PNEC of a pharmaceutical using acute toxicity tests only. Chronic toxicity tests are 
arguably more sensitive than acute toxicity tests and are reflective of actual 
environmental concentrations and loads (Webb, 2001).  
 
There are, however, some reservations to this ERA approach. The first is that the ERA 
only examines individual pharmaceutical toxicity. This is not environmentally realistic as 
drugs in the environment are seldom found as single contaminants but instead occur as 
mixtures. There is therefore the potential for pharmaceuticals to behave synergistically 
(the presence of one pharmaceutical enhances the effects of another), antagonistically 
(the presence of one pharmaceutical inhibits the effects of another) or independently (the 
effects of a pharmaceutical are not affected by the presence of another) (Laenge et al, 
2006). At least 50 pharmaceuticals have been detected in the aquatic environment and so 
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there is the potential for complex drug-interactions, which should be evaluated (albeit 
simplistically at first) in the ERA (Cleuvers et al, 2004). Secondly, pharmaceutical tests 
cover only a small set of laboratory organisms, which are not sensitive enough to unravel 
the adverse effects of pharmaceuticals. Furthermore, the physiological endpoints used do 
not necessarily address the pharmaceutical mechanism of action and therefore have 
limited use when trying to extrapolate to different scenarios (Forbes et al, 2006). Thirdly, 
the fish early life stage test examines for mortality over a 10-day period only. 
Considering that the effects of environmentally relevant concentrations of 
ethinyloestradiol have not been measured in any staged fish under a 10-day period 
suggests that its toxicity would probably not have been detected using the current ERA 
physiological endpoints (Sumpter, 2007).  
 
1.7 Emergence and application of “omic” technologies to environmental monitoring 
A biomarker can be defined as a “measurable biological response to a chemical or 
chemicals that gives a measure of exposure, and sometimes, also of toxic effect (Peakall, 
1994). For example in current ERA assessments, the physiological responses of algae, 
daphnia or fish are used as biomarkers of exposure to individual pharmaceuticals. The 
emergence of “omic” techniques has considerably enhanced the potential of subtle, 
mechanism of action-revealing biomarker discovery in the field of environmental 
monitoring. The use of genomics, which is the “study of an organism‟s collection of 
genes in an attempt to describe the functions they perform, the products they create and 
their interaction with one another” (Kuska, 1998; Shugart & Theodorakis, 1998), 
provides considerable advantages over standard physiological biomarkers as it is 
sensitive, provides early detection of response and allows for comparison between 
species (Ankley et al, 2006; Hook et al, 2007). As a result “ecotoxicogenomics”, which is 
defined as “the study of gene and protein expression in non-target organisms in response 
to environmental contaminant exposure”, and combines genomics, proteomics and 
transcriptomics, has emerged (Snape et al, 2004). Several studies have examined the 
response of aquatic organisms to pharmaceutical exposure using an ecotoxicogenomic 
approach, including  measuring changes in gene expression levels to both individual 
(Kohno et al, 2008) and pharmaceutical mixtures (Filby et al, 2007) and measuring 
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changes in steroidal levels, such as cytochrome P450 aromatase activity (Fossi et al, 
2006; Hinfray et al, 2006; Lyssimachou et al, 2006) and plasma sex steroid levels 
(Mauder et al, 2007; Ankley et al, 2008); most of this work has examined for endocrine 
disruption upon exposure to EE2. However, to date, none of these biomarkers have been 
adopted for further ERA use. One of the most recent “omic” techniques to emerge is 
metabolomics. Metabolomics is defined as the quantitative and comprehensive analysis 
of all metabolites in a biological sample (Nicholson & Wilson, 2003). Metabolites are bi-
products of metabolism, which is itself the process of converting food energy into 
mechanical energy or heat. There are around 2,000 to 3,000 different metabolites in the 
human body, compared to an estimated 30,000 genes and 1,000,000 proteins (Schmidt, 
2004). Of the estimated 3,000 metabolites, secondary metabolites and signaling 
molecules, researchers are particularly interested in the small, low-molecular weight 
compounds, such as lipids and sugars and amino acids, which serve as substances and 
products in various metabolic pathways. Metabolomics can therefore be used to 
investigate metabolic regulation in response to environmental stressors or stimuli 
(Nicholson et al, 2002). The metabolome is defined as “the total quantitative collection of 
metabolites present in a cell or organism which participate in metabolic reaction required 
for growth, maintenance and normal function” and represents the final “omic” level in a 
biological system. Therefore, unlike genomics, transcriptomics and proteomics, which 
may only indicate the potential for biochemical change, metabolomics reveals actual 
functional changes in a study organism (Nicholson & Wilson, 2003; Goodacre et al, 
2004). Additionally, there are far fewer metabolites than genes or gene products to be 
studied and, unlike the other aforementioned omics‟, metabolomics does not require a 
sequenced genome for the study organism. Also, the two most widely used metabolomic 
techniques – mass spectrometry (MS) and nuclear magnetic resonance (NMR) – can be 
rapid and highly automated, lending themselves to effective high-throughput analysis 
(Ekman et al, 2008). Accordingly, albeit with some debate, metabolomics has been 
proposed as the “greatest omic” technology (Ryan & Robards, 2006). The use of 
metabolomics for biomarker development has been used extensively within the 
pharmaceutical industry as an effective preclinical screen in drug discovery and also in 
clinical and biomedical studies (Robertson, 2005). For example, metabolomics has been 
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used measures changes in metabolite profiles over time (Nicholson et al, 2002) and it has 
been proposed that by using metabonomics to measure changes in specific blood plasma 
metabolite over time as biomarkers to specific drug treatments, one could personalize 
drug therapy treatment (Clayton et al, 2006). 
 
1.7.1 Use of metabolomics in environmental studies 
Metabolomics has been used in several aquatic environmental toxicology studies 
measuring the response of organisms to natural environmental stressors including 
response of the common carp (Cyprinius carpio), Japanese medaka (Oryzias latipes) and 
killfish (Austrofundulus limnaeus) to hypoxia (Borger et al, 1998; Pinccetich et al, 2005; 
Prodrabsky et al, 2007) and juvenile rainbow trout (Oncorhynchus mykiss) to elevated 
water temperatures (Viant et al, 2003). Additionally, the response of aquatic organisms to 
diseases, such as red abalone (Haliotis rufscens) to the Rickettsiales-like prokaryote 
Candidatus Xenohaliotis californiensis (Rosenblum et al, 2005), have also been 
examined using metabolomics. Metabolomics has also been used to examine for the 
response of aquatic organisms to environmental pollutants including the red abalone and 
the common carp to copper (Viant et al, 2002 and De Boeck et al, 1997, respectively), 
Japanese medaka embryogenesis to trichloroethylene (Viant et al, 2005) and the fathead 
minnow to the fungicide vinclozolin (Ekman et al, 2007).  
 
To date, only a handful of aquatic toxicity studies have used metabolomics to understand 
the subtle responses to pharmaceutical exposure. Samuelsson and colleagues (2006) and 
Ekman and colleagues (2008) both used metabolomics to examine for the effects of EE2 
on the rainbow trout and fathead minnow, respectively. Samuelsson and colleagues 
examined the metabolomic profiles of rainbow trout exposed to 10ngL
-1
 EE2 and were 
able to measure the standard EE2 biomarker vitellogenin, and its metabolites. Ekman and 
colleagues examined the metabolite profiles of male fathead minnows exposed to 10ngL
-1
 
and 100ngL
-1
 EE2 and suggested that there were striking similarities in the metabolite 
profiles between the exposed males and control females. Both studies demonstrated the 
proof-of-principle that metabolomics can be used to identify biomarkers of EE2 exposure. 
However the effects of EE2 are well understood and, in the instance of Samuelsson et al, 
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measuring vitellogenin has been achieved using far cheaper and simpler methods such as 
enzyme-linked immunosorbant assays (ELISAs). As such, further validation studies 
using pharmaceuticals that induce a subtle effect are required to fully appreciate the 
potential advantages metabolomics has to offer. 
 
1.8 Aims and objectives 
The aim of the PhD was to develop an intelligent testing approach to understand 
pharmaceutical toxicity in fish. Using the non-specific β-blocker propranolol and fathead 
minnow as the test pharmaceutical and test species, respectively, the first aim was to 
establish whether the fathead minnow possessed and expressed the β3-AR in fish. A 
previous study had identified the β1- and β2-AR in the fathead minnow (Giltrow, 2008), 
and so by identifying the β3-AR, one completes the picture in terms of understanding β-
AR expression in the fathead minnow. This is particularly important for justifying an in 
vivo exposure assay to propranolol that in humans interacts with all three β-AR subtypes. 
Secondly, the use of metabolomics and Real Time β3-AR expression studies were 
examined for their suitability in identifying sensitive, mechanism of action-revealing 
biomarkers of propranolol exposure, thereby evaluating their potential as suitable 
techniques for environmental monitoring studies. 
 
As part of an EU-collaboration to conduct a risk assessment on β-blockers, propranolol 
was selected as the test-pharmaceutical for this study. Propranolol is the most widely 
used of all β-blockers and is the most highly lipophillic. Therefore, of all the β-blockers, 
it is most likely to induce a toxic effect in an aquatic organism.  The fathead minnow (as 
described in more detail in Section 3.1.3) is a widely used test species for 
ecotoxicological studies and, as such, a robust pair-breeding in vivo assay has been 
developed to examine for effects on survival, reproduction, growth and behaviour. As 
part of the EU risk assessment of β-blcokers, the pair-breeding in vivo assay was used to 
examine the effects of atenolol on the fathead minnow and therefore, to allow for a direct 
comparison to be made between atenolol and propranolol, the same assay was adopted 
for this study. 
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CHAPTER 2: IDENTIFYING THE β3-AR IN THE 
FATHEAD MINNOW 
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2.1 INTRODUCTION 
Traditionally, aquatic-based ecotoxicology tests have investigated the response of an 
organism(s) to a particular compound(s) (e.g. heavy metal, xenobiotic) by examining for, 
and quantifying, anticipated physiological, biological and biochemical changes. The 
medical applications of pharmaceuticals are achieved by binding with specific drug 
targets (e.g. receptor) in a tissue(s) and triggering a cascade of desirable responses. By 
understanding the mechanism of action of a particular pharmaceutical in mammals, one 
can design an ecotoxicological experiment that looks at mechanism of action-related 
responses in a test-species. This approach has been applied in ecotoxicology tests; for 
example previous assessments of beta-blocker exposure to fish have investigated for 
cardiovascular changes in rainbow trout as the heart is one of the principal targets for 
beta-blockers in humans (Larsson et al, 2006; Owen et al, 2007). However, this 
mechanism of action approach has not necessarily been adopted for use prior to 
conducting an in vivo experiment. It can be assumed that for a drug to elicit a response in 
an aquatic organism, the organism in question must express the intended drug target, 
albeit in different tissues. Therefore before running an in vivo pharmaceutical exposure 
procedure, the intended drug-target should be first identified in the test-organism. From 
this, a test-species and mechanism-of-action-specific in vivo exposure procedure can be 
developed, which also has ethically beneficial ramifications.   
 
Before running an in vivo fish exposure to the non-specific β-blocker propranolol, the 
practical aim was to identify whether the fathead minnow expressed the β3-AR target for 
propranolol. Prior to this study Giltrow (2008) identified the β1- and β2-AR in the heart 
and liver tissues of the fathead minnow, respectively, which are the same tissue locations 
as in humans. Therefore, the fathead minnow was likely to possess the β3-AR, which 
would justify conducting an in vivo study. 
 
 2.1.1 The β3-adrenergic receptor structure 
The β3-AR is a single polypeptide chain of up to 366 amino acids with an extracellular 
amino (N) terminus and an intracellular carboxyl (C) terminus and resides embedded in 
the plasma membrane of cells. The membrane bound receptor is coupled to an 
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intracellular guanine nucleotide regulatory protein (G-protein) that, upon ligand binding 
to the receptor, mediates a response (Watson & Arkinstall, 1994). The β3-AR shares a 
similar topological structure to all G-protein coupled receptors (GPCRs) and other 
serpentine receptors as it characteristically spans the lipid bilayer of the cell membrane in 
seven distinct α-helical trans-membrane domains (TMDs); see figure 7. Each TMD 
contains 18-30 hydrophobic amino acids (Lekowitz & Caron, 1988).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All GPCRs serve a similar function in that their role is to bind to a ligand and therefore 
there is considerable sequence homology between them. A series of “fingerprint” amino 
acid residues, or motifs, such as the TMDs, are responsible for the three-dimensional 
structure and functional properties of GPCRs and are conserved in 95-98% of the 
receptors (Schwartz, 1996).  
 
In β3-ARs, the ligand binding site is composed from an arrangement of four of the seven 
TMDs. Noradrenaline, for example, binds to aspartic acid in TMD 3 by the formation of 
 1  2  3  4   5   6   7   membrane 
extracellular 
intracellular 
  NH2 
  COOH 
 IL1 
 IL2 
 IL3 
 EL1 
 EL2 
 EL3 
Figure 7. A schematic representation of a β-AR in a cell membrane showing the external N terminus 
(NH2) and internal C terminus (COOH). IL = intracellular loop; EL = extracellular loop. Figure 
adapted from that documented by Blockaert & Pin (1999). 
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a salt bridge, two serine residues in TMD 5 and a serine residue in TMD 4 via hydrogen 
bonds and a phenylalanine in TMD 6 by van der Waals interactions. Although 
noradrenaline also binds to aspartic acid and tyrosine in TMDs 2 and 7, respectively, this 
is more important for signal transmission to the G-protein than for actual ligand binding 
(Strosberg & Pietri Rouxel, 1996). The arginine residue located at the intracellular pole 
of TMD 3 (seen as part of the „DRY‟ motif) also plays a crucial role in the signal 
transduction process and is the only amino acid that is totally conserved across every 
GPCR (Schwartz in Foreman & Johansen, 1996). 
 
The three-dimensional structure is established via a series of chain folding and bridging 
between amino acid residues, as shown in figure 8 The N-linked glycosylation process, 
although not directly important for ligand binding, is the principle posttranslational 
modification to proteins which, through recognition by specific proteins in the rough 
endoplasmic reticulum, ensures that the protein folds correctly (Schwartz, 1996). The site 
for N-glycosylation in the β3-AR, and all GPCRs, is the asparagine residue in the NH2 
terminal region before TMD 1 (Blin et al, 1993). The disulfide bridge formed between 
the cysteine residues found in the second and third extracellular loops is common to all 
GPCRs and this effectively closes the gap between TMD 3 and TMD 4, which is 
generally considered to be the central column in the seven-helical bundle (Schwartz, 
1996). 
 
Additional motifs necessary for ligand interaction include the conserved proline residues 
located in TMDs 5, 6 and 7. They create weak points in the TMD helices and so it has 
been suggested that they enable the protein receptor wobble to allow ligands and G-
protein subunits to associate and dissociate (Lodish et al, 1995). The interaction between 
the asparagine and arginine residues located in TMDs 2 and 3, respectively, are involved 
in intramolecular signal-transduction and subsequent G-protein signalling (Schwartz, 
1996).
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Figure 8. Structural characteristics of the rhodopsin-like GPCR family. Residues located in the transmembrane helices are shaded in light grey. The 
key fingerprint residues of each helix are highlighted in black: AsnI:18, CysIII:01, ArgIII:26, TrpIV:06, ProV:16, ProVI:15 and ProVII:17. Image 
taken from Schwartz (1996). 
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Two further post-translation events are involved with receptor desensitisation and 
subsequent regulation of G-protein signal transduction. The first is palmitoylation, which 
occurs at the cysteine residue found 15-20 amino acids C-terminally to the TMD 7, 
creating a fourth intracellular loop. Palmitoylation has been shown to mediate adenylyl 
cyclase stimulation by an agonist-bound receptor, possibly by promoting the insertion of 
several adjacent residues in the membrane, thus forming an additional intracellular loop 
which results in an active conformation for G-protein coupling (Strosberg & Pietri-
Rouxel, 1996). The second is phosphorylation, whereby a phosphate group is added to 
amino acid in the presence of protein kinase A, which is regulated by cAMP (Lodish et 
al, 1995; Schwartz in Foreman & Johansen, 1996). Stimulation of GPCRs will therefore 
lead to phosphorylation of the serine and threonine residues in the 3
rd
 intracellular 
cytoplasmic loop (between TMDs 4 and 5) and in the COOH terminal region.  
 
The necessary motifs required for ligand binding, three-dimensional structure 
maintenance and G-protein signal transduction and desensitisation, therefore, should be 
present in a fathead minnow β3-AR. 
 
2.1.2 β-ARs in higher vertebrates 
Beta-adrenergic receptors have been found in many species. Table 4 summarises the list 
of higher vertebrates β-ARs have been found in. Many of the sequences, especially in 
those species that are not commonly used as test models (e.g. the jaguar) have been 
computer-software generated from genomic sequence studies on the national centre for 
biotechnology information (NCBI) database (http://www.ncbi.nlm.gov/entrez/) and have 
not yet been confirmed. One must therefore be cautious when using these sequences for 
further analysis. 
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2.1.3 β-ARs in fish 
Table 5 details the β-ARs found in fish. However, only four β-ARs have actually been 
confirmed in the laboratory. The trout β2- and β3-ARs (highlighted in red) were identified 
by Nickerson et al in 2001 and 2003, respectively. The black bullhead β2- and β3b-ARs 
were identified by Dugan et al in 2008, however these sequences have not yet been 
Mammal Latin name β–AR subtype Accession numbers 
Brown rat Rattus norvegicus β1, β2, β3 NM_012701; NM_012492; NM_03108 
Cattle Bos taurus β1, β2, β3 NM_194266; NM_174231; NM_174232 
Chimpanzee Pan troglodytes β2, β3 XM_521608; Q28509; AAB53939.1 
Cotton top tamarin Saguinus oedipus β2, β3 AY091938; AY091947 
Dog Canis familiaris β1, β2, β3 NM_001008713; NM_001003234; 
NM_001003377 
Domestic cat Felius catus β1, β2, β3 AF192344; NM_001009247; Q9TST4 
Goat Capra hircus β3 AAD26148 
Golden hamster Mesocricetus auratus β1 X03804 
Gorilla Gorilla gorilla β2, β3 AY091936; AY091945 
Grey short tailed 
possum  
Mododelphis 
domestica 
β2 XM_001380743 
Human Homo sapiens β1, β2, β3 NM_000684; AAB82149; AAA35550 
Jaguar Panthera onca β2 AY011308 
Mouse Mus musculus β1, β2, β3 NM_007419;  NM_007420; AAI32001 
Pig Sus scrofa β1, β2, β3 NM_00112307; NM_001128436; 
Q95252 
Rhesus monkey Macaca mulatta β1, β2, β3 X75540.1; NM_001042774; Q28524 
Sheep Ovis aries β1, β2, β3 AF072433; NM_001130154;  
NP_0011532929 
Turkey Meleagris gallopavo β1 U14958 
Table 4. Summary of β-ARs found in non-fish species. Sequences found using a blast search on the NCBI 
database.  
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registered on the NCBI database. The remaining sequences were all predicted from NCBI 
computational analysis. Interestingly, two subtypes of the β3-AR were identified in the 
trout. Both sequences were analogous to the human β3-AR, however they were expressed 
in different tissues (β3a predominantly in the heart and gill, whilst β3b predominantly in 
the blood) and were only 84% identical, and so were considered to be two different 
subtypes.  
 
 
 
 
 
Interestingly a putative β4C-AR was identified in the Atlantic salmon (highlighted in 
blue). It has been suggested that a β4-AR is expressed in the human atrium (Molenaar et 
al, 1997) and that there is considerable sequence homology, and resultant receptor 
activity, between the β3-AR and β4-AR. Furthermore, it has been demonstrated that a β3-
Fish species Latin name β-AR subtype Accession numbers 
Zebrafish Danio rerio β1, β2, β3bi, β3bii NM_001128689; XP_700720; 
NW_001513985; NW_001513970 
Rainbow trout Oncorhynchus 
mykiss 
β2, β3a, β3b AAK94672.1; AY216465; AY216466 
Tiger puffer fish Takifugu rubripes β2, β3 http://ensembl.fugu-sg.org 
AAQ02695.1; CAG42650.1 
Spotted green 
puffer fish 
Tetraodon 
nigroviridis 
β2, β3 http://ensembl.fugu-sg.org 
CAG10129.1; CAG12607.1 
Three-spined 
Stickleback 
Gasterosteus 
aculeatus 
β1 http:pre.ensembl.org/Gaserosteus_a
culeatus/Info/Index 
IPR000507 
Hagfish Myxine glutinosa β2 CAA06539.1 
Marine lamprey Petromyzon marinus β1 EB084301 
Black bullhead Ameiru melas β2, β3b Not registered 
Catfish Ictalurus punctatus β2 AF127775 
Atlantic salmon Salmo salar β4C NM_001140454 
Table 5. Summary of β-ARs found in fish. Rainbow trout sequences highlighted in red as they are the only 
sequences to be confirmed in the laboratory. The Atlantic salmon was the only fish species to have a predicted β4-
AR sequence and is highlighted in blue. Accession numbers collected from NCBI database, unless stated. 
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AR agonist initiated the same cardiostimulant effect observed in mice lacking a 
functional β3-AR gene (β3-AR knockout) as wild-type mice, thus supporting the notion 
that a β4-AR is expressed in atrial tissues (Kaumann et al, 1997). Therefore it is possible 
for any species belonging to the vertebrate lineage to express a β4-AR. The Atlantic 
salmon β4C-AR was 90% and 97% similar to the trout β3a- and β3b-ARs, respectively, 
suggesting that either the receptor is a β4C-AR, or that with such a close similarity score, a 
β3b-AR. There are contradictory reports about the existence of a β4-AR in humans, and it 
has been suggested that the β4-AR is a β1-AR derivative (Konkar et al, 2000). Therefore 
the Atlantic salmon β4-AR could in fact be a β1-AR, and therefore the trout β3b-AR could 
also be a β1-AR derivative (the β1-AR has not yet been identified in the trout). There are 
still considerable gaps in knowledge regarding sequence information for all fish species. 
 
The two zebrafish beta β3b-AR sequences seem to be the most suitable starting templates 
for designing primers to find the β3-AR in the fathead minnow as both fish species belong 
to the same Cyprinidae family and consequently sequence homology is likely to be 
highest between these fish. However, as demonstrated above, there are considerable 
difficulties involved with using sequences that firstly have not been confirmed and 
secondly may not have been labelled correctly. One must therefore use these sequences 
conservatively and with a degree of caution. 
 
2.1.4 Aim 
As a suitable first testing stage for an intelligent-testing protocol, the aim of the study was 
to establish whether the fathead minnow expresses the β3-AR before starting a fathead 
minnow pair-breeding assay exposure to the non-specific β-blocker propranolol. 
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2.2 METHODOLOGY 
 
2.2.1 Tissue acquisition 
The fathead minnow (Pimephales promelas) and the zebrafish (Danio rerio) (figure 9 
were both selected as test species for experimental procedures. Tissue acquisition, and 
subsequent genomic deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) isolation, 
from both species was thus conducted in the same manner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prior to any dissection work, all work surfaces and equipment were cleaned with 100% 
industrial methylated spirit (IMS) (Fisher Scientific, Cat # M/4400/25) and RNase away 
(Molecular Bioproducts, Cat # 7000) to ensure complete removal of any potential RNA 
contamination. Additionally, all microcentrifuge tubes were autoclave sterilised to 
remove any contaminants. All fish were culled via anaesthetisation with 100mgL
-1
 Ethyl 
3-aminobenzoate methanesulfonate salt (MS-222) (Sigma, Cat # A5040) buffered with 
200mgL
-1
 NaHCO3. Individual fish were checked for complete anaesthetisation by 
rolling them onto on side and observing no fin movement and balancing response. The 
Figure 9. Adult male fathead minnow (A) and adult male zebrafish (B). 
Images taken from www.mblaquaculture.com/content/organisms/pime and 
www.focusonnature.be/gallery/zebraifsh, respectively. 
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fish were subsequently blotted dry and killed by lobotomy. The caudal tail was firstly 
removed and blood collected in a heparinised micro capillary tube and emptied into a pre-
weighed microcentrifuge tube. The microcentrifuge tube was subsequently centrifuged at 
12,000 x g for 10 minutes at 4
o
C and the upper blood plasma layer removed. The 
remaining whole red blood cell samples from each male within the same species were 
pooled together to increase the likelihood of extracting sufficient quantities of RNA and 
snap frozen in liquid nitrogen. The hearts, livers, brains, adipose tissues, gonads and gills 
were quickly dissected, transferred into individual clean microcentrifuge tubes and snap 
frozen in liquid nitrogen. All microcentrifuge tubes were subsequently stored at -80
o
C to 
reduce RNA degradation. To minimise the risk of RNA contamination between different 
tissues belonging to the same fish and also individual fish, all dissecting equipment was 
wiped down with RNase away in between removing individual tissue samples. 
 
2.2.2 Preparation for PCR and subsequent cloning work 
For all molecular-based experimental work, including cloning, all procedures were 
conducted under strict sterile conditions. All work surfaces, including pipettes, were 
wiped down with 70% IMS and RNase away. Gloves were worn. All pipette tips and 
microcentrifuge tubes were autoclave sterilised prior to use. 
 
The principal technique for rapid gene identification is polymerase chain reaction (PCR) 
(as described in section 2.2.8) and the starting material required is either genomic DNA 
or RNA. 
 
2.2.3 Genomic DNA isolation from tissues 
Prior to examining whether fathead minnow tissues expressed the β3-AR, it was deemed 
more useful to determine whether the fathead minnow possessed the β3-AR at the 
genomic level, thereby removing the variable of tissue choice and life-cycle stage. For 
example, it was possible to begin examining for β3-AR expression in a tissue that does 
not express it or examine for expression in selected tissues from a particular aged fish, for 
example an adult, that no longer expressed the β3-AR because the functioning purpose of 
it in the fathead minnow was during early fry development. Genomic DNA was therefore 
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extracted from both the fathead minnow and the zebrafish (which served as a positive 
control for the zebrafish-template designed primers) tissues. Genomic DNA was 
extracted directly from tissues using the „DNeasy purification of total DNA from animal 
tissues‟ (QIAGEN; 69504). An individual tissue sample (up to 25mg) was removed from 
the -80
o
C freezer and placed on ice to slowly thaw. 360µl of a lysis buffer
*
 and 20µl 
proteinase K was added and subsequently mixed thoroughly by vortexing and then 
incubated at 56
o
C for 3 hours to allow for complete lysis. Proteinase K is an endolytic 
proteinase that is used to digest proteins and rapidly inactivate nucleases that might 
otherwise degrade the DNA or RNA during purification. To ensure the genomic DNA 
was RNA-free, 4µl RNase A (100mgL
-1
) was added and the sample was vortexed for 15 
seconds. 200µl of a second lysis buffer (and 200µl ethanol (100%)) were added to the 
sample in successive fashion, with the sample mixed by vortexing after adding each 
reagent. The mixture was subsequently pipetted into a 2ml DNeasy mini spin column and 
centrifuged at 8,000 x g for 1 minute at room temperature. The genomic DNA selectively 
bound to the spin column membrane. The flow-through was thus discarded and the 
DNeasy mini spin column containing the membrane-bound genomic DNA was placed in 
a new 2ml microcentrifuge collection tube. The remaining contaminants and enzymes 
were removed by adding 500µl of two individual wash buffers; centrifuging the sample at 
17,900 x g for 3 minutes at room temperature in between the addition of each buffer. The 
DNeasy spin column with contaminant-free genomic-bound DNA was then placed into 
another clean 2ml microcentrifuge tube and 200ul of an elution buffer was pipetted 
directly onto the spin-column membrane and incubated at room temperature for 1min. 
During the incubation period, the genomic DNA was released from the membrane. The 
spin-column was subsequently centrifuged at 17,900 x g for 1 minute at room 
temperature to elute the genomic DNA. The 200µl purified genomic DNA was 
consequently stored at -20
o
C until required for a PCR reaction. 
 
To measure the quantity and quality of isolated genomic DNA, 1.5µl of sample was 
analysed on a Nanodrop N-1000 spectrophotometer (Fisher Scientific, Loughborough) 
against a blank reading of 1.5 µl dH2O water.  This same procedure was used to examine 
isolated RNA, mRNA, cDNA and cloned cDNA.  
* Note, unless stated, all buffers belonged to a particular kit(s) and due to trade secrecy it was not possible to ascertain buffer 
ingredients. 
 45 
2.2.4 Direct mRNA isolation from tissues 
Of the four types of RNA (messenger RNA, transfer RNA, ribosomal RNA and micro 
RNA), it is messenger RNA (mRNA) that carries the coding information obtained from 
DNA during transcription and which is used for translating information into proteins 
(Weaver, 2002) and therefore is considered most useful for examining receptor 
expression. It is possible to examine total RNA for receptor expression, however for 
optimal sensitivity it is recommended to use mRNA (Sambrook & Russell, 2006). 
Messenger RNA, however, makes up only 1-5% of total RNA and is therefore difficult to 
obtain in sufficient quantities. Moreover, it usually requires a two-step procedure to 
firstly isolate total RNA and secondly isolate mRNA, and so there is the potential for a 
poor yield of mRNA. Advances in scientific technology meant that it was possible to 
directly isolate mRNA from fish tissues using a GenElute direct mRNA miniprep kit 
(Sigma; Cat # DMN10). An individual tissue sample (up to 25mg) was removed from the 
-80
o
C freezer and immediately placed on ice. Once thawed, 1ml of lysis solution 
containing proteinase K was added to the sample. The sample mix was subsequently 
homogenised until no visible tissue pieces were visible. The mix was then incubated at 
65
o
C for 10 minutes to allow for complete degradation of nucleases and other proteins. 
Subsequetly, the mixture was removed from the heat and, to facilitate mRNA bead-
binding, 64µl of 5M NaCl was added to the digested tissue lysate. Prior to addition to the 
sample mix, the oligo dT beads were thoroughly vortexed to ensure complete 
resuspension in buffer and, following on from this, 25µl of the resuspended oligo dT 
bead mix was added to the sample mix. The mix was vortexed thoroughly and 
subsequently incubated at room temperature for 10 minutes. During this incubation the 
poly(A) tails of the mRNA hybridised with the oligo dT on the beads. The bead-mRNA 
complex was collected in the form of a pellet via centrifugation at 17,900 x g for 5 
minutes at room temperature. The DNA and protein-containing supernatant was carefully 
removed and discarded, leaving behind the pellet. To get a more highly enriched mRNA 
preparation, the bound mRNA material was released from the beads into a fresh lysis 
solution and then rebound to the same beads. This incorporation of re-binding helped to 
remove any unwanted material that may have been pelleted. To achieve this, 0.5ml of 
lysis solution and 32µl of 5M sodium chloride solution was added to the pellet and 
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vortexed thoroughly to resuspend the pellet. The mixture was subsequently incubated at 
65
o
C for 5 minutes and then incubated at room temperature for 5 minutes. The 
supernatant was subsequently removed leaving behind a more highly enriched mRNA-
bead complex. The pellet was subsequently washed in 350µl of a high salt wash solution. 
The pellet-wash solution mixture was transferred into a spin filter-collection tube and 
centrifuged at 17,900 x g for 2 minutes at room temperature. The flow-through was 
disregarded, whilst the spin filter that contained the mRNA-bead complex was washed a 
further 2 times in 350µl of a low salt wash solution, each time the flow through was 
disregarded. The spin filter was transferred into a fresh, sterile collection microcentrifuge 
tube and 50µl of pre-heated (65
o
C) elution buffer was pipetted onto the filter surface, 
ensuring that contact was made between the elution buffer and the mRNA-bead complex. 
The mix was subsequently incubated at 65
o
C for 2 minutes before centrifugation at 
17,900 x g for 2 minutes at room temperature. The mRNA-containing flow-through was 
subsequently collected and stored at -80
o
C. 
 
2.2.5 Total RNA isolation from fathead minnow blood 
Nickerson et al (2003) documented that the β3-AR was expressed in rainbow trout 
(Oncorhynchus mykiss) whole blood cells. It was therefore important to examine whether 
the fathead minnow also expressed the β3-AR in whole blood cells. It was not possible, 
however, to use the GenElute direct mRNA miniprep kit to directly extract mRNA from 
fathead minnow whole blood cells and an alternative quick-step method was not 
available. Therefore, total RNA was firstly extracted using the two-step Tri reagent for 
blood derivatives protocol (Sigma; Cat # T3809) and this was followed by the mRNA 
isolation procedure. The Tri reagent method is an improvement on the single step method 
for total RNA extraction reported by Chomczynski and Sacchi (1987). The whole red cell 
samples were thawed slowly on ice. Once thawed, 0.75ml of tri reagent, supplemented 
with 20µl of 5N acetic acid was added to the whole red plasma sample and mixed via 
shaking. To ensure complete dissociation of nuclear protein complexes, the sample was 
incubated at room temperature for 5 minutes. Following that, 0.2ml chloroform was 
added and the sample was shaken vigorously for 15 seconds and incubated for 3 minutes 
at room temperature. The mixture was subsequently centrifuged at 17,900 x g for 15 
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minutes at 4
o
C. The centrifugation procedure separated the mixture into 3 layers; the 
lower red organic phase (containing protein), the interphase (containing DNA) and the 
colourless upper aqueous phase (containing RNA). 
 
The colourless RNA layer was carefully transferred into a clean microcentrifuge tube via 
pipetting and 0.5ml isopropanol was added and then the sample mixed and incubated for 
10 minutes at room temperature. The sample was then centrifuged at 17,900 x g for 8 
minutes at room temperature, which produced a precipitated RNA pellet. The supernatant 
was removed and the pellet washed with 1ml 75% ethanol (prepared in-house from 99% 
ethanol; Fisher Scientific, Cat # A405P-4) via vortexing followed by centrifugation at 
17,500 x g for 5 minutes at room temperature. The ethanol was subsequently removed 
and the pellet air-dried for 10mins. Finally, the pellet was solubilised in 20µl double-
distilled water (dH2O). The purified RNA sample was stored at -80
o
C. 
 
In addition to examining the RNA quantity and quality by Nanodrop, 1-2μg of RNA in 
9µl of dH2O with 2 μl of loading buffer was also examined on a 1.2% agarose gel for any 
signs of DNA contamination and/or RNA degradation. The gel was run for 45 minutes at 
80volts against a 1Kb DNA ladder (Helena Bioscience, Cat # N3232) (see section 2.2.9 
for further details). 
 
2.2.6 Isolation of poly A
+
 mRNA from total RNA 
Following total RNA isolation, red blood cell mRNA was isolated using the Oligotex 
mini mRNA isolation kit (QIAGEN; Cat # 72022). This protocol works on the principle 
of binding the poly A
+ 
tails of the mRNA to oligo dT-coated polystyrene-latex particles, 
thus dissociating them from total RNA and finally eluting the captured mRNA. A total 
RNA sample (20μl) was first thawed slowly on ice as to minimise RNA degradation. The 
total RNA sample was pipetted into an RNase-free 1.5ml microcentrifuge tube and the 
volume was adjusted to 250µl with diethylpyrocarbonate (DEPC) water. 250µl of 
digestion buffer and 15µl of Oligotex suspension, both of which had been pre-heated to 
37
o
C, were pipetted into the microcentrifuge tube. The contents were thoroughly mixed 
by reverse pipetting. The mixture was subsequently incubated for 3 minutes at 70
o
C in a 
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water bath. After removal from the water bath, the sample was stored for 10 minutes at 
20
o
C. The mixture was pelleted by centrifugation at 17,900 x g for 2 minutes at room 
temperature and the supernatant was removed. The pellet was re-suspended in 400µl of a 
wash buffer and transferred into a small spin column within a microcentrifuge tube. The 
sample was then centrifuged at 17,900 x g for 1 minute room temperature. The spin 
column was transferred to a new RNase-free 1.5ml microcentrifuge tube and a further 
400µl of a second wash buffer was added to the column. The flow through was discarded. 
The column was again centrifuged at 17,900 x g for 1 minute at room temperature and 
the flow-through was again discarded. The spin column was again transferred to a new 
RNase-free 1.5ml microcentrifuge tube. 20µl of a hot elution buffer (heated to 70
o
C) was 
added to the spin column and reverse pipetted to resuspend the poly A
+
 mRNA. The 
column was again centrifuged at 17, 900 x g for 1 minute at room temperature. The flow-
through contained the poly A
+
 mRNA and was thus kept. To maximise yield of mRNA, a 
further 20µl of hot elution buffer was added to the spin column, centrifuged and mRNA 
collected. The mRNA samples were stored at -20
o
C until required for synthesis of first-
strand copy DNA (cDNA). At this stage, there was suitable mRNA from several fathead 
minnow tissues. 
 
2.2.7 Generation of complementary DNA by reverse transcription 
Complementary cDNA was created from the isolated mRNA using the SuperScript III 
First-Strand synthesis system for reverse transcription-PCR kit (Invitrogen, Cat # 18080-
051). In a single 0.5ml microcentrifuge tube, 1µl of 50µM oligo(dT)20 primer, 1µl of 
10mM deoxyribonucleotide triphosphate (dNTP) mix and 8µl of mRNA (up to 5μg) 
sample were combined together, the mixture briefly centrifuged, and incubated at 65
o
C 
for 5 minutes and then placed on ice for 1 minute. This step annealed the oligo(dT)20 
primer to the mRNA. Following on from that, 2µl of 10 x RT buffer, 4µl of 25mM 
MgCl2, 2µl of 0.1M DTT, 1µl of RNaseOUT
TM
 (40 U/µl) and 1µl of SuperScript
TM
 III 
RT (200 U/µl) was added, mixed by reverse pipetting and then briefly centrifuged at 
17,900 x g. The mixture was subsequently incubated at 50
o
C for 50 minutes to create the 
cDNA product. The reaction was terminated by incubation at 85
o
C for 5 minutes and the 
mixture was then chilled on ice for approximately 2mins. Residual RNA was removed by 
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adding 1µl of RNase H (2 U/µl) to the reaction and incubating it at 37
o
C for 20 minutes. 
The newly-created cDNA was stored at -20
o
C until required for a PCR reaction. 
 
2.2.8 Polymerase Chain Reaction (PCR) 
The polymerase chain reaction (PCR) is an in vitro technique which allows the 
amplification of a specific DNA sequence in a complex mixture where the ends of the 
sequence are known. Primers, which are designed to complement the DNA region of 
interest, bind to the DNA and are extended by the enzyme DNA polymerase in the 
presence of dNTPs. Under optimum conditions, this reaction synthesises a new 
complementary DNA strand. Over the course of 30-40 cycles, the quantity of desired 
DNA increases exponentially, as shown in figure 10 (Newton & Graham, 1994). The 
PCR is a robust, relatively cheap, sensitive and easy to use technique and, as such, has 
been utilised in many ecotoxicological studies examining the effects of pharmaceutical 
pollutants including the fathead minnow (Halm et al, 2002; Zerulla et al, 2002; Miracle et 
al, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Overview of PCR reaction. Figure adapted from Vierstraete (1999).   
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2.2.8.1 Factors affecting PCR 
There are several factors that can influence a PCR reaction and resultant success: 
 
1. Primers 
 
Primer designing 
 
Template sequences 
The only published data on putative fish β3-ARs was that by Nickerson et al (2003) who 
identified two probable β3-AR‟s in the rainbow trout (Oncorhynchus mykiss) as β3a- and 
3b-AR. Additionally, using the NCBI database engine, two β3b-AR sequences were found 
in the zebrafish. The zebrafish belongs to the same Cyprinidae family as the fathead 
minnow (Linnaeus, 1758) and so the likelihood of sequence conservation between the 
two species was higher than between the fathead minnow and the rainbow trout. 
However, the zebrafish β3-AR sequences were computer-software generated and had not 
been supported by laboratory findings. Therefore, in addition to using the published 
primers by Nickerson et al (2003), the two zebrafish β3b-AR sequences, which for the 
ease of designing primers for this project were named β3bi-AR and β3bii-AR, were used as 
templates for designing primers. Table 6 summarises the primer sets successfully used to 
isolate the β3-adrenergic receptor in the fathead minnow. 
 
Primer conditions 
All primers were between 16 and 30 nucleotides long and were ordered from Sigma 
Genosys (http://orders.sigma-genosys.eu.com) and dissolved with Milliq water to a 
concentration of 100μM. Each primer had a guanine and cytosine (G and C) content of 
40-60% and, in most cases, had a guanine or cytosine nucleotide at the 3‟ end. Guanine 
and cytosine bind to each other using 3 covalent bonds, which make a stronger link 
compared to the link between adenine and thymine, which only uses 2 covalent bonds. As 
such, a high GC content and a 3‟end guanine or cytosine nucleotide strengthened the 
bond between DNA template and primer, thus assisting with the amplification process. 
DNA Taq polymerase has a melting point of 72
o
C, therefore each primer pair was 
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designed to have a melting point between 58-68
o
C; the higher the melting point, the more 
specific the binding between primer and DNA template and the less likelihood of a 
primer binding non-specifically. If the annealing temperature was too low, the primer 
could bind non-specifically to undesired regions of DNA producing unwanted PCR 
products. Each primer pair was designed to have a similar, if not the same, melting point; 
these were calculated using the oligo-calculator on the Sigma Genosys website 
(www.sigmaaldrich.com/life-science/custom-oligos.html). To improve the likelihood of 
isolating the desired sequence, nested primers were also used. These were primers 
designed to the same DNA template as the initial primers but were „inside‟ of the first 
pair and therefore they were used in a second PCR reaction to further amplify the product 
obtained from the first PCR and minimize the profile of any non-specific products 
amplified in the first round.  
 
In addition to optimizing the PCR temperature conditions, the risk of primers binding 
non-specifically, either to themselves producing primer dimmers or to other regions of 
DNA, was minimized by first examining the likelihood of that happening using 
programmes such as http://frodo.wi.mit.edu/ and 
www.basic.northwestern.edu/biotools/oligocalc.html.  A primer was re-designed if it had 
the potential for binding non-specifically. 
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Primer 
name 
β3bi-AR 
5’ - 3’  
β3bii-AR 
5’ - 3’  
Annealing 
Temp 
(
o
C) 
Round 1 
forward 
reverse 
 
GTAACCTCCTGGTCATCATTG 
GTAGATGATAGGGTTGAGTCC 
 
GCGTTGGTCATCTTCTTGACG 
GCGTAGATGATTGGGTTCAG 
 
62 
Nested 
round 2 
forward 
reverse 
 
 
CCTCCAGCTGCAGACTAC 
GCCTAACCAGTTTAAGAGACG 
 
 
CTCTCCTCCACACCACCAC 
CGTAGCCCAGCCAGTTCAAC 
 
 
62 
Nested 
round 3 
Forward 
reverse 
 
 
GCCAGCATAGAGACTCTATG 
GCGTAGATGATGTTCGCCAC 
 
 
CGCTAGCATTGAGACATTGTG 
GCCAACAGAGACTGAAGATG 
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2. DNA polymerase enzyme 
Several DNA polymerase enzyme kits are available, all with varying levels of accuracy. 
Platinum Taq DNA polymerase high fidelity (Invitrogen, Cat # 11304-011) was used. 
This was an enzyme mixture composed of two DNA Taq polymerases which improved 
both the accuracy and efficiency of the PCR reaction.  
 
3. Temperature 
The entire PCR reaction relies upon several stages of temperature. Initially the 
temperature must be between 95
o
C and 100
o
C for the denaturation of template DNA, 
whilst from the second cycle onwards it is sufficient for the temperature to be between 92 
and 95 ºC. Denaturation temperatures are unlikely to be changed. The annealing 
temperature of the primer to the DNA strand is particularly crucial and specific to each 
primer. The optimum temperature for primer extension was 72
o
C. 
 
Table 6. Primer sets used to isolate the β3bi- and β3bii-ARs in the fathead minnow. 
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4. Number of cycles 
As standard, the number of PCR cycles ranges from 25 – 35 cycles. As the number of 
cycles exceeds 30, the amount of DNA Taq polymerase enzyme in the reaction tube 
becomes limited. This in turn limits the efficiency of the PCR reaction. Figure 11 outlines 
a typical PCR thermal cyclic programme used for this project.  
 
 
 
 
 
 
 
 
 
 
 
 
5. Quantities of additional PCR components 
A specific buffer is used to complement the specific DNA Taq polymerase enzyme, 
which further improves the efficiency of the enzyme. Additionally, magnesium sulphate 
(MgSO4) is required to form a soluble complex with dNTPs to allow them to be 
incorporated into the extending strand.  Hence the concentration of MgSO4 and dNTP, 
and their corresponding ratio, in the final reaction mix was of paramount importance and 
can dramatically affect the yield of PCR reactions; insufficient MgSO4 results in a low 
yield of PCR product; too much MgSO4 can produce high levels of non-specific products. 
Table 7 summarises quantities, and resultant final concentrations, of components used in 
the PCR first and nested rounds. The only difference between the first round PCR and a 
nested round was the quantity of added DNA template. Only 0.5µl of DNA template was 
added to the nested PCR reaction as the quantity of DNA was significantly higher than in 
the first round as it was the product of exponential amplification from the 1
st
 PCR round. 
 
30 cycles 1 cycle 1 cycle 
Holding 
temperature 
Denaturation Elongation Amplification 
72.0
o
C 
10.0mins 
95.0
o
C 
  2.0mins 30s 
30s 15.0
o
C 
95.0
o
C 
     oC 
72.0
o
C 
30s 
    ∞ 
 
Figure 11. PCR protocol.  indicates temperature specific to GSP.  
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2.2.9 Gel electrophoresis 
To visualise the PCR reaction, and determine whether a product had been generated, each 
PCR reaction mixture was run on an agarose gel via electrophoresis. The principle of gel 
electrophoresis, in brief, is that DNA formed during the PCR reaction is negatively 
charged. When added to an agarose gel matrix and exposed to an electrical current, DNA 
products migrate towards the positive anode; smaller products will move further and 
faster than large products, thereby separating DNA according to product size in a series 
of bands. A DNA ladder was used as a means of indicating the size of DNA bands. 
Visualisation was achieved by subsequent ultraviolet (UV) illumination of the gel 
(Sambrook & Russell, 2006). Expected correct band size was estimated at the primer-
designing stage.  
Component 1
st
 Round 
PCR 
Final 
concentration 
Nested rounds 
PCR  
Final 
concentration 
10 x high fidelity 
PCR Buffer 
2.5μl 1 x 2.5μl 1 x 
10 mM dNTP 
mixture 
0.5μl 0.2mM 0.5μl 0.2mM 
50mM MgSO4  1μl 2mM 1μl 2mM 
Forward primer 0.5μl 0.4μM 0.5μl 0.4μM 
Reverse primer 0.5μl 0.4μM 0.5μl 0.4μM 
Platinum Taq high 
fidelity 
0.25μl 1.0 unit 0.25μl 1.0 unit 
Sample 2.5μl genomic 
DNA or 
cDNA 
 0.5μl PCR 
product from 
previous round 
 
Double distilled 
water 
To 25μl not applicable To 25μl not applicable 
Table 7. Quantities and respective final concentrations of components added to a standard first round and 
nested PCR reaction. 
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The gel was made by adding 1.2g of certified biological agarose (Bio-Rad, Cat # 163-
2111) with 100ml, 1 x Tris borate ethylenediaminetetraacetic acid (EDTA) (TBE) buffer 
(see appendix 1) in a 250ml conical flask, producing a 1.2% gel. The mixture was heated 
in a microwave for approximately 2.5 minutes until boiling point. The conical flask was 
shaken and reheated in the microwave to ensure the agarose powder had fully dissolved 
in the buffer. Once cooled, 5μl of ethidium bromide (Sigma, E1510) was added to the 
flask and the solution mixed by swirling. Ethidium bromide stains DNA under U/V 
conditions.  The gel was poured into a plastic mould that had been taped at either end 
with autoclave tape. The comb, used to create wells for the PCR product samples, was 
inserted 1 cm from the top edge.  The gel was left to cool and solidify for 30 - 45 
minutes. The gel-loading buffer was prepared by adding 750μl 40% Ficol (Fisher 
Scientific, Cat # 26873-85-8), 100μl 10 x TBE, 150μl dH2O and 8μl 0.1% xylene cyanol 
(Sigma, Cat # 220-167-5). 2.5µl of gel-loading buffer was added to 20µl of sample. The 
gel-loading buffer gives both colour and weight to a sample, thus aiding in loading the 
sample into the gel and ensures the sample does not dissipate out of the well. Once each 
sample had been loaded into the gel, a 1Kb DNA ladder (Helena Bioscience, Cat # 
N3232) was loaded. The gel was then run for 45 minutes at 80 volts. The gel was then 
examined under UV and a photograph taken. 
 
2.2.10 Cutting and gel-extraction of PCR product 
Upon examination, if a band of the correct size was observed, it was excised from the gel 
under UV light using a clean, sharp scalpel (Swan-Morton, Sheffield) and transferred to a 
clean 2.0ml microcentrifuge tube. UV rapidly breaks-down DNA and so this process was 
conducted quickly. The gel slice was weighed and the DNA extracted from the gel 
according to the protocol from the MinElute gel extraction kit (Qiagen, Cat # 28604). 
Firstly, the gel slice was weighed and three volumes of digestion buffer were added to 1 
volume of gel. The mixture was then incubated at 50
o
C for 10 minutes to ensure the gel 
had been completely dissolved. One gel volume of isopropanol was added to the sample 
and mixed by inverting the tube several times. The mixture was then transferred to a 
MinElute column inside a 2ml collection tube, which was centrifuged at 17,900 x g for 1 
minute at room temperature. The flow-through was discarded and 500µl of a wash buffer 
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was added to the spin column, which was centrifuged at 17,900 x g for 1 minute at room 
temperature. The flow through was again discarded and 750µl of a second wash buffer 
was added to the spin column, which was left for 3.5 minutes and centrifuged at 17,900 x 
g for 1 minute at room temperature. The flow through was disregarded and the spin 
column was centrifuged for an additional minute. The MinElute column was placed into a 
clean microcentrifuge tube. 10µl of sterile dH2O was added to the spin column, which 
was centrifuged at 17,900 for 1 minute at room temperature. The eluate that contained the 
DNA was collected, quantified and stored at -20
o
C to await either cloning or sequencing 
preparation. 
 
2.2.11 Recombinant DNA cloning 
One problem of using PCR is that a DNA band of the correct size may actually be 
comprised of several DNA bands, all of which have the same size. This is particularly 
problematic when examining for an unknown DNA sequence with primers that may not 
be specific to the sequence. Recombinant DNA cloning presents an additional method of 
separating and identifying all potential DNA sequences that may be found within a single 
DNA band of interest and subsequently amplifying the desired DNA product. The 
process of recombinant DNA cloning is divided into two principal stages. The first stage 
is ligation; the DNA product is inserted into a bacterial plasmid vector. The second stage 
is transformation, where the plasmid is inserted into a suitable bacterial host cell and 
subsequently grown on agar plates to amplify the desired DNA product (Watson et al, 
1992).  
 
2.2.11.1 Ligation 
The DNA formed during a PCR reaction has single adenine residues formed at either end, 
which is referred to as a “sticky end” as it allows for insertion into a plasmid vector that 
have a uracil overhang. Only a single DNA product can be inserted into a plasmid vector, 
thus separating different DNA products of the same size. Ligation was achieved using the 
PCR cloning kit (Qiagen, Cat # 231222). 4μl of extracted DNA solution was added to 1μl 
pDrive cloning vector (50ng/μl) and 5μl 2 x ligation master mix.  The solution was made 
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up to 10μl with distilled water and incubated for 2 hours at 15oC in an incubator. During 
this incubation time, the adenine (5‟ end) and uracil (3‟ end) residues in the DNA product  
and cloning vector, respectively, hybridized together to produce a complete plasmid (see 
figure 12). In addition to the region where exogenous DNA fragments can be inserted, 
there is also, importantly, a drug-resistant gene present in the plasmid which confers 
resistance to the antibacterial compound ampicillin. The drug-resistance offers a 
screening process so that only cells with the inserted plasmid can colonise on ampicillin-
containing agar and reduces that risk of bacterial contamination. 
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1 
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2 
2 
Figure 12. Schematic representation of ligation procedure with insertion of DNA PCR 
product. Green boxes 1 and 2 represent the promoter genes SP6 and M13R, respectively. A 
hydrogen bond was formed between the adenine and uracil nucleotide bases at either end of 
the PCR product. 
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2.2.11.2 Transformation 
Immediately following the ligation incubation period, 2µl of the ligation mix was added 
to quickly thawed QIAGEN EZ Competent cells (Qiagen, Cat # 231222) and left on ice 
for 5 minutes.  The cell mixture was then heat shocked for 30 seconds at 42 ºC and 
returned immediately to ice.  250μl of room temperature super optimum broth with 
catabolite repression (SOC) medium was added, briefly mixed by reverse pipetting and 
spread over 4 agar plates using a sterilised glass spreader.  The agar plates were made of 
100 ml agar (see appendix 2), 100μl ampicillin, 192μl Xgal and 50μl Isopropyl β-D-1-
thiogalactopyranoside (IPTG). Ampicillin provided the means of preventing growth of 
cells without plasmids on the agar, Xgal expresses the β-galactosidase enzyme, which is 
encoded in the lacZ gene and was used to facilitate the differentiation between cells with 
and without an inserted DNA sequence within the plasmid vector (which appeared as 
white and blue colonies, respectively). The DNA insert within the plasmid breaks the 
LacZ gene and therefore the colour remains white, whilst those colonies without a DNA 
insert within the plasmid vector have an intact lacZ gene and so the colour remains blue. 
IPTG further induces the transcription of β-galactosidase and thus enhances the colour 
differentiation.  
 
The plates were incubated overnight at 37 ºC. The following day, the plates were 
incubated at 4
o
C to facilitate colour development (i.e. blue and white colonies) and white 
colonies were selected for PCR checking of DNA insert. 
 
2.2.12 PCR-checking of colonies 
White colonies were checked with SP6 (5‟ AT TTA GGT GAC ACT ATA G 3‟) and 
M13 reverse (M13 R) (5‟ CAG GAA ACA GCT ATG ACC ATG 3‟) primers in a PCR 
reaction. These are primers designed to amplify the region between both promoters, 
which was the exogenous DNA PCR product insert, as shown in figure 9. Up to 58 
colonies were selected for PCR-checking and they were subsequently visualised on a 1% 
agarose gel to determine that DNA PCR products of the correct size had been inserted 
into the plasmid vectors. Those colonies that had the correctly sized DNA inserts were 
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selected and grown in individual 5ml cultures of Luria broth (L-broth) (see appendix 3) 
and 5µl ampicillin overnight at 37
o
C to maximise the quantity of DNA insert.   
 
2.2.13 Preparation of glycerol stocks 
Once the cultures had grown overnight, 250µl of a culture mix was added to 250μl of 20 
% glycerol in a 2ml microcentrifuge tube and subsequently stored at -80
o
C. This provided 
a stock of cells that could be re-used repeatedly for future sequencing work. 
 
2.2.14 Plasmid (mini-prep) preparation 
The remaining culture mix was centrifuged at 2,000 x g at room temperature for 10 
minutes, which produced a pelleted culture. The supernatant was disposed of into a 
previously-prepared multi-purpose disinfectant solution (Virkon; RMS, Cat # VIR-05) 
whilst the pelleted culture underwent plasmid preparation using the QIA prep spin 
miniprep kit (Qiagen, Cat # 27104). Firstly, 250µl of a lysis buffer containing RNase A 
was added and the cells re-suspended by repeat pipetting. 250µl of a second lysis buffer 
was then added, followed by 350µl of a suspension buffer. The tube was thoroughly 
mixed by inserting the tube upside down several times. The subsequent mixture was 
centrifuged at 17,900 x g for 10 minutes at room temperature, which produced a white 
pellet. The supernatant was then pipetted onto a QIA prep spin column and centrifuged 
for at 17,900 x g for 1 minute at room temperature. 500µl of a wash buffer was then 
added to the spin column and centrifuged. During these steps, the bacterial lysate 
adsorbed to the silica-gel QIA prep spin column membrane and all impurities were 
washed away in the buffer. The DNA was finally eluted in 50μl of elution buffer. The 
DNA quality and quantity was subsequently examined using the Nanodrop 
spectrophotometer. In addition 2μl loading buffer was added to 5μl of DNA sample and 
was run on a 1.2% agarose gel at 80V for 45 minutes and visually examined for correct 
product size. 
 
2.2.15 Sequencing 
Plasmid mini-prep DNA products of the correct size were diluted to a concentration of 
600ng in 30ml of dH2O. The diluted samples were then sent to the Sequencing Service, 
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Dundee University (www.dnaseq.co.uk) for direct sequencing analysis. Sequencing 
analysis ran from either the SP6 or M13R promoter region, or both as required. The 
results from the sequencing were sent back as a chromas plot indicating the nucleotide 
sequence of the DNA product, as shown in figure 13a. Once the nucleotide peaks had 
become large, sharp and well defined, the sequence was taken. Figure 13b shows a 
sequence that had been obtained from a PCR sample without cloning. It can be clearly 
observed that there was more than one nucleotide sequence; hence sequencing of cloned 
PCR products was the preferred method.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 13a. Example of a chromas file indicating the nucleotide sequence. The red arrow indicates where the 
strength of sequence peaks was judged to be satisfactory. 
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2.2.16 Rapid amplification of cDNA ends (RACE) PCR 
Once a fragment of the β3-AR had been characterised, it was possible to identify the 
entire sequence using RACE PCR. Using gene specific primers (GSP) designed to the 
known sequence, RACE PCR was used to fill in both the 5‟ (5‟ RACE) and 3‟ (3‟ RACE) 
ends; figure 14 illustrates the principle of RACE PCR. The SMART RACE cDNA 
amplification kit (Clonetech, Cat # 634914) was used to amplify the β3-AR 5‟ and 3‟ 
ends. For both types of RACE PCR, the starting mRNA template was firstly reverse 
transcribed into cDNA. The 3‟ end of an mRNA sequence has a string of adenine 
residues (referred to as a poly A
+
 tail) and therefore during reverse transcription an 
oligo(dT) adapter primer (AP) with an enriched GC end was incorporated into the cDNA. 
A PCR was then run using the existing GSP and AP to amplify the specific β3-AR 
product. Nested PCR rounds were then used to increase the specificity of the PCR. 
 
The 5‟ end of an mRNA sequence does not have a distinguishable feature such as a poly 
A
+ 
tail and, therefore once the reverse transcriptase enzyme reached the 5‟end of the 
mRNA sequence during reverse transcription, it added several cytosine residues, thereby 
Figure 13b. Example of a chromas file taken from a PCR sample without cloning. The sequence is not clean and 
there are many overlaps suggesting that there is more than one sequence. This sequence would not have been used for 
further analysis. 
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extending the cDNA sequence slightly. This extended 5‟ tail anchor served as a template 
for a 5‟ end-specific primer. Similarly to the 3‟ RACE, a PCR was then run using the 
GSP and 5‟end-specific primer. A nested PCR round was used to increase specificity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The GSPs and 5‟ and 3‟ primers used to amplify the β3-AR sequence used are 
summarised in table 8.  
 
 
 
Figure 14. Rapid amplification of cDNA ends (RACE) schematic. GSP = gene specific primers; GSP (N) = nested gene 
specific primers; AP = adapter primer; NUP = nested universal primer. The yellow box represents the identified β-3-AR 
fragment; the green line represents the entire sequence from 5‟ to 3‟ end. 
5’ 3’ 
 AAA 
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 TTT AP   GSP 
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 TTT NUP 
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The PCR cycle protocol adopted for both RACE experiments is outlined in figure 15. The 
main stage of annealing and subsequent exponential amplification of PCR product was 
stage 3. The annealing temperatures naturally varied depending on which set of primers 
were used, as shown in table 8, above. 
 
  
 
 
 
 
 
 
 
 
 
 
 
In addition to running the RACE PCR primers, additional primers were designed to 
confirm regions of the β3bi-AR sequences, to resolve any discrepancies. In total, two sets 
of primers were used, as shown in table 9 and were run according to the PCR protocol 
outlined in figure 14, using the indicated annealing temperature.  
 
    GSP AP/Anchor primer 
3'RACE Round 1 
TTCAATCGAGATCTGCTAACC 
(68
o
C) 
CTAATACGACTCACTATAGGGC 
(70
o
C) 
  Nested 
CAGAGTTTCGTGCGGCCTT 
(68
o
C) 
AAGCAGTGGTATCAACGCAGAGT 
(70
o
C) 
5'RACE Round 1 
CGATGTCCATAATCTGCACG  
(68.9
o
C) 
CTAATACGACTCACTATAGGGC 
(70
o
C) 
  Nested 
GGTCTGCAGATGGGAGGT  
(69.6
o
C) 
AAGCAGTGGTATCAACGCAGAGT 
(70
o
C) 
Table 8. Summary of primers used for 3‟ and 5‟RACE. Annealing temperatures specified in brackets. 
5 cycles 5 cycles 25 cycles 
   30s 
  3mins 
30s 
   30s 
 3mins 
   30s 
30s 
 3mins 10mins 
 94.0
o
C 
 72.0
o
C  72.0
o
C 
 94.0
o
C 
 70.0
o
C 
 94.0
o
C 
     oC 
    72.0
o
C   72.0
o
C 
   15.0
o
C 
      ∞ 
 
  1 cycle 
Figure 15. RACE PCR protocol.  indicates temperature specific to GSP. Annealing temp ranged from 68.0oC to 
70.0oC depending on the GSP. Stage number indicated in brackets. 
(1) (2) (3)   (4)       (5) 
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2.2.17 Confirmation of β3bi-AR by primer walking 
To ensure that both RACE products and additional PCR products were from the same 
sequence and to confirm the β3bi-AR, additional first round and nested primers were 
designed in the 5‟ and 3‟ untranslated regions (UTR), which are regions specific to the 
proposed β3-AR. A PCR and nested PCR reaction was subsequently performed. The 
product from the nested round was gel extracted and purified, inserted into a plasmid 
vector, transformed into competent cells and grown on agar plates. Suitable colonies were 
PCR checked for the correct insert and a single colony was subsequently grown in L-
broth and served as the template for the whole primer walking process, which was 
conducted by the Sequencing Service. Primer walking is a process whereby the entire 
sequence is characterised in the 5‟3 and 3‟5 direction using a series of overlapping 
primers. Unlike in a PCR, the primers are not used to produce a product but as probes to 
continue the sequencing process. Sequencing accuracy is limited to approximately 750 
nucleotides. Therefore, with an anticipated sequence of approximately 2,100 nucleotides, 
additional primers (termed „internal primers‟) designed by the Sequencing Service were 
used to enable the complete sequencing, and confirmation, of the β-3bi-AR product in 
both the 5‟3 and 3‟5 direction. Table 10 summarises the primers used. 
 
 
 
 
 
 
 
 
  
Forward 
5’ – 3’ 
Reverse 
5’ – 3’ 
Test 1 
GCGACTACTCACACGACGCTGCTATCTGC 
(76
o
C) 
CATAGAGTCTCTATGCTGGCAGTGACGC 
(72
o
C) 
Test 2 
GCGTCACTGCCAGCATAGAGACTCTATG 
(72
o
C) 
GCGTAATGATGTTCGCCACAAAGAAAG 
(73
o
C) 
 Table 9. Summary of primers used for examining sequence discrepancies. Annealing temperatures specified in brackets. 
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2.2.18 Computational analysis  
 
2.2.18.1 Sequence alignments 
Nucleotide sequence products were analysed for both similarity to other β3-AR sequences 
and for annotation. The nucleotide sequences were analysed in their sense (5‟3‟) 
direction. In cases where the sequence product was in the anti-sense direction, the 
nucleotide sequence was reverse complemented using the website 
www.bioinformatics.vg/bioinformatics_tools/reversecomplement.shtml. The nucleotide 
sequences were subsequently run on the blastx programme on the NCBI database, where 
the protein database was searched using the translated nucleotide sequence. Regions of 
similarity between the query sequence (proposed fathead minnow β3bi-AR) and all other 
amino acid sequences listed on the NCBI database. Those sequences that were 
significantly similar to the query sequence were listed in rank order of most similar to 
least similar. Alongside each sequence was an E value, which describes the number of 
likelihood of “hitting” the specific sequence by chance. The closer the E value was to 
zero, the more significant the match.  
 
Primer 
Sequence 
5’ – 3’ 
5'3 CACGCTGACTGAACCTCCTCC (68
o
C) 
5'3 nested GCGGACTACTTCAACACGACGGC (73
o
C) 
    
3'5 CCGGGCTGAAGTGGATTGCTCCAGTAC (76
o
C) 
3'5 nested CTCCATGTTACACTCCTTCATGAACAGTACC (70
o
C) 
    
Internal 1 (5‟3) ACCTCCCAGCTGCAGACC 
Internal 2 (5‟3) TTCAATCGAGATCTGCTAACC 
  
Internal 1 (3‟5) AAGGCCGCACGAAACTCTG 
Internal 2 (3‟5) CGATGTCCATAATCTGCACG 
Table 10. Summary of primers used to confirm sequence in both 5‟3 and 3‟5 directions. 
Annealing temperatures specified in brackets. The internal primers were those designed by 
and used by the Sequencing Service to enable complete sequencing of the β3bi-AR product. 
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Sequences were aligned using the ClustalW (1.83) multiple sequence alignment database 
(www.ebi.ac.uk/Tools/clustalw/index.html) using default settings for pairwise alignment. 
The proposed fathead minnow β3-AR nucleotide sequences were run against the 
zebrafish, trout and human β3-ARs to examine for regions of similarity. The fathead 
minnow sequences were also aligned against other fish and human β-adrenergic receptors 
to examine for the possibility that the sequences may have been a β1 or β2-AR.  
 
The accession numbers of selected sequences from the NCBI database, unless stated 
otherwise, used for ClustalW sequence alignment were as follows: For β3-ARs, Danio 
rerio: NW_001513985; Oncorhynchus mykiss β3a-AR: AY216465, Oncorhynchus mykiss 
β3b-AR: AY216466, Takifugu rubripe: CAG42650.1, Tetraodon nigoviridis: 
CAG12607.1, Homo sapiens: X70811.  
 
For β1-ARs: Danio rerio: XP 685300, Pimephales promelas AR: characterised by 
Giltrow (PhD thesis 2008) and as yet does not have an NCBI accession number, 
Tetraodon nigoviridis: CAG12607.1, Homo sapiens: NP00675.1. 
 
For β2-ARs: Danio rerio:  XP_700720, Pimephles promelas β2i-AR and β2ii-ARs: 
characterised by Giltrow (PhD thesis 2008) and as yet do not have NCBI accession 
numbers:  Oncorhynchus mykiss: AAK94672.1, Tetraodon nigroviridis: CAG10129.1, 
Takifugu rubripe: AAQ02695.1, Myxine glutinosa: CAA06539.1, Petromyzon marinus: 
CAA06540.1, Homo sapiens; AAB 82149. 
 
The nucleotide sequence products were subsequently translated into protein sequences 
using the ExPASy proteomics server of the Swiss Institute of Bioinformatics 
(www.expasy.ch/tools/dna.html). The nucleotide was translated into all 6 possible 
reading frames. Frame 1 was obtained from translating from the first nucleotide, frame 2 
from the second and frame 3 from the third. Frames 4 to 6 were the same as frames 1 to 3 
but in the reverse direction. The frame that produced the longest reading frame with no 
stop codons was selected. The protein sequences were also aligned against other β3-, β2- 
and β1-AR protein sequences using ClustalW. 
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2.2.18.2 Hydropathy analysis 
The seven hydrophobic transmembrane domains synonymous to GPCRs must be of a 
length ranging from 23 to 30 hydrophobic amino acids to span the hydrophobic cell 
membrane bilayer (Strosberg & Peitri-Rouxel, 1996). Accordingly, hydrophilic amino 
acids are commonly found outside of the bilayer. To examine for these seven 
hydrophobic amino acid chains, the ExPASy proteomics server of the Swiss Institute of 
Bioinformatics (www.expasy.ch/_tools/dna.html) was used and several programmes 
utilised. Using the Kyte-Doolittle hydropathy index (Kyte & Doolittle, 1982),   which 
ranged from -4.5 (hydrophilic) to 4.5 (hydrophobic), each amino acid was allocated a 
hydropathy score. It is the hydrophobicity of the amino acid that determines its position 
in the final protein structure. Those regions of hydrophobic amino acids were 
subsequently allocated a TMD, and those hydrophilic positioned outside of the TMD. 
The software programmes used to identify the TMDs were as follows:  
 
1. TMpred – Prediction of Transmembrane Regions and Orientation (Hofmann & 
Stoffel (1993). (www.ch.embnet.or/software/TMPRED_form.html) 
2. TMHMM (2.0) Prediction of transmembrane helices in proteins, The Centre for 
Biological Sequence Analysis at the Technical University of Denmark, (Krogh et 
al, 2001). (www.cbs.dtu.dk/services/TMHMM-2.0/) 
3. SOSUI Result Classification and Secondary Structure Prediction of Membrane 
Proteins (Hirokawa et al, 1998; Mitaku et al, 2002). (http://bp.nup.nagoya-
u.ac.jp/sosui/cgi-bin/adv_sosui.cgi) 
4. HMMTOP transmembrane topology prediction server (Tusnády & Simon, 2001). 
(www.enzim.hu/hmmtop/) 
5. Dense Alignment Surface (DAS) Transmembrane Prediction server (Cserzo et al, 
1997). (www.sbc.su.se/~miklos/DAS/tmdas.cgi) 
 
The allocated hydrophobic amino acid chains varied between the different programmes. 
Therefore, additional criteria based on information about GPCR and β-AR biology was 
used to help with the decision process of allocating TMDs to particular hydrophobic 
amino acid regions.  
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2.2.18.3 Phosphorylation sites analysis 
Potential phosphorylation residues of serine, threonine and tyrosine in the third 
intracellular loop and cytoplasmic tail were identified using NetPhose 2.0 
(http://www.cbs.dtu.dk/services/NetPhose/) (Bloom et al, 1999). 
 
2.2.18.4 Phylogenetic analysis 
Phylogenetic trees are binary-rooted trees constructed from multiple sequence 
alignments, and are used to illustrate genetic distance and species relationships (Penny et 
al, 1992). For the purpose of this study, the β3-, β2- and β1-AR amino acid sequences 
were aligned using a multiple cluster and topological algorithm alignment server using 
the GeneBee software programme (www.genebee.msu.su) (Brodsky et al, 1995). The 
results were presented in the form of a rectangular tree. Bootstrap values indicate the 
significance of relationship between the sequences, much like p values are used in 
statistical analysis, which is particularly important when examining the relevance of a 
particular phylogenetic tree (Thompson et al, 1994). Bootstrap values were calculated by 
re-sampling each alignment 100 times and expressing the similarity as a percentage.  
 
2.2.19 Examining β3bi-AR expression in fathead minnow tissues 
Once the sequence had been classified as a β3bi-AR, several tissues from both adult male 
and female fathead minnows were examined for β3bi-AR expression via PCR. The GSP 
pair designed in the 3‟ end UTR, and consequently used for real-time PCR analysis (see 
section 5.2.4), were used to examine the heart, liver, brain, gill, red blood cell, adipose 
and gonad tissues for β3bi-AR expression.  
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2.3 RESULTS 
 
2.3.1 RNA extraction from blood 
Unlike fathead minnow tissues, from which mRNA could be directly extracted, RNA was 
first extracted from fathead minnow whole blood cells and visually examined on a 1% 
agarose gel to give an indication of quality. Figure 16 shows an example of RNA 
inspection and demonstrates both a clean set of extracted RNA samples (16A), note the 
two distinct 28S and 18S bands and an unclean extracted RNA sample (16B). The 28S 
band should be approximately twice as strong as the 18S. There were no signs of DNA 
contamination. The blurring in figure 15B was indicative of RNA degradation.    
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.2 Identifying the zebrafish β3-AR 
The primers used to identify the fathead minnow β3bi-AR were originally designed using 
the zebrafish β3-AR nucleotide sequences. Therefore, prior to looking for the β3-AR in 
the fathead minnow, zebrafish heart mRNA was examined for β3-AR expression. The 
heart was chosen as Nickerson et al (2003) found the β3-AR in the rainbow trout heart. 
Figure 17 shows a very strong band presence for both β3bi-AR and β3bii-AR. The band 
was of the correct size of approximately 800bp.  
 
Primer dimer 
  200bp 
  500bp 
 1,000bp 
     200bp 
    500bp 
 1,000bp 
        18S 
   28S A B 
Figure 16. UV images of RNA samples run on a 1% agarose gel. Image A shows a cleanly extracted set of RNA samples. 
Note the clear S bands. Image B shows some blurring (as highlighted by the red circle), which is indicative of RNA 
degradation. 
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2.3.3 Identifying the fathead minnow β3bi-AR 
The fathead minnow genomic DNA was examined for the β3bi-AR as a first screening to 
indicate that the fathead minnow possessed the β3bi-AR before trying to find which fish 
tissues and life-stages the receptor was expressed in. Figure 18 shows the results from 3 
nested genomic PCR rounds. Both β3bi-AR subtypes were amplified during each PCR 
round. Product bands at the correct size were identified for both receptor subtypes in PCR 
nested rounds 2 (approximately 800bp) and nested 4 (approximately 600bp). There was, 
however a higher degree of non-specific binding in nested round 4. This was anticipated 
for each round since the primers were designed against a different fish species, albeit 
from the same family. There was no amplification in PCR nested round 3, which 
suggested that primers did not work. There was no relationship between strength of band 
and β3-AR subtype as the β3bii-AR band was stronger from nested round 2 but the β3bi-AR 
band was stronger in nested round 4. Confirmation of sequence amplification was 
achieved via direct sequencing.  
 
 
 
 
1,000bp 
650bp 
800bp 
500bp 
  3bi  3bii 
Figure 17. UV image of zebrafish heart mRNA β3bi-AR 
and β3bii-AR sequences. Bands were at approximately the 
correct size. 
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Subsequently, heart mRNA from the fathead minnow was examined for β3-AR 
expression. The nested round 3 primers were excluded as they did not produce a product 
in the genomic PCR investigation and thus the nested round 4 primers served as nested 
round 3 primers. The results from both β3-AR subtype PCR rounds are shown in figure 
19. The product bands are seen at the correct size for each corresponding PCR round. The 
nested round 3 products were cut out of the gel and subsequently gel extracted. 
 
 
 
 
 
 
 
 
 
 
 
  800bp 
 
  600bp 
 
 1,000bp 
 
  400bp 
 
3bi 
 
3bii 
 
  3bi 
 
 3bii 
 
  3bi 
 
3bii 
 
      1,000bp 
 
   800bp 
 
   400bp 
 
   600bp 
 
 R2 R3 R4 
Figure 18. UV image showing genomic PCR nested rounds 2, 3 and 4. Clear product bands for 
both β3bi- and β3bii-AR at the correct sizes can be seen in rounds 2 and 4. There as a higher degree 
of non-specific binding in round 4. 
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The gel extracted products were subsequently ligated into a cloning vector and 
transformed into competent cells. Selected colonies were PCR checked for the insert, as 
shown in figure 20. Each colony had the correct sized insert. The products were 
approximately 200 nucleotides larger than their original size as there was additional 
cloning vector sequence. Several colonies were selected, grown overnight in L-broth, 
mini-prepped and subsequently sent off for sequencing. 
 
 
 
 
 
 
 
 
 
 
  R1   R2 R3 R2   R3 R1 
400bp 
600bp 
800bp 
400bp 
600bp 
800bp 
Β-3bi-AR Β-3bii-AR 
Figure 19. UV image of PCR rounds 1, 2 and 3 for identifying the β3bi- and β3bii-AR. Both 
nested rounds 2 and 3 have clear, clean product bands at approximately the correct size of 
800 and 600bp, respectively. Both products from nested round 3 (highlighted in red circles) 
were cut out and subsequently gel extracted. 
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The results from the sequencing analysis confirmed that the male fathead minnow 
expressed both the β3bi-AR and β3bii-AR in the heart. Figure 21 shows that the fathead 
minnow β3bi-AR and β3bii-AR were 46% similar to each other, however when compared 
to their zebrafish counterparts were 92% (figure 22) and 76% (figure 23) identical, 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. UV PCR-colony check image. Each colony had the same-sized product insert. The original product size was 
600bp, however on the gel it is 800bp due to additional vector sequence. Several colonies were selected for sequencing 
analysis.  
    800bp 
     1,000bp 
    800bp 
     1,000bp 
Β-3bi-AR 
Β-3bii-AR 
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3bi    CATCATTACAGTGGATCGGTATATTGCGATCACACGGCCACTGCGGCATAAAGTGCTTCT 60  
3bii   CGCCATCGCCGTTGAGCGTTATGTTGCGGTCACAAGACCCCTCGAGCATCAGGTCCTCCT 60  
*  ***  * ** ** ****** ***** ******* ** **    *** * ** ** **  
 
3bi   GAATAAGTGCAGAGCTCGAATTATTGTTTGCATTGTGTGGATAGTATCGGCTTGCATCTC 120  
3bii   GGGCAAGCGCAGAGCCGTCTACATCGTATGCATAGTGTGGATGGTGTCGTCCCTGGTTTC 120  
*   *** *******       ** ** ***** ******** ** *** *     **** 
 
3bi   CTTTATCCCCATAATGTACGGTTTTTGGCGTAGAGACCCTAATGATGATGTAGCAACTGC 180  
3bii   CTTCGTGCCAATCATGCACCATTATTCTCATGCA------AATGCCACCGTTCCGGAAGA 174 
***  * ** ** *** ** *** **  * *         ****     **  *    * 
 
3bi   ATGTTATAGTGATACAAACTGCTGTGATTTTATAACAAACATGACCTATGCCATCATTTC 240  
3bii   CTGTTACAATAACGAAGAGTGCTGTGATTTCCATACTAACGAGGTCTATGCCATCTTCTC 234  
 ***** * * *   * * ***********     * ***  *  ********** * **  
 
3bi   ATCAGTGGTTTCATTCTACATCCCACTCTTCATCATGATTTTTGTATATGCACGTGTGTT 300  
3bii   CTCAGTGGTGTCATTCTATGTGCCCCTCGTGATTATGGTGTGTTTGTACGGGAAGGTGTT 294 
              ******** ********  * ** *** * ** *** * * * * ** *     *****  
 
3bi   TCTCATTGCCACACGACAGGTTCAGTTAATTGACAAGAGCCGTCTGAGGTTCCAAAACGA 360 
3bii   TGCCATCGCGACCAGACAGCTGAAACTCATCGAAAAAGACAGACTGCGCTTTCCGAGCAC 354  
*** ** ** ***** * * * ** ** ** * * *** * ** * * * 
 
3bi   GTACATGGGAAATCAGGTACAGCCACCGACCATTGGCAACAATAACTTGCCATCTATGTG 420  
3bii   AGGCATGGAAGAT--------GCTAGTGA--------AAGTACAGTT-----TCTGCAAG 393  
   ***** * **        ** *   *        **  * *  *     ***    *  
 
3bi   TAATAACGTCGGAGGGATGACAGCAAAGAGGAAGAGTTCTCGAAGGCGACCTTCCAGATT 480 
3bii  CAA-AACAGCTGGTGGTTG--------TAGGAGGAAGTCGACGAGGC----------ATT 434  
 ** ***  * *  ** **         **** **  **    ****          ***  
 
3bi   AACTGTAATCAAGGAGCACAAGGCCCTCAAGACACTGGGCATCATCATGGGCGTCTTTAC 540 
3bii   A--TGTAA---AAGAACACAAGGCGCTCAAAACACTAGGGATTATTATGG---------- 479  
*  *****   ******************* ***** ** ***** ****  
 
3bi   GCTGTGCTGGCTACCTTTCTTT 562  
3bii   ----------------------  
 
Similarity score = 46% 
Figure 21. ClustalW alignment of the fathead minnow β3bi-AR and β3bii-AR sequences. Sequences shared a 46% 
similarity.  
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zf3b_i_-AR      TGCATCATTGCAGTGGATCGGTATATTGCGATCACACGGCCACTGCGGCATAAAGTGCTT 960 
FHM3bi          --CATCATTACAGTGGATCGGTATATTGCGATCACACGGCCACTGCGGCATAAAGTGCTT 58 
                  ******* ************************************************** 
 
zf3b_i_-AR      CTGAATAAGTGCAGAGCTCGAATTATTGTTTGCATTGTGTGGATAGTATCGGCTTGCATC 1020 
FHM3bi          CTGAATAAGTGCAGAGCTCGAATTATTGTTTGCATTGTGTGGATAGTATCGGCTTGCATC 118 
                ************************************************************ 
 
zf3b_i_-AR      TCCTTTATCCCCATAATGTACGGTTTTTGGCGTAGAGACCCTAATGATGATGTAGCAACT 1080 
FHM3bi          TCCTTTATCCCCATAATGTACGGTTTTTGGCGTAGAGACCCTAATGATGATGTAGCAACT 178 
                ************************************************************ 
 
zf3b_i_-AR      GCATGTTATAGTGATACAAACTGCTGTGATTTCATAACAAACATGACCTATGCCATCATT 1140 
FHM3bi          GCATGTTATAGTGATACAAACTGCTGTGATTTTATAACAAACATGACCTATGCCATCATT 238 
                ******************************** *************************** 
 
zf3b_i_-AR      TCATCAGTGGTTTCATTCTACATCCCACTCTTCATCATGATTTTTGTATATGCACGTGTG 1200 
FHM3bi          TCATCAGTGGTTTCATTCTACATCCCACTCTTCATCATGATTTTTGTATATGCACGTGTG 298 
                ************************************************************ 
 
zf3b_i_-AR      TTTCTCATTGCCACACGACAGGTTCAGTTAATTGACAAGAACCGTCTGAGGTTCCAAAAC 1260 
FHM3bi          TTTCTCATTGCCACACGACAGGTTCAGTTAATTGACAAGAGCCGTCTGAGGTTCCAAAAC 358 
                **************************************** ******************* 
 
zf3b_i_-AR      GAGTACATGGGAAATCAGGTACAGCCACCGACCATTGGCAACAATAACTTGCCATCTATG 1320 
FHM3bi          GAGTACATGGGAAATCAGGTACAGCCACCGACCATTGGCAACAATAACTTGCCATCTATG 418 
                ************************************************************ 
 
zf3b_i_-AR      TGTAATAACGTCGGAGGGATGACAGCAAAGAGGAAGAGTTCTCGAAGGCGACCTTCCAGA 1380 
FHM3bi          TGTAATAACGTCGGAGGGATGACAGCAAAGAGGAAGAGTTCTCGAAGGCGACCTTCCAGA 478 
                ************************************************************ 
 
zf3b_i_-AR      TTAACTGTAATCAAGGAGCACAAGGCCCTCAAGACACTGGGCATCATCATGGGCGTCTTT 1440 
FHM3bi          TTAACTGTAATCAAGGAGCACAAGGCCCTCAAGACACTGGGCATCATCATGGGCGTCTTT 538 
                ************************************************************ 
 
zf3b_i_-AR      ACGCTGTGCTGGCTGCCTTTCTTTGTGGCGAACATCATCTACGCGTTTGTACCACAAGAC 1500 
FHM3bi          ACGCTGTGCTGGCTACCTTTCTTT------------------------------------ 562 
                ************** *********        
 
Similarity score = 92% 
 
 
Figure 22. ClustalW alignment of fathead minnow (FHM) and zebrafish (zf) β3bi-AR sequences. Sequences were 
92% identical 
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2.3.4 Identifying entire fathead minnow β3bi-AR sequences using RACE PCR  
The β3bi-AR sequence was identified by piecing together several different fragments that 
were obtained from PCR, 5‟ RACE PCR and 3‟ RACE PCR. It was not possible to obtain 
the entire β3bii-AR sequence beyond the first fragment. Figure 24 shows an outline of how 
the different PCR fragments fitted together. The 3‟RACE was used to successfully 
identify the poly (A
+) tail, whilst the 5‟RACE was able to identify up to 950 nucleotides 
in the 5‟UTR.  One clear observation made was that the overlap between the 1st fragment 
and 5‟RACE fragment and also between the 1st fragment and 3‟RACE fragment was not 
100% similar. This was unusual as the 1
st
 fragment was representative of the middle of 
FHM3bii  ----------CGCCATCGCCGTTGAGCGTTATGTTGCGGTCACAAGACCCCTCGAGCATC 50  
zf3bii    AGACATTGTGCGCTATCGCTGTTGAGCGATACATTGCGATTACCAGACCTCTGGAGCATC 540  
    *** ***** ******** **  ***** * ** ***** ** *******  
 
FHM3bii  AGGTCCTCCTGGGCAAGCGCAGAGCCGTCTACATCGTATGCATAGTGTGGATGGTGTCGT 110  
zf3bii   AGGTACTGTTGGGAAAACGCAGAGCCGGCTACATCGTATGCATGGTGTGGATCGTGTCAT 600 
   **** ** ***** ** ************************** ******** ****  * 
 
FHM3bii  CCCTGGTTTCCTTCGTGCCAATCATGCACCATTATTCTCATGCAAATGCCACCGTTCCGG 170  
zf3bii  CCTTAGTGTCCTTCGTGCCAATAATGAACCATAATTCTCGTGCAAATTATTTAGCAGCAA 660  
** * ** ************** *** ***** ****** *******      *   *  
 
FHM3bii  AAGACTGTTACAATAACGAAGAGTGCTGTGATTTCCATACTAACGAGGTCTATGCCATCT 230  
zf3bii  ACGACTGCTACAACAACTCAGAGTGCTGCGATTTCCATACTAACCAGCACTACGCCATCT 720 
* ***** ***** ***  ********* ******************  *** *******  
 
FHM3bii  TCTCCTCAGTGGTGTCATTCTATGTGCCCCTCGTGATTATGGTGTGTTTGTACGGGAAGG 290  
zf3bii  TCTCCTCTGTGGTTTCCTTCTATGTGCCTCTTCTTGTTATGGTGTTTCTGTACGGGAAGG 780 
   ******* ***** ** *********** **  *  ********* * ************ 
 
FHM3bii  TGTTTGCCATCGCGACCAGACAGCTGAAACTCATCGAAAAAGACAGACTGCGCTTTCCGA 350 
zf3bii  TGTTTGCCATTGCAAACAAGCAGTTGAAACTCATCGGTAAGGACAGACTTCGTTTTCTGA 840 
   ********** ** * **  *** ************  ** ******** ** **** **  
 
FHM3bii  GCACAGGCATGGAAGATGCTAGTGAAAGTACAGTTTCTGCAAGCAAAACAGCTGGTGGTT 410  
zf3bii  GCTCTTGCAATGAAGACTCTTGTGAAA------TTCCTGAAGGTT---CGGCTCGAAGTT 891  
** *  ***  *****  ** ******      ** *** * *     * *** *  ***  
 
FHM3bii  GTAGGAGGAAGTCGACGAGGCATTATGTAAAAGAACACAAGGCGCTCAAAACACTAGGGA 470  
zf3bii  ACAGTCGGAGAACAACAAAGCATGTCGTGAAAGAACACAAGGCGCTCAAGACTCTAGGGA 951  
  **  ***   * ** * ****   ** ******************** ** *******  
 
FHM3bii TTATTATGG--------------------------------------------------- 479  
zf3bii  TTATCATGGGCATCTTCAGTCTCTGTTGGCTGCCCTTCTTCATCTTCAATATCATCAAAA 1011 
   **** ****  
 
Similarity score = 76% 
 
Figure 23. ClustalW alignment of fathead minnow (FHM) and zebrafish (zf) β3bii-AR sequences. Sequences 
were 76% identical. 
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the sequence and covered the 2
nd
 to the 6
th
 trans-membrane regions; a section that is 
usually highly conserved and is partly responsible for the structure of the receptor. The 
test 1 and test 2 fragments were highly similar in sequence to the 5‟RACE and 3‟RACE 
products, but were also not 100% similar to the 1
st
 PCR fragment. It could be possible 
that the 1
st
 fragment had identified a β3bi.1-AR, whilst the other fragments belonged to a 
β3bi.2-AR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.5 Confirmation of sequence 
The β3bi-AR sequence was conservatively pieced together and two sets of primers were 
designed to the 5‟ and 3‟UTR, the second pair was used as nested primers. The primers 
were then run against the fathead minnow heart tissue cDNA template in a PCR and the 
products were subsequently visualised on a 1.2% agarose gel, as shown in figure 25. The 
product from PCR round 1 was cleaner than round 2 and was therefore cut out, cloned 
and subsequently evaluated by PCR to identify suitable colonies.  
 
 
 
1. 1
st
 PCR fragment 
2. 5’RACE 
UTR UTR 
3. 3’RACE 
4. Test 1  
5. Test 2  
Trans-membrane regions 
Figure 24. Outline schematic illustration of the five different fragments used to construct the entire molecular 
sequence of the β3bi-AR.  
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A single colony of the correct sized was grown overnight and subsequently analysed by 
primer-walking sequencing. Figures 26 and 27 outline the complete β3bi-AR nucleotide 
and amino acid sequences, respectively. The nucleotide sequence was 2,203 nucleotides 
long and the translated protein sequence was 434 amino acids long. Typically the 
transcription initiator sequence, commonly referred to as a TATAA box because of its 
nucleotide sequence, is found 25-35bp before the start codon. It was not possible to 
accurately identify the TATAA box in the fathead minnow β3bi-AR sequence.   
 
 
 
 
 
 
 
 
 
 
 
1,000bp 
2,000bp 
  500bp 
  R1  R2 
Figure 25. UV image of 1.2% agarose gel. R1 = 
round 1 and R2 = round 2. The red circled band was 
cut out of the gel for subsequent gel extraction. 
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5’ GAATTCAGATTCACGCTGACTGAACCTCCTCCACTTCAGCTCAAACTCCACTTCAG 
CGGACTACTTCAACACGACGGCTGCTTATCTGCCTTTTCTCTGCTGGTTTCAAGAGCTTTT
CTAAAAGTTAAAATATTTTTATTTCCCCCATTTCTCTCGGACCAGTTTTAACTCAGAATA
AAAGGGGCTTTTTGTTTTCTTTCCTCCTACATCTTCAGTTCAGATGTGTGGAACATGGCAT
ATATGTTTGCTTCAAACGCCACAGGACTGCTGGATATGCACTATTTTTCAGGATGACTGA
ATAATATCCCAAAAGGAATTGATGCTGTTGCTCAACATTTGGAGATATGGTGGTATAAA
ATGCAAGATTAAATACATCATCGTCATGGTATCTCAATCACTCGACTGAAGACCGAATA
GCACCTAGCTATGTCTCTTTGCTGCTCGTTTCTGACATACAGTTTGAAAAACCACAAACA
TTGATCTCTGAATACTGAAACATGGAATCTCTGACAAACAGCTCTCAAACAACCCCTGT
GCCAACAAGTGCACCTCTTCAAGGGTGGACATCATTTCAGCTGTTCATCATGATCATCAT
CATCGCGATTATCGTTGTGGGTAACCTTATGGTCATCATCGCCATAGCACGCACCTCCC
AGCTGCAGACCACGACGAATATCTTCATTATGTCGTTGGCATGTGCTGACCTCATAATG
GGGGTGGTGGTGGTGCCACTGGCTGCCATGATTGTTGTAAAAGGGGAATGGACACTTGG
TGAGGTACCGTGCAGATTATGGACATCGGTTGATGTTTTATGTGTCACAGCCAGTATA
GAGACCCTTTGCATCAACGCAGTGGATCGGTATATTGCGATCATGCGGCCACTGCGGTA
TAAAGTGCTCCTGAATAAGTGCAGGGCTCGAATCATCGTTTGTGTCGTGTGGCTGCTCTC
AGCTCTAATCTCCTTCGTCCCAATCATGAACGACTGGCATGCTGGGGCCGATACAGGAA
ACAAAAATGACACAGACAATTACAAAGACACCTGTGCTTTTGATACAAACATGGCCTTT
GCTATATTTTCATCAGGGATTTCGTTCTACATCCCACTACTCATCATGATTTTTGTCTATG
CACGCGTCTTCCTCGTCGCCACAAGACAGGTACAGCTCATTGGCAATAACCGTCTGAGG
TTCCAAAACGAGTGCATAGGAAATCAGGTCCATGGCAACAACAACTTGCCTTCGATGTG
CAATAACGTCGGTGGGATGACGGCAAGGCGGAAAAGTTCCCGGAGGCGACCGTCCAAA
TTAACCGCTGTGAAGGAGCACAAGGCCCTCAAGACGCTGGGCATCATCATGGGCATCTT
CACACTGTGCTGGCTGCCTTTCTTCGTGGCGAACATCATCAATGTTTTCAATCGAGATC
TGCTAACCATGTATGTTTTTCGATATTTAAACTGGTTAGGCTACATCAACTCCAGCCTCA
ATCCCATCATCTACTGCCGCAGCCCAGAGTTTCGTGCGGCCTTCAAGAACCTTCTCGG
CTGTCCCTGGGTATCCCCGCTGAGAATGAACTTCCTTTACAAGGAGCTTCGGACTCGATG
CACTTGCTTCCTGGGTTCCGCAGAGTCGGGAATGCCTGGATCGTTCGAGAAGCCCCCCA
CATCCCCAGGGGCACTGCCTGGGGAAGGGAGCAGCCAGAGCAGCTACAGGAGCGAGGA
GCCGTCGCCGGGACCACCGCACTCCAACGGACGCACGTTCTTCAGTGATTTCTCCGAGC
CGGAGACGGAGTTCTGTAACCTATAGGAGCAGGATGGCTGAGAGTCTCTAGCATGGCTG
AAATGAAAGGACGATGAGGAAGAAGAAACAGGGAAAAGGACTGACTTACATCACAGTT
GGCGGGACTTTCCCAGCAGAGACCACAAGGGCCCAGCAAAAAACATCCATGAAAGCCA
TCAGGGGAGCCTGCTCCAAAACTGAAAGACAGAAGAGTGCAAAGATATAACCATAGAG
AGGCAAGCACTATGGGAACTTTCTCACAAACAGCTCGTCTATGGAAAGAACGACTGAAC
TGGTACTGTTCATGAAGGAGTGTAACATGGAGTGATCCGATACTGCTAACGTTCTATTAA
GTACTGGAGCAATCCACTTCAGCCCGGTTTGTTTTAGTTCGTTTGACAAAAAAAAAAAA
AAAAAAAAAAAAAAAA 3’ 
 
Figure 26. Fathead minnow β3bi-AR nucleotide sequence. The start (ATG) and stop (TGA) codons are highlighted in bold 
pink. The blue and red highlighted sequences represent the primers used to confirm the sequence in the 5‟ and 3‟ direction 
by the Sequencing service, respectively. The green and orange sequences represent the 5‟ and 3‟ UTR‟s, respectively. The 
highlighted yellow sequences represent primers used to identify the entire β3-AR sequence.  
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2.3.6 Characterising the β3bi-adrenergic receptor 
 
2.3.6.1 Hydropathy analysis 
To identify the TMDs in the fathead minnow β3bi-AR sequence, the ExPASy proteomics 
server of the Swiss Institute of Bioinformatics (www.expasy.ch/ tools/dna.html) was used 
and several hydropathy programmes were used. None, however, produced the same 
results. Therefore, additional information on GPCRs and β-adrenergic receptors, 
summarised in table 11, was used to compare the information produced by the 
hydropathy software programmes. For example it was used to examine whether a specific 
motif common to β-adrenergic receptors was located in the designated TMD or, because 
of incorrect hydropathy analysis, was outside of the TMD. 
 
 
 
 
 
 
 
 
 
 
 
N’ MESLTNSSQTTPVPTSAPLQGWTSFQLFIMIIIIAIIVVGNLMVIIAIARTSQLQTTTNIFI 
MSLACADLIMGVVVVPLAAMIVVKGEWTLGEVPCRLWTSVDVLCVTASIETLCINAVDR
YIAIMRPLRYKVLLNKCRARIIVCVVWLLSALISFVPIMNDWHAGADTGNKNDTDNYKDT
CAFDTNMAFAIFSSGISFYIPLLIMIFVYARVFLVATRQVQLIGNNRLRFQNECIGNQVHGN
NNLPSMCNNVGGMTARRKSSRRRPSKLTAVKEHKALKTLGIIMGIFTLCWLPFFVANIINV
FNRDLLTMYVFRYLNWLGYINSSLNPIIYCRSPEFRAAFKNLLGCPWVSPLRMNFLYKELR
TRCTCFLGSAESGMPGSFEKPPTSPGALPGEGSSQSSYRSEEPSPGPPHSNGRTFFSDFSEPET
EFCNL  C’ 
 Figure 27. Fathead minnow β3bi-AR amino acid sequence. 
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Motif Amino Acid 
sequence 
Reference 
N-terminal region is extracellular, asparagine-linked 
and glycosylated 
NxS/T Emorine et al (1988) 
Cysteine residues between the second and third 
extracellular loops. Required for disulfide bond 
formation and essential for ligand binding. 
C,C Foreman & Johansen (1996) 
Motif occurring at the end of the TMD 3. DRY Devic et al (1997) 
Residues required for αs activation found in TMD3 
(N) and TM 7 (Y).  
N, Y Strosberg & Peitri-Rouxel 
(1996) 
Ligand binding residues found in TMD 2 (D) TMD 3 
(D), TMD 5 (S, S) and TMD 6 (F) 
D, D, S,S, F Strosberg & Peitri-Rouxel 
(1996), 
Tryptophan reside (W) found in the middle of TMD 4 
and TM 6. 
W Devic et al (1997) 
Cysteine residue is located 10-20 residues C-
terminally to TM 7 and is palmitoylated 
C Foreman & Johansen (1996) 
Proline residues located in TMD 5, TMD 6 and TMD 
7. Facilitates interchange between different 
conformations of associated and dissociated receptor.  
P Foreman & Johansen (1996) 
Arginine residue located in the second intracellular 
loop just below TMD 3. Involved in signal 
transduction process 
R Blin et al (1993) 
Residues found in TMD 7 and are characteristic of 
the α-rhodopsin group. 
NSxxNPxxY Friedriksson et al (2003) 
Found in β-1-AR receptors at the start of the COOH 
loop after TM 7. 
RSPDFRKA 
FKR 
Mason et al (1999) 
 
Figure 28 summarises the results from the hydropathy analysis. The GPCR- and β-AR-
specific motifs summarised in table 12 are also included. It was clear that most motifs 
Table 11. Summary of motifs found specifically in GPCRs and β-adrenergic receptors, amended from that described by 
Giltrow (2008).  
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were found at their specified locations in the fathead minnow β3bi-AR. The exception to 
this, however, was that the TMHMM and HMMTOP programmes did not produce a 7
th
 
TMD and therefore in these cases all motifs associated with the 7
th
 TMD were not 
included. To evaluate which hydropathy analysis programme or combination of 
programmes was most suitable for allocating the TMD to the fathead minnow β3bi-AR 
sequence, all the information was first summarised, as shown in tables 13 and 14.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TM region TMpred TMHMM SOSUI DAS HMMTOP 
1 22 22 23 23 22 
2 26 23 23 25 26 
3 19 23 23 20 10 
4 19 20 23 20 20 
5 24 23 24 24 27 
6 22 23 23 20 22 
7 20 0 23 18 6 
Table 12. Summary of TM regions produced by all five different hydropathy programmes. Red highlighted figures 
represent those TMDs that were too small (18-30 amino acids) according to Strosberg & Peitri-Rouxel (1996).  
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TMpred  MESLTNSSQTTPVPTSAPLQGWTSFQLFIMIIIIAIIVVGNLMVIIAIARTSQLQTTTNI  60  
TMHMM  MESLTNSSQTTPVPTSAPLQGWTSFQLFIMIIIIAIIVVGNLMVIIAIARTSQLQTTTNI  60  
SOSUI  MESLTNSSQTTPVPTSAPLQGWTSFQLFIMIIIIAIIVVGNLMVIIAIARTSQLQTTTNI  60  
DAS   MESLTNSSQTTPVPTSAPLQGWTSFQLFIMIIIIAIIVVGNLMVIIAIARTSQLQTTTNI  60 
HMMTOP  MESLTNSSQTTPVPTSAPLQGWTSFQLFIMIIIIAIIVVGNLMVIIAIARTSQLQTTTNI  60        
 
TMpred    FIMSLACADLIMGVVVVPLAAMIVVKGEWTLGEVPCRLWTSVDVLCVTASIETLCINAVD  120  
TMHMM  FIMSLACADLIMGVVVVPLAAMIVVKGEWTLGEVPCRLWTSVDVLCVTASIETLCINAVD  120  
SOSUI  FIMSLACADLIMGVVVVPLAAMIVVKGEWTLGEVPCRLWTSVDVLCVTASIETLCINAVD  120  
DAS  FIMSLACADLIMGVVVVPLAAMIVVKGEWTLGEVPCRLWTSVDVLCVTASIETLCINAVD  120  
HMMTOP  FIMSLACADLIMGVVVVPLAAMIVVKGEWTLGEVPCRLWTSVDVLCVTASIETLCINAVD  120  
 
TMpred  RYIAIMRPLRYKVLLNKCRARIIVCVVWLLSALISFVPIMNDWHAGADTGNKNDTDNYKD  180  
TMHMM  RYIAIMRPLRYKVLLNKCRARIIVCVVWLLSALISFVPIMNDWHAGADTGNKNDTDNYKD  180 
SOSUI RYIAIMRPLRYKVLLNKCRARIIVCVVWLLSALISFVPIMNDWHAGADTGNKNDTDNYKD 180  
DAS   RYIAIMRPLRYKVLLNKCRARIIVCVVWLLSALISFVPIMNDWHAGADTGNKNDTDNYKD 180  
HMMTOP  RYIAIMRPLRYKVLLNKCRARIIVCVVWLLSALISFVPIMNDWHAGADTGNKNDTDNYKD 180  
 
TMpred TCAFDTNMAFAIFSSGISFYIPLLIMIFVYARVFLVATRQVQLIGNNRLRFQNECIGNQVHG   240  
TMHMM TCAFDTNMAFAIFSSGISFYIPLLIMIFVYARVFLVATRQVQLIGNNRLRFQNECIGNQVHG   240  
SOSUI  TCAFDTNMAFAIFSSGISFYIPLLIMIFVYARVFLVATRQVQLIGNNRLRFQNECIGNQVHG   240 
DAS   TCAFDTNMAFAIFSSGISFYIPLLIMIFVYARVFLVATRQVQLIGNNRLRFQNECIGNQVHG   240  
HMMTOP  TCAFDTNMAFAIFSSGISFYIPLLIMIFVYARVFLVATRQVQLIGNNRLRFQNECIGNQVHG   240  
 
TMpred  NNNLPSMCNNVGGMTARRKSSRRRPSKLTAVKEHKALKTLGIIMGIFTLCWLPFFVANIIN  300 
TMHMM  NNNLPSMCNNVGGMTARRKSSRRRPSKLTAVKEHKALKTLGIIMGIFTLCWLPFFVANIIN  300 
SOSUI   NNNLPSMCNNVGGMTARRKSSRRRPSKLTAVKEHKALKTLGIIMGIFTLCWLPFFVANIIN  300 
DAS   NNNLPSMCNNVGGMTARRKSSRRRPSKLTAVKEHKALKTLGIIMGIFTLCWLPFFVANIIN  300 
HMMTOP NNNLPSMCNNVGGMTARRKSSRRRPSKLTAVKEHKALKTLGIIMGIFTLCWLPFFVANIIN  300 
 
TMpred  VFNRDLLTMYVFRYLNWLGYINSSLNPIIYCRSPEFRAAFKNLLGCPWVSPLRMNFLYKEL  360  
TMHMM  VFNRDLLTMYVFRYLNWLGYINSSLNPIIYCRSPEFRAAFKNLLGCPWVSPLRMNFLYKEL  360  
SOSUI  VFNRDLLTMYVFRYLNWLGYINSSLNPIIYCRSPEFRAAFKNLLGCPWVSPLRMNFLYKEL  360  
DAS   VFNRDLLTMYVFRYLNWLGYINSSLNPIIYCRSPEFRAAFKNLLGCPWVSPLRMNFLYKEL  360 
HMMTOP VFNRDLLTMYVFRYLNWLGYINSSLNPIIYCRSPEFRAAFKNLLGCPWVSPLRMNFLYKEL  360  
 
TMpred  RTRCTCFLGSAESGMPGSFEKPPTSPGALPGEGSSQSSYRSEEPSPGPPHSNGRTFFSDFSEPE 420  
TMHMM  RTRCTCFLGSAESGMPGSFEKPPTSPGALPGEGSSQSSYRSEEPSPGPPHSNGRTFFSDFSEPE 420  
SOSUI  RTRCTCFLGSAESGMPGSFEKPPTSPGALPGEGSSQSSYRSEEPSPGPPHSNGRTFFSDFSEPE 420  
DAS  RTRCTCFLGSAESGMPGSFEKPPTSPGALPGEGSSQSSYRSEEPSPGPPHSNGRTFFSDFSEPE 420 
HMMTOP RTRCTCFLGSAESGMPGSFEKPPTSPGALPGEGSSQSSYRSEEPSPGPPHSNGRTFFSDFSEPE 420 
 
TMpred  TEFCNL 434  
TMHMM  TEFCNL 434  
SOSUI TEFCNL 434 
DAS   TEFCNL 434  
HMMTOP  TEFCNL 434  
 
Figure 28. Results of the hydropathy analysis of the fathead minnow β3bi-AR sequence. Different results were obtained from the 
available hydropathy programmes. The highlighted TM regions are TMpred = red, TMHMM = green, SOSIU = yellow, DAS = 
pink and HMMTOP = blue. Motifs highlighted in bold. Blue highlighted motifs indicate potential phosphorylation sites identified 
by NetPhos 2.0 (Bloom et al, 1999). 
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Tables 12 and 13 demonstrate that each topology programme highlighted different 
TMDs. As each topology programme used different criteria to allocate TMDs, it was 
important that only a single programme was chosen to select each TMD. Accordingly, 
TMHMM was not selected as it did not produce a TMD 7 and HMMTOP was excluded 
as it produced a TMD that was smaller than 18 nucleotides in length. The SOSUI 
programme did not produce a DRY motif immediately after TMD 3 (it was found within 
TMD 3) as so was not used, whilst TMHMM did not have a C motif at the COOH end of 
TMD 7. Both TMpred and DAS produced very similar results. Giltrow (2008) used 
TMpred to allocate TMDs in the fathead minnow β1- and β2-ARs and, accordingly, 
TMpred was used to assign TMDs to the fathead minnow β3bi-AR. 
 
Motif TMpred TMHMM SOSUI DAS HMMTOP 
Number of TMDs 7 6 7 7 7 
NxS Yes Yes Yes Yes Yes 
C,C Yes Yes Yes Yes Yes 
DRY Yes Yes No Yes Yes 
N (TM 3), Y (TM 7) Yes Yes Yes Yes Yes  
D (TMD 2 & 3), S,S (TMD 5), 
F (TMD 6) 
Yes Yes Yes Yes yes 
W in the middle of TM 4  
and TMD 6 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
C at COOH end of TMD 7 Yes No Yes Yes Yes 
P in TMD 5, 
 6  
and 7 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
R in 2
nd
 intracellular loop Yes Yes Yes Yes Yes 
NSxxNPxxY Yes No Yes Yes No 
RSPDFRKAFKR No No No No No 
Table 13. A summary showing which motifs are associated with the TMDs according to the different hydropathy programmes. 
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Table 13 indicates that the amino acid sequence RSPDFRKAFKR was not found in the 
sequence, which suggested that the sequence was not a β1-AR. 
 
2.3.6.2 Comparison of the fathead minnow β3bi-AR sequence with other β3-ARs 
The fully annotated proposed fathead minnow β3bi-AR amino acid sequence was aligned 
with fish and human β3-AR sequences and is shown in figure 29 and the similarity scores 
across the TMDs highlighted in table 14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tetraodon3  ------------------------------------------------------------  
human3   ----MAPWPHENSSLAPWPDLPTLAPNTANTSGLPG-------VPWEAALAGALLALAVL 49  
Fugu3   ------------------------------------------------------------  
trout3a   MHEKSILPLCMSFLMKMDFNLSSIVLYAVNTTVTPFHNNTGPYHPAAGPWSLLLLVIIIM 60  
trout3b   MHEKSILPLCMSFLMKMDFNLSSIVLYAVNTTVTPFHNNTGPYHPAAGPWSLLLLVIIIM 60  
zebrafish3  -----------------------MTNNTQNVTQN----------EGFKS-LLFVMVIIIT 26 
FHM3   --------------------MESLTNSSQTTPVPTSAP-----LQGWTSFQLFIMIIIIA 36  
 
Tetraodon3  ---------IVAIAWTPRLQTMTNVFVTSLAAADLVMGLLVVPPAATLALTGHWPLGATG 51 
human3   ATVGGNLLVIVAIAWTPRLQTMTNVFVTSLAAADLVMGLLVVPPAATLALTGHWPLGATG 109 
Fugu3   ---------IVAIAWTPRLQTMTNVFVTSLAAADLVMGLLVVPPAATLALTGHWPLGATG 51  
trout3a   TIMVGNLLVIIAIARTSQLQTITNIFIMSLGCADLIMGVLVVPLGATIVLTGNWQLSDTS 120  
trout3b   TIVVGNLLVIIAIARTSQLQTMTNIFIMSLACADLIMGVLVVPLGATIVVTGNWQLSDMS 120 
zebrafish3  ITIVGNLLVIIAIARTSQLQTTTNIFIMSLACADLIMGVLVVPLGATIVVTGQWKLNNTF 86 
FHM3   IIVVGNLMVIIAIARTSQLQTTTNIFIMSLACADLIMGVVVVPLAAMIVVKGEWTLGEVP 96            
            *:*** *.:*** **:*  **..***:**::*** .* :.:.*.* *. 
 
Tetraodon3  CELWTSVDVLCVTASIETLCALAVDRYLAVTNPLRYGALVTKRCARTAVVLVWVVSAAVS 111  
human3   CELWTSVDVLCVTASIETLCALAVDRYLAVTNPLRYGALVTKRCARTAVVLVWVVSAAVS 169  
Fugu3   CELWTSVDVLCVTASIETLCALAVDRYLAVTNPLRYGALVTKRCARTAVVLVWVVSAAVS 111  
trout3a   CELWTSVDMLCVTASIETLCVIAVDRYIAITRPLRHKVLLNKWRARLIVCVVWIVSALIS 180  
trout3b   CELWTSVDVLCVTASIETLCVIAVDRYIAITRPLRHKVLLNKWRARLIVCVVWIVSALIS 180 
zebrafish3  CELWTSVDVLCVTASIETLCIIAVDRYIAITRPLRHKVLLNKCRARIIVCIVWIVSACIS 146 
FHM3   CRLWTSVDVLCVTASIETLCINAVDRYIAIMRPLRYKVLLNKCRARIIVCVVWLLSALIS 156  
   *.******:***********  *****:*: .***: .*:.*  **  * :**::** :*
             
 
Tetraodon3  FAPIMSQWWRVGADAE--AQRCHSNPRCCAFASNMPYVLLSSSVSFYLPLLVMLFVYARV 169  
human3   FAPIMSQWWRVGADAE--AQRCHSNPRCCAFASNMPYVLLSSSVSFYLPLLVMLFVYARV 227  
Fugu3   FAPIMSQWWRVGADAE--AQRCHSNPRCCAFASNMPYVLLSSSVSFYLPLLVMLFVYARV 169  
trout3a   FVPIMNQYWRAEDDPE--AVLCYQDPACCDFLINRTFAIISSVVSFYIPLLIMIFVYAKV 238  
trout3b   FVPIMNQLWRAEEDPE--AMVCYQDPACCDFMTNSTFAIISSVVSFYIPLLIMIFVYVKV 238 
zebrafish3  FIPIMYGFWR-RDPNDDVATACYSDTNCCDFITNMTYAIISSVVSFYIPLFIMIFVYARV 205 
FHM3   FVPIMNDWHAGADTGNKNDTDNYKDT--CAFDTNMAFAIFSSGISFYIPLLIMIFVYARV 214 
   * ***          :      :.:.  * *  * .:.::** :***:**::*:***.:*       
 
Tetraodon3  FVVATRQLRLLRGELGRFPPEESPPAPS------RSLAPAPVGTCAP-----PEGVPACG 218  
human3   FVVATRQLRLLRGELGRFPPEESPPAPS------RSLAPAPVGTCAP-----PEGVPACG 276  
Fugu3   FVVATRQLRLLRGELGRFPPEESPPAPS------RSLAPAPVGTCAP-----PEGVPACG 218  
trout3a   FLIATRQVQLIDKIRLRFQSECPVPQTQQLSHHSNNILPLGYGGSCSRSSTSSARKRSSR 298  
trout3b   FLIATRQVQLIDKTRLRFQSEWPAPTTTQLSNHSCNILPLGYGGSS--SCTSSPRKRSSK 296 
zebrafish3  FLIATRQVQLIDKNRLRFQNEYMGNQVQPPTIGNNNLPSMCNNVGG-----MTAKRKSSR 260 
FHM3   FLVATRQVQLIGNNRLRFQNECIGNQVH----GNNNLPSMCNNVGG-----MTARRKSSR 265  
   *::****::*:     **  *     .: .   .         .    :. 
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Figure 29. ClustalW aligned amino acid sequences of the fathead minnow (FHM), zebrafish (ZF), trout a and b, Tetraodon, fugu and 
human β3-AR sequences. Calculated TMDs for fathead minnow highlighted in yellow, documented TMDs for trout β3a- and β3b-ARs 
highlighted in red and proposed TMDs for human β3-AR highlighted in green. GPCR and β-adrenergic receptor motifs highlighted in 
blue font. Highlighted purple amino acid residue at alignment position 75 represents a potential tryptophan (W) replacement for 
arginine (R) in the human β3-AR compared to other vertebrates (including the fathead minnow); only confirmed amino acid residues 
highlighted. 
 
Tetraodon3  RRPARLLPLREHRALCTLGLIMGTFTLCWLPFFLANVLRALGGPSLVPGPAFLALNWLGY 278  
human3   RRPARLLPLREHRALCTLGLIMGTFTLCWLPFFLANVLRALGGPSLVPGPAFLALNWLGY 336  
Fugu3   RRPARLLPLREHRALCTLGLIMGTFTLCWLPFFLANVLRALGGPSLVPGPAFLALNWLGY 278  
trout3a   RRPSRLTVIKEHKALKTLGIIMGTFTLCWLPFFVANIINVFDRN-VPPGEIFRLLNWLGY 357  
trout3b   RRPSRLTVVKEHKALKTLGIIMGTFTLCWLPFFVANIINVFDRN-VPPGEIFRLLNWLGY 355 
zebrafish3  RRPSRLTVIKEHKALKTLGIIMGVFTLCWLPFFVANIIYAFVP---QDKYFFRLLNWLGY 317 
FHM3   RRPSKLTAVKEHKALKTLGIIMGIFTLCWLPFFVANIINVFNRD-LLTMYVFRYLNWLGY 324  
   ***::*  ::**:** ***:*** *********:**:: .:          *  ****** 
 
Tetraodon3  ANSAFNPLIYCRSPDFRSAF---------------------------------------- 298  
human3   ANSAFNPLIYCRSPDFRSAFRRLLCRCGRRLPPEPCA---------AARPALFPSGVPAA 387  
Fugu3   ANSAFNPLIYCRSPDFRSAF---------------------------------------- 298  
trout3a   VNSGLNPIIYCRSPEFRTAFKNLLGCPWFSTPR--FNIF--YKELRTRCPCFLGSAEAG- 412  
trout3b   INSGLNPIIYCRSPEFRTAFKNLLGCPWFSTPR--LNTLGVYKEKRTHCPCFLGSPEA-- 411 
zebrafish3  INSGLNPIIYCRSPEFRTAFKNLLACPWIPSIK--MNFL--YKEFQIRCPCFLGSAEPGM 373 
FHM3   INSSLNPIIYCRSPEFRAAFKNLLGCPWVSPLR--MNFL--YKELRTRCTCFLGSAESGM 380 
    **.:**:******:**:**  
 
Tetraodon3  ------------------------------------------------------------  
human3   RSSPAQPRLCQRLDGASWGVS--------------------------------------- 408  
Fugu3   ------------------------------------------------------------  
trout3a   AASFQKPPAAATPEG--------------------------------------------- 427  
trout3b   ASSFQKPPAAARPEGDESLASSQSSDKSEEPSPGPPHFNGNTQFSEFSKPENELNWTGEK 471 
zebrafish3  SGSFQKPPTSPDALPED--GSSQSSYRSEEPSPGPPHSNGSTFFSEISEPETEL------ 425 
FHM3   PGSFEKPPTSPGALPGE--GSSQSSYRSEEPSPGPPHSNGRTFFSDFSEPETEFCNL--- 435  
 
Tetraodon3  ------  
human3   ------  
Fugu3   ------  
trout3a  ------  
trout3b   LTFTTD 477  
zebrafish3  ------  
FHM3    ------  
 
 87 
 
 
 
 
Overall, the proposed fathead minnow β3bi-AR was 57% and 61% similar to the trout β3a-
AR and β3b-AR sequences, respectively, 74% similar to the zebrafish β3bi-AR, 50% 
similar to the Tetraodon and fugu β3-ARs and 40% similar to the human β3-AR. 
However, the location of the TMDs (excluding Tetraodon and fugu as they have not been 
documented) varied considerably between the sequences and therefore, the percentage 
similarity across the TMDs varied significantly. This was most obvious for the trout β3a-
AR and β3b-AR TMDs 4 and 5, where there was no overlap between the sequences and 
the fathead minnow β3-AR. The TMDs, documented by Nickerson et al (2003) were not 
long enough to span the cell membrane bilayer; for example TMDs 2 and 3 were only 12 
amino acids long and, as such, may have been incorrectly identified. The location of the 
TMDs in the human β3-AR, as proposed by Strosberg & Pietri-Rouxel (1996), were in 
line with the fathead minnow, and this was reflected in the percentage similarity scores. 
Several amino acid motifs specific to GPCRs and β-adrenergic receptors were found in 
all the sequences, although in the case of the trout β3a-AR and β3b-ARs, not necessarily in 
the correct locations, which was possibly due to the incorrect allocation of TMDs. 
 
In July, 2008, the zebrafish β3bi-AR sequence classified on the NCBI database, and used 
as the template for original primer designing, was re-classified as a β1-AR sequence 
(NM_001128335). This, therefore, suggested that the fathead minnow β3bi-AR sequence 
was potentially a β1-AR. To examine this possibility, the pre-existing zebrafish β1-AR 
amino acid sequence and the fathead minnow β1-AR amino acid sequence characterised 
by Giltrow (2008) were compared to the newly classified zebrafish β1-AR amino acid 
                Whole  
  1 2 3 4 5 6 7 sequence 
human β3-AR 33 53 90 47 61 72 70 40 
trout β3a-AR 55 66 16 0 0 89 73 57 
trout β3b-AR 61 75 25 0 0 89 78 61 
Tetraodon  β3-AR        50 
Fugu  β3-AR        50 
Table 14. Percentage similarity scores of TMDs between the fathead minnow β3-, trout β3a- and β3b- and human β3-AR amino acid 
sequences. 
Fathead minnow β-3-AR 
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sequence. Table 15 shows that the fathead minnow and current zebrafish β1-AR were 
91% identical whilst the proposed zebrafish β1-AR was only 45% similar to both β1-AR 
sequences. Moreover the amino acid motif sequence typically found in all β1-ARs (see 
table 11) was absent from both the fathead minnow β3bi-AR and the proposed zebrafish 
β1-AR sequences, thus providing further evidence that the sequences were more likely to 
be β3-ARs. 
 
 
 
 
 
 
Table 16 compares similarity of the fathead minnow β3bi-AR with the fathead minnow β1-
AR and β2-AR sequences at the amino acid level. The level of similarity between the 
fathead minnow β3-AR and other characterised fathead minnow β-ARs ranged from 38% 
to 43% for the fathead minnow β-1-AR and fathead minnow β2-ARs respectively. This 
suggests that the proposed fathead minnow is unlikely to be a β1-AR or β2-AR. At 435 
amino acids long, the β3-AR was also considerably longer than other β-AR sequences. 
 
 
 
 
 
 
 
 
 
 
  FHM β-1-AR zebrafish β 1-AR zebrafish β-?-AR 
FHM β-1-AR   91 44 
zebrafish β 1-AR 91   45 
zebrafish β-?-AR 44 45   
  
Amino acid sequence 
lengths 
Similarity with FHM 
β3bi-AR 
 
FHM β1-AR 402 43 
FHM β2.i-AR 378 38 
FHM β2.ii-AR 397 38 
FHM β3bi-AR 435  
Table 15. Percentage alignment scores between the fathead minnow and current zebrafish β1-AR, the fathead minnow 
β3bi-AR and the newly suggested zebrafish β1(?)-AR. Scores in red highlight similarity between fathead minnow and 
current zebrafish β1-AR. Scores in blue highlight similarity between newly proposed zebrafish β1-AR and the fathead 
minnow and current zebrafish β1-AR. 
Table 16. Sequence lengths and similarity scores (%) between the proposed fathead 
minnow β3bi-AR and the classified fathead minnow β1-AR and β2-ARs amino acid 
sequences. 
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2.3.6.3 Phylogenetic analysis 
The results from the phylogenetic analysis (figure 30) both supports and adds further 
observations to those, made in tables 14 - 17. The fathead minnow β3bi-AR was most 
similar to the zebrafish β3-AR. However, it was then most similar to the human β1-AR. 
The human β3-AR was closely similar to the fugu and tetraodon. However, neither the 
fugu nor the tetraodon sequences have been confirmed and it could be possible that the 
human β3-AR was used as a template to identify a similar sequence in the fugu and 
tetraodon genome using software analysis but that the identified receptor sequences 
actually function as different receptors. The three characterised fish β3-ARs (trout and 
fathead minnow) are all more closely linked to the human β1-AR than β3-AR. The fathead 
minnow β3bi-AR was distinctly different to other fish β1- and β2-ARs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. A phylogenetic tree for all fish and human β-adrenergic receptors; with bootstrap values.  
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2.3.7 β3bi-AR expression in fathead minnow tissues 
β3bi-AR expression was visualised in several tissues via a 2.0% agarose gel (figure 31). 
β3bi-AR was expressed in all tissues examined and expression levels appeared to be 
highest in the heart, gill and blood in both male and female fathead minnows suggesting 
the receptor role is the same in both sexes and maybe similar to that proposed by 
Nickerson et al (2003) in the trout. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 2 3   4    5 6 8 9  10  11    12 13 14 
100bp 
200bp 
Figure 31. UV image of tissue expression of the β3bi-AR in the fathead minnow. 1 – 6 = male liver, 
brain, gill, heart red blood cell, adipose and gonad; 7-13 = female heart, liver, brain, gill, red blood cell, 
adipose and gonad. 
  7 
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2.4 DISCUSSION 
 
2.4.1 Expression of β3bi-AR in the fathead minnow 
Both adult male and female fathead minnows expressed the β3bi-AR, as did the adult male 
zebrafish. The total length of the characterised fathead minnow β3bi-AR sequences was 
2,203 nucleotides and the amino acid sequence contained all the characteristic motifs at 
the specified locations that are associated with both GPCRs and β-ARs. 
 
With the exception of the fathead minnow (present study), the only fish to have a fully 
characterised β3-AR is the rainbow trout (Nickerson et al, 2003). The fathead minnow 
β3bi-AR was 57% and 61% similar to the trout β3a- and β3b-AR. However there were some 
marked differences in similarity across the TMDs. The allocation of TMDs varied greatly 
between the fathead minnow β3bi-AR and the trout β3-AR sequences to the extent that 
there was minimal alignment between the respective TMD 3 sequences and no alignment 
similarity between TMDs 4 and 5. Nickerson et al used a gene conversion event database, 
GENECONV (version 1.7), to examine for TMDs but the length of some of the TMDs 
characterised in the trout were less than 18 amino acids in length and therefore, according 
to Lekowitz and Caron (1988), would not span a cell membrane. For example, TMDs 2 
and 3 were only 12 amino acids long and of the seven TMDs, only TMDs 5 and 7 were 
long enough to span a membrane, which suggests that TMD allocation in the trout was 
possibly incorrect. The allocation of TMDs in the human β3-AR (Strosberg & Peitri 
Rouxel, 1996), however, was very similar to those in the fathead minnow β3bi-AR, thus 
supporting the findings from this study.  
 
The fathead minnow expressed two different β3b-AR subtypes, namely β3bi-AR and β3bii-
AR. Both sequences were 46% identical at the nucleotide level and 53% identical at the 
amino acid level across the TMD 3 and TMD 4 region, which was unusually low as the 
TMD sequences are usually highly conserved across these functional domains. The trout 
β3a- and β3b-AR sequences were 84% identical across the entire sequence length; however 
it was not possible to identify the entire fathead minnow β3bii-AR sequence and therefore 
examine the similarity between the complete β3b-AR subtypes. In humans and higher 
vertebrates (all of which are diploid) there are three types of β-ARs, namely β1-AR, β2-
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AR and β3-AR. Teleost fish, however, have undergone additional gene duplication events 
and are tetraploid and therefore may potentially express many more β-AR subtypes 
(Froschauer et al, 2006); the fathead minnow could potentially express a β3ai – and β3aii-
AR. As a result of these genomic duplication events in both diploid and tetraploid 
species, polymorphisms of genomic sequences can occur. Polymorphisms are variations 
in genomic sequences at an allele frequency of >1% in a single population and are often 
presented as single nucleotide substitutions. As such, polymorphisms may encode 
different amino acids (nonsynonymous polymorphisms) or may have no effect on the 
encoded amino acid (synonymous polymorphisms) (Small et al, 2003). A 
nonsynonymous polymorphism observed in the β3-AR gene has been reported that results 
in a substitution of arginine for tryptophan at amino acid position 64, as shown in figure 
29 (Clement et al, 1995). This residue is located either at the distal end of TMD 1 or 
within the first intracellular loop of the receptor. In higher vertebrates arginine is found at 
position 64, however in humans tryptophan has been found to replace arginine with an 
allele frequency of 8-10%, which suggests that there was a human-specific evolutionary 
pressure for dominance of the tryptophan residue. Both the fathead minnow and the trout 
β3-AR sequences express arginine at alignment position 75, which corresponds to 
position 64 in the human β3-AR. It is very unlikely, however, that both nonsynonymous 
and synonymous polymorphism events are responsible for the differences between the 
fathead minnow β3bi- and β3bii-AR sequences as the sequences are considerably different 
from one another. It is possible that a gene conversion event, which is the alteration of a 
sequence that does not affect its function, extending across the known sequence regions 
of both the β3bi- and β3bii-AR is responsible for the difference in sequence homology 
(Cantor & Smith, 1999; Betts & Russell, 2003).  
 
Furthermore, results from the RACE PCR indicated that a β3bi-AR sequence taken from 
approximately TMD 2 to TMD 5 was different to other PCR and RACE PCR products, 
including the confirmation primer-walking sequence. The sequence was also different to 
the β3bii-AR sequence. Considering the occurrence of genomic duplication events and 
possible gene conversion events in teleost fish, this sequence may represent a second β3bi-
AR sequence. 
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2.4.2 Comparison with fathead minnow β1- and β2-AR sequences 
The β3bi-AR, consisting of 435 amino acids, was considerably longer than the fathead 
minnow β1-AR and β2i- and β2ii-AR sequences which were 402, 378 and 397 amino acids 
long (Giltrow, 2008), respectively, which  differs from the human β1-, β2- and β3-ARs, 
where β1 and β2 are longer than β3-AR (Skeberdis, 2004). It is difficult at this stage to 
postulate whether the differences in amino acid sequence lengths has any bearing on 
functional differences between the different β-AR subtypes. The fathead minnow β3bi-AR 
was more similar to the β1-AR (43% similar) than the β2-ARs (38% similar to both 
subtypes) which goes someway to support previous suggestions that perhaps the β3-AR is 
derived from a β1-AR (Skeberdis, 2004).  
 
Cluster algorithm analysis of aligned vertebrate β-AR amino acid sequences including the 
fathead minnow β-AR sequences produced a tree with three major groups corresponding 
to the three pharmacologically defined β-AR subtypes and placed the fathead minnow 
β3bi-AR at the base of the β3-AR group with strong statistical support (99%). All three 
groups of receptors were closely related according to the bootstrap values. The 
phylogenetic tree did support previous observations that the fathead minnow β3bi-AR was 
more similar to the fathead minnow β1-AR than the β2-AR. Moreover, β3-AR receptors in 
general were more similar to β1-ARs than β2-ARs, which further supports the theory that 
β3-ARs may be the product of β1-AR evolutionary divergence. However, since the 
fathead minnow β1- and β3-AR sequences were not closely similar, one can assume that 
they are different β-AR types. For absolute confirmation, kinetic ligand binding assays 
are required to examine the binding potential of both β-ARs to different catecholamines 
and to examine for different G-protein mediated responses to ligand binding. 
 
2.4.3 Expression of the β3bi-AR in fathead minnow tissues 
The β3bi-AR was found in all examined tissues, those being the heart, liver, brain, red 
blood cell, gonad, adipose tissue and gill from both adult male and female fathead 
minnows. Nickerson et al (2003) documented that the β3a- and β3b-ARs were found in the 
trout heart and gill and red blood cells, respectively, and suggested that the function of 
the β3b-AR was to control the β-AR Na
+
/H
+
 exchanger (β-AR/β-NHE), which regulates 
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red blood cell intracellular pH, and in turn enhances the affinity of hemoglobin for 
oxygen, thus allowing for increased oxygen transport by the blood. Although the function 
of the β3bi-AR in the fathead minnow heart and gill is not known, both tissues are 
arguably the most important for fish in regulating blood flow, in particular the gill with 
regards to binding oxygen to blood.  As the β3bi-AR appeared to be expressed most highly 
in the heart, gill and blood (although this was subjectively assessed and needs to be 
repeated), it is possible that the β3bi-AR performs a similar role in the fathead minnow as 
in the trout. However, as it was expressed in all examined tissues, it is possible that the 
β3bi-AR may perform a number of functions.  
 
In humans and higher vertebrates, the β3-AR is found predominantly in brown adipose 
tissue, although it has also been identified in the human brain, gallbladder, colon, internal 
mammary artery, bladder, mouse oocytes and the pig duodenum (Krief et al, 1993; 
Rodriguez et al, 1995 Bardou et al, 1998; Horinouchi & Koike, 1999; Takeda et al, 1999; 
Čikoš et al, 2005). Accordingly, the suggested principal role of the β3-AR is to facilitate a 
thermogenic response, although researchers have postulated its role in other tissues, for 
example in brain development in juveniles and urine storage in adults. Unsurprisingly the 
β3bi-AR was found in several tissues including the adipose tissue, albeit at apparently 
lower levels than the heart, blood and gill. According to Giltrow (2008), neither the 
fathead minnow β1-AR nor the β2-ARs were found in adipose tissue, providing further 
evidence that the β3bi-AR belonged to the β3-AR family, although its function in the 
fathead minnow is unknown since it is unlikely that a poikilothermic fish requires a 
thermogenic response. However, there is the possibility that the β3bi-AR could mediate 
the mobilisation of energy reseves during fasting, migration or egg laying in fathead 
minnows via lipolysis. Ligand binding assays would need to be employed to examine the 
role of the β3bi-AR in the fathead minnow. 
  
There were sex-based differences in the expression patterns of the β3bi-AR in the fathead 
minnow; however the technique of examining expression levels was, in comparison to 
RT-PCR, less sensitive and semi-quantitative. Therefore, before examining this anomaly, 
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a comprehensive, sensitive and accurate means of examining expression levels, such as 
RT-PCR, is required. 
 
2.4.4 Limitations of the study 
One of the main problems encountered was the interpretation of the outcomes from the 
different topology programmes used to predict the TMDs. The 5 different EXPasy 
programmes produced identified TMDs at different locations and, despite there being a 
level of agreement between the programmes on isolated TMDs, there was not a 
unanimous agreement between any two programmes for all seven TMDs. Furthermore, 
TMHMM and HMMTOP did not identify a TMD 7; this problem was also encountered 
when identifying the fathead minnow β1- and β2-ARs (Giltrow, 2008) suggesting that this 
may be an inherent problem with using these programmes. Using the information from 
each topology programme, along with the motif criteria, the TMDs were selected 
according to the TMpred programme. 
 
The rainbow trout is the only fish to have a sequenced β3-AR and therefore the use of all 
other sequences, including the zebrafish that was used as the template for primer 
designing, are based entirely on NCBI sequences produced by automated processing of 
existing genomic data and are therefore predicted sequences. This problem was 
highlighted further in the current study when the existing zebrafish β3bi-AR sequence was 
changed from a predicted β3bi-AR to a β1-AR, which indicated that the fathead minnow 
sequence could be a β1-AR. Upon further inspection, the sequence did not express the 
motif tag associated with all β1-ARs (as suggested by Mason et al, 1999). Additionally, 
Giltrow (2008) identified the fathead minnow β1-AR through PCR and cloning and the 
similarity between this sequence and the pre-existing zebrafish β1-AR was 91%, whilst 
the similarity between the re-assigned zebrafish β1-AR and the fathead minnow β1-AR 
was 44%. Therefore, it is unlikely that that the zebrafish sequence is a β1-AR but more 
likely a β3-AR. This example demonstrates one of many problems when working with 
sequences that have not been confirmed in the laboratory. 
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2.4.5 Recommendations for future work 
The tissue distribution of the β3bi-AR supports findings from other studies that it is a β3-
AR subtype. However, for accurate confirmation, kinetic competitive ligand binding 
assays are required. 
 
The fathead minnow, and certainly the zebrafish, represent a potentially suitable 
alternative model test species for pharmaceutical development. As the β3-AR in humans 
is primarily located in adipose tissue and is directly involved in thermogenesis and 
lipolysis, activation of the β3-AR is thought to be a possible treatment approach for 
obesity, type 2 diabetes, mellitus and frequent urination (Arner & Hoffstedt, 1999; Sawa 
& Harada, 2006). Therefore, in this context, it is extremely important that the β3-AR 
identified in both the fathead minnow and zebrafish is confirmed as the use of either fish, 
most likely the zebrafish, as a test species may aid in anti-obesity drug development. 
Accordingly, it is also important to explore the number of β-AR subtypes in the fathead 
minnow to aid understanding from both an evolutionary, drug-development and 
environmental monitoring perspective. 
 
2.4.6 Conclusion 
The current study demonstrated that the fathead minnow expresses the β3-AR in several 
fathead minnow tissues. Together with the previous study by Giltrow (2008), all three β-
ARs have been identified in the fathead minnow, which provides suitable justification for 
a fathead minnow pair-breeding assay exposure to the non-specific β-blocker, 
propranolol. This study represents a successfully first stage of an intelligent test-protocol 
for examining pharmaceutical toxicity on fish. 
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CHAPTER 3: FATHEAD MINNOW EXPOSURE TO 
PROPRANOLOL 
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3.1 INTRODUCTION 
The aim of the exposure experiment was to generate tissues suitable for metabolomic 
analysis and β3-AR expression studies using real-time PCR. Accordingly, adult fathead 
minnows were exposed to several concentrations of the non-specific β-blocker 
propranolol, ranging from 0.001mgL
-1
 to 10mgL
-1
, and tissues collected for metabolomic 
and β3bi-AR expression analysis. 
 
3.1.1 Pharmacokinetic properties of propranolol 
Propranolol works by competitively inhibiting β-ARs, thus reducing the effects of 
adrenaline and noradrenaline, and is prescribed to patients suffering with angina and 
hypertension (high blood pressure), adrenal cushing‟s syndrome and corticotrophin-
independent bilateral adrenal hyperplasia and to treat patients after a heart attack to 
prevent further attacks (Lacroix et al, 1997; UAB Health System, 2006; Fent et al, 2006). 
Upon consumption, propranolol undergoes extensive first stage hepatic metabolism by 
the cytochrome 2C19 and 2D6 P450 enzymes and only approximately 10% of the parent 
compound is excreted, most often in urine (Perkinson, 1996; Huggett et al, 2003a). Once 
excreted, propranolol enters wastewater treatment facilities. Ternes (1998) found that a 
German sewage treatment work (STW) removed 96% of propranolol, although this figure 
is likely to be lower in wet weather conditions. According to these calculations, 0.4% of 
the original propranolol product passes through the STWs into the aquatic environment. 
However, propranolol has been detected in the aquatic environment at concentrations 
ranging from <10ngL
-1
 to 2.2µgL
-1
 (Huggett et al, 2003a; Ashton et al, 2004), as shown 
in table 17. In the UK, Thomas & Hilton (2004) collected 45 STW water effluent samples 
and detected propranolol in every sample. These figures reflect the enormous usage of 
propranolol, especially across the developed Western countries.  
 
Propranolol has an n-octanol-water partition coefficient (log Kow) value of 3.67 and a half 
life of 16.8 days at 5.0
o
C in winter indicating that it has the potential to accumulate in 
either biota or partition into sediments, thus prolonging the length of time it resides in the 
aquatic environment and therefore increase the likelihood of inducing an effect in 
resident biota. Like all drugs designed to be taken orally, propranolol is relatively 
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hydrophobic and it is therefore unlikely that propranolol will degrade via hydrolysis 
(Huggett et al, 2003b; Lee et al, 2007).  
 
 
Sewage 
concentration 
(ngL
-1
) 
Surface water 
concentration 
(ngL
-1
) 
Location Reference 
10-40  Germany Ferrari et al (2004) 
180 590 Germany Ternes (1998); Ternes 
et al (2003) 
16-284 <10-115 U.K Thomas & Hilton 
(2004); Ashton et al 
(2004) 
300 100 U.K. ENDS (2005) 
26-2200  U.S.A Huggett et al (2003a) 
 
3.1.2 Measured effects of propranolol on the aquatic environment 
Several in vivo studies have examined the acute toxicity of propranolol to both 
invertebrates and vertebrates. Algae and plant inhibition of growth studies suggested the 
50% effective concentration (EC50) values were 0.73 and 0.8mgL
-1
 (48hr tests) (Huggett 
et al, 2002, Cleuvers, 2004), whilst the crustacean Daphnia magna appeared to be less 
sensitive to propranolol than algae and plants, having a recorded 48 hour EC50 for 
immobilisation of 7.7mgL
-1
. However, contrary information from a 48-hour mortality 
tests suggested Daphnia magna had an observed 50% mortality (LC50) at a concentration 
ranging from 1.66 – 2.75mgL-1 (Huggett et al, 2002; Ferrari et al, 2004). Regardless of 
these different observations, these measured EC50
 
and LC50 values do not reflect actual 
environmental concentrations. There is very little information that addresses the possible 
effects of long-term, chronic, exposure to propranolol. Early data suggested that over a 
chronic 10-day exposure to propranolol, Dapnia magna showed signs of reduced growth 
(lowest observed effect concentration (LOEC) = 0.44mgL
-1
), fecundity (LOEC = 
0.11mgL
-1
 and heart rate (0.055mgL
-1
) (Dzialowski et al, 2006). Thus, there is the 
Table 17. Reported levels of the β-blocker propranolol in sewage discharges and surface waters. 
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potential for propranolol to have a cardiovascular effect on Daphnia magna in the 
environment, suggesting it may have the same target tissues in aquatic organisms as in 
humans. 
 
The acute toxicity of propranolol has also been investigated in a handful of fish test 
species including the Japanese medaka (Huggett et al, 2003b), the zebrafish (Fraysse et 
al, 2006) and the rainbow trout (Larsson et al, 2006). Huggett and colleagues observed 
50% mortality in 3 – 4 day old Japenese medaka exposed for 48hr to propranolol at a 
concentration of 24.3mgL
-1
. Fraysse and colleagues (2006) examined the response of 4-
day-old zebrafish larvae exposure to propranolol for 24, 48 and 80 hours. After 24 hours 
of exposure to propranolol, there was an observed decrease in the number of spontaneous 
tail movements (EC50 = 1.5mgL
-1
), after 48 hours, there was a reduction in heart rate 
(EC50 = 1.5mgL
-1
) and after 80 hours, no hatching was observed (32mgL
-1
). Larsson and 
colleagues (2006), however, found no effect of exposure to propranolol in the rainbow 
trout at a concentration of 0.00709mgL
-1
, which is not unusual considering the 
concentration was considerably lower than those that triggered a response in the Japanese 
medaka and zebrafish. Although this difference in response to propranolol could be due 
to species sensitivity, age sensitivity, it is thus most likely the result propranolol 
concentration levels; as propranolol concentrations increases, the magnitude of response 
increases. Similarly to the acute toxicity studies using invertebrates, the measured EC50 
values do not reflect actual environmental concentrations. 
 
The more environmentally realistic effects of chronic exposure to propranolol have also 
been examined in a handful of fish studies. The reproductive effects of chronic exposure 
of propranolol to fish have been detected in the Japanese medaka (Huggett et al, 2002). 
Following on from the acute exposure of 3 – 4 day old Japanese medaka to propranolol, 
Huggett and colleagues cultured the medaka in different concentrations of propranolol for 
14 days and found that propranolol inhibited growth at a concentration of 0.5mgL
-1
 and 
reduced testosterone and increased oestradiol concentrations at a concentration of 
0.001mgL
-1
. Huggett and colleagues also exposed sexually-viable adult Japanese medaka 
pairs to propranolol concentrations for 4 weeks and observed a reduction in egg 
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production and hatchability at a concentration of 0.0005mgL
-1
. However, there were 
several discrepancies regarding this data. Firstly, the data was no repeated, secondly, the 
exposures were not carried out in a flow-through system but rather in a semi-static 
system, indicating that exposure to propranolol could have been in acute “doses”, thirdly, 
propranolol was dissolved in ethanol, which seemed unnecessary as propranolol readily 
dissolves in water at the assigned concentrations and so ethanol may have induced a toxic 
response. Finally, the reproductive and hatchability response of Japanese medaka to a 
chronic 4-week propranolol exposure was only observed at the lowest concentration. 
Accordingly, to date our understanding of fish response to chronic exposure to 
propranolol is limited. 
 
As propranolol has the lowest log Kow
 
value of all beta blockers, it is the most lipophilic 
and therefore the most likely to bioaccumulate in fatty tissues. Several studies indicate 
that the sensitivity, and consequential response, of aquatic organisms to propranolol 
exposure is higher than other beta-blockers detected in the environment (Fent, 2006). 
Therefore, for the purpose of examining a measurable response of fish tissues, 
propranolol was the most suitable beta-blocker candidate. 
 
3.1.3 Test organism: the fathead minnow (Pimephales promelas) 
The fathead minnow (Pimephales promelas) along with the zebrafish (Danio rerio) and 
the Japanese medaka (Oryias latipes) is one of the most commonly used small fish test 
species used in ecotoxicological research.  
 
The fathead minnow is a gonochoristic teleost species belonging to the family 
Cyprinidae, order Cypriniformes (Linnaeus, 1758). Etymology of the minnow‟s name 
derives from the shape of the head (Pimephales – “fathead”) and it‟s colour in breeding 
males (promelas – “forward” and “black”) (Mettee et al, 1996). The fathead minnow is a 
small freshwater fish; adults typically reach a maximum total length of 50mm and have a 
moderately compressed laterally-shaped body, a short blunt snout and a slightly 
subterminal snout (Rook, 1999; Yonkos et al, 2000). Sexually mature males have a 
striking appearance and are easily distinguished from the females – they are larger (3-5g 
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versus 2-3g respectively) and darker in colour with vertical bands on the body and head, 
they also have nuptial tubercules on the face and a prominent fatpad on top of the head 
(referred to as secondary sexual characteristics). In contrast females are olive/silver in 
colour and have a more pointed head (figure 32) (Yonkos et al, 2000).  
 
Under optimal conditions the fathead minnow reaches sexual maturity at four to six 
months post-hatch. The sexually mature males select and prepare the nest site, which are 
typically located on the under-surface of submerged stones or branches. Females spawn 
every 2-16 days producing up to 10,000 eggs in the three month breeding season. The 
brooding males protect the eggs from predation and cannibalism and fan the egg masses 
with their caudal and dorsal fins to increase oxygen availability. The spongy dorsal fatpad 
is used for scrubbing the nest site to remove parasites. Eggs hatch within 4-5 days 
depending on temperature and begin feeding almost immediately (Harries et al, 2000; 
Yonkos et al, 2000; Jensen et al, 2001).  
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Female (top) and male (bottom) fathead minnow, Pimephales promelas. The male is illustrated 
in breeding condition. Illustrations taken from Yonkos et al (2000). 
 
3.1.3.1 Role of the fathead minnow in ecotoxicological research 
The fathead minnow has been, and still is, used as a model test species in routine 
regulatory toxicity tests by a multitude of agencies including the environmental 
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protection agency (EPA), the environment agency (EA) and the organisation for 
economic cooperation and development (OECD). These tests encompass short-term 
48/96-hr lethality assays, complex partial and full life-cycle tests involving a battery of 
both apical (whole animal) and mechanistic/diagnostic endpoints (Harries et al, 2000). 
With developments in genomic, proteomic and histological techniques, the fathead 
minnow has become an established biomarker test species for a diverse number of 
contaminants including several pharmaceuticals; arguably the most extensively studied of 
which has been ethinyloestradiol (EE2) (Harries et al, 1998; Harries et al, 2000; Halm et 
al, 2002; Zerulla et al, 2002; Leino et al, 2005; Ankley & Villeneuve, 2006; Miracle et 
al, 2006). The fathead minnow represents a potentially more advantageous test-species 
compared to an alternative OECD test species, the zebrafish, when examining the 
reproductive response to pharmaceutical exposure. Thorpe et al (2007) examined 200 
different pair-breeding assays using the fathead minnow as the test species and found that 
egg production was more consistent and robust compared to the zebrafish, which 
according to Paull et al (2008) required higher levels of replication pairs when examining 
the reproductive response to EDCs. 
 
To date, only a single study has examined the response of fathead minnows to β-blocker 
exposure. Winter and colleagues (2008) examined the impacts of chronic 21-day 
exposure of atenolol on both the reproductive output and subsequent embryo-larval 
development of fathead minnows. The results from the assay suggested that atenolol 
(concentrations ranging from 0.1mgL
-1
 to 10mgL
-1
) did not have an impact on the 
reproductive potential or embryo-larval survival, suggesting that it is less toxic than 
propranolol. 
 
3.1.4 Aim of study 
There were two aims for the study: to firstly examine the response of fathead minnows to 
chronic 21-day exposure to propranolol using the same pair-breeding assay and 
physiological endpoints originally described by Winter et al (2008); and to secondly 
acquire tissues suitable for NMR-metabolomic and Real Time PCR (RT-PCR) β3-AR 
expression analysis for subtle biomarkers of propranolol exposure. 
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3.2 METHODOLOGY 
 
3.2.1 Propranolol experimental design  
The propranolol pair breeding assay adopted for this study was originally proposed by 
Harries et al (2000) and Ankley et al (2001) and subsequently adapted by Winter et al 
(2008) for examining the response of the fathead minnow to the β-blocker atenolol. In 
Brief, sexually viable adult fathead minnows aged 1 year post hatch (Thorpe et al, 2007), 
were housed in discrete male-female pairs and their reproductive potential assessed over 
two concurrent 21-day periods: one prior to propranolol exposure (referred to as the 
„baseline period‟) and one during exposure to propranolol („exposure period‟). The 
nominal concentrations of propranolol were set at the environmentally relevant 
concentration of 0.001mgL
-1
 plus 0.01mgL
-1
, 0.1mgL
-1
, 1.0mgL
-1
 and 10.0mgL
-1
 and a 
dilution water control (DWC). The endpoints measured were survival, egg production, 
standard length, wet weight and condition index (CI), gonad weight and gonadosomatic 
index (GSI) and secondary sexual characteristics and also first generation (F1) survival.  
 
The entire pair-breeding assay was repeated, which was in part due to experimental room 
size limitations, but it also presented both an ethical and statistical advantage. Ethically, if 
no physiological effect was observed in the first experiment, there would be no need to 
conduct the second experiment and unnecessarily expose adult fathead minnows to 
propranolol. Statistically, by repeating the study it was possible to examine how robust 
the first data set was and if there were no significant differences between the same 
treatment groups between the experiments, the data could be pooled to produce a larger 
and more statistically-powerful replicate number. 
 
3.2.2 Preparation of experimental room 
Prior to running the pair-breeding assay the walls and floors of the experiment room were 
washed with „Pinefresh‟ detergent and subsequently washed with water. The header tanks 
were bleached and the bleach was left overnight to ensure any algae that may have 
accumulated in the system was killed. The glass tanks that were used to house the fish 
pairs were cleaned with Scale-Free and washed and rinsed in the tank washing machine 
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to ensure that any residual chemical or substance from a previous experiment was 
removed. The flow meters that were used to control the rate of header tank water entering 
the mixing chamber were also dismantled and cleaned, after which fresh PTFE tape was 
put around the screws; this was again to ensure any residual chemical or substance was 
removed.  
 
3.2.3 Preparation of stock solutions and dosing of tanks and water quality 
A continuous flow-through system was employed, ensuring a complete water change of 
dechlorinated tap water in each pair-breeding tank every 2.5hrs. Propranolol-
hydrochloride (DL-Propranolol hydrochloride, 1–isopropylamino-3-(1-naphthyloxy) 
proprano-2-ol hydrochloride) (CAS 318-98-9) (figure 33) was used as the source of 
propranolol. Propranolol hydrochloride is a racemic mixture that is 99% pure and was 
supplied from Astrazeneca, Brixham laboratories and because it is light sensitive was 
stored in a foil-wrapped beaker at 4
o
C. 
 
 
 
 
 
 
 
 
Propranolol was readily dissolved in dilution water by vigorous shaking. Individual 
stocks of propranolol were prepared for each dosing concentration; table 18 shows the 
calculated volumes of propranolol used for each test concentration. To minimize photo-
degradation of propranolol, each stock bottle was wrapped in foil. Figure 34 shows a 
close-up of the propranolol stock bottles and the peristaltic pump which was used to 
deliver each propranolol stock to their respective concentration tanks. 
 
 
 
Figure 33. Chemical structure of propranolol hydrochloride. 
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Nominal concentration of Propranolol-
HCl (mgL
-1
) in fish tanks 
Amount of propranolol-HCl added 
to each 4L bottle (g) 
0.001 0.0016 
0.01 0.016 
0.1 0.16 
1.0 1.6 
10.0 16.0 
Table 18 Calculated volumes of propranolol required for each test concentration in 4L. 10mgL-1 
concentration, highlighted in red, was only used for the first study and not the repeat. 
Figure 34. Close-up photograph of the a) the stock bottles wrapped in foil; b) the peristaltic pump; c) the 
magnetic stirrers used to ensure complete mixing of propranolol stocks and d) the tubing taking each 
propranolol stock to their respective concentration mixing vessel. 
a) 
b) 
  c) 
  d) 
 107 
During the exposure period, all propranolol stocks were dosed at 1.0ml min
-1
, using a 
Watson Marlow (Cornwall, UK) multi-channel peristaltic pump, into glass mixing 
vessels where they mixed with dilution header-tank water (400ml min
-1
) before delivery 
into their respective test tanks at a flow rate of 80ml min
-1
; see figure 35. All tubing 
within the system was medical grade silicon. Each stock was replenished every 2.78 days. 
Direct measurements of dilution water flow rates were made twice per week throughout 
the exposure period, with daily checks to ensure the correct operation of the dosing 
system. The flow rates of the concentrated propranolol stocks were checked twice per 
day.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35.  A photograph of one side of the experimental room. a) represents the header tank; b) shows 
the mixing vessels from which water from the header tank and propranolol from the stock bottles mixed 
before flowing into the individual fish tanks (c)); d) indicates one of the flow meters; e) shows one of the 
clamps used to regulate water flow from the mixing vessel into each tank. 
a) 
b) 
c) 
d) 
e) 
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In the first experiment five test concentrations were used, however in the repeat 
experiment the four test concentrations used were 0.001mgL
-1
, 0.01mgL
-1
, 0.1mgL
-1
 and 
1.0mgL
-1
 and also DWC. 
 
3.2.4 Test apparatus 
The tanks used for the adult pair-breeding study had a working volume of 10.5L and were 
constructed of glass. Screens were placed around the sides of all test vessels to prevent 
fish interacting with those in neighbouring tanks and to minimize disturbance due to 
operator movements. A spawning tile and tray (which consisted of a rectangular glass 
tray covered with a 0.5cm
2
 stainless steel mesh (see figure 36) were placed in each 
vessel. The tile served as the nest-site for spawning whilst any eggs that fell of the tile 
were collected in the tray; the mesh allowed eggs to fall through into the tray, while 
preventing passage of the fish. Studies have suggested that this type of system of egg 
collection is highly robust and reduces the variability of egg numbers produced per 
couple per batch (Harries et al, 2000; Thorpe et al, 2007) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 36. Spawning tank with a) male and b) female fathead minnow. c) shows the spawning 
tile; d) shows the glass tray and e) shows the metal mesh. Eggs were counted from c), d) and 
e). 
a) 
b) 
c) 
d) 
e) 
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3.2.5 Water, light and feeding parameters 
Throughout the study the water temperature was maintained at 25 ± 1
o
C, dissolved 
oxygen (DO2) was maintained above 75% saturation (equivalent to 6.2mgL
-1
) and pH and 
water hardness were also recorded. Water from all exposure concentrations and DWC 
were tested for temperature and DO2 on day 0 of initiation and recorded twice per week 
thereafter. Water hardness and pH were also tested for on day 0 and then on once per 
week thereafter. The photoperiod regime was set at 16 hours of light followed by 8 hours 
of darkness, with a 20 minute dawn: dusk transition. 
 
The fish were fed twice a day with frozen adult brine shrimp (Artemia salina) during the 
week and once a day during the weekend.  Fish flakes were also fed once a day. The sides 
and bottoms of all tanks were cleaned and the tanks siphoned to remove debris twice per 
week. All tanks were cleaned at the same times so that all received approximately equal 
levels of disturbance. 
 
3.2.6 Test procedure 
Figure 37 outlines a simplified timeline of the pair-breeding assay test procedure. 
 
 
 
 
 
 
 
 
 
      
 
 
 
 
3 
days 
2 
days 
21 
days 
21 
days 
21 
days 
Total time = 67 days 
Acclimation phase 
Breeding compatibility 
assessment 
   Baseline period    Exposure period 
  Transitional period  
Figure 37. Test procedure schematic highlighting the acclimation phase, breeding compatibility assessment and baseline, 
transitional and exposure periods. Only data from the baseline and exposure period were analysed. 
Data collection and analysis 
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3.2.6.1 Acclimation and breeding compatibility assessment 
To initiate the test, sexually mature male and female fish (1 year old) were selected at 
random and a pair of fish (1 male and 1 female) were placed into each test vessel tank, 
which were all receiving dilution water only. According to Thorpe et al (2007), fathead 
minnow pairs spawn at a „normal‟ rate up to and including 16 months. There were 6 
tanks per treatment, 4 were used to hold fish pairs (n = 4) and 2 were used for 
hatchability trials (see below), totaling 36 tanks.  
 
The fish were then left to acclimate with minimal disturbance for 3 days. During this 
period, fish were only fed (water parameters were measured prior to introduction of the 
fish). After 3 days, the fish were left for a further 21 days to assess breeding 
compatibility. Breeding compatibility was assessed via determination of normal breeding 
behaviour, egg numbers, egg quality (egg viability and presence of abnormalities) and 
spawning ability (e.g. site where the female laid her eggs). This was achieved by 
examining the underside of each breeding tile once a day for egg production, as shown in 
figure 36. In the instance that eggs had been produced, the tile, mesh and glass base was 
removed from the tank and replaced with a clean set. The eggs were examined under the 
microscope to determine whether they were alive or not, dead eggs appear as opaque (as 
shown in figure 38). Egg numbers were counted, using a ticker counter, on the tile, mesh 
and base and recorded accordingly. The ratio of live: dead eggs was subsequently 
calculated. All eggs were subsequently killed via immersion in boiling hot water and then 
washed away. The tile, mesh and base was subsequently washed and dried. 
 
To be deemed suitable for the pair-breeding assay, each fish pair must have spawned at 
least 4 times by the 21
st
 day of the acclimation period; any fish that did not meet the 
breeding requirements were replaced by fish from the original batch. All fish movements 
were recorded. Any signs of distress and mortality were also recorded. 
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3.2.6.2 Baseline period 
After the initiation and acclimation period, the 21-day baseline reproduction period 
commenced. During this time, all tanks received dilution water only and breeding 
compatibility recorded. Each pair would thus serve as their own control. Each pair-
breeding tank was examined once a day for egg production.  
 
3.2.6.3 Transitional period 
Following on directly from the baseline period a transitional period was undertaken 
where propranolol was introduced into the test vessels at the relevant concentrations. To 
ensure that the test vessels had reached their nominal concentrations prior to reproductive 
assessment the transitional period lasted for two days, during which the fish were left 
with minimal disturbance. 
 
Figure 38. Close-up photograph of fathead minnow eggs laid on the underside of the tile, as 
highlighted by the red arrow. 
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3.2.6.4 Exposure period 
The exposure period lasted for a further 21 days, during which the assessment of 
reproductive performance under conditions of propranolol exposure were monitored in 
the same breeding pairs. 
 
Water samples were collected from 3 randomly selected test vessels from each test 
concentration, including DWC, for offsite analysis of propranolol on exposure days 0, 4, 
7, 14 and 21. Water samples (20ml) were collected in 40ml amber glass vials (Sword 
Scientific, Cat # 51-500), which had been previously washed twice with methanol and 
once with ethanol and dried, and stored at -20
o
C until transportation to AstraZeneca 
Brixham Environmental Laboratory (Devon, UK) on dry ice for subsequent analysis. 
 
3.2.7 Water chemistry analysis 
Water samples were analysed by liquid chromatography for analyte separation with 0.1% 
ammonia in water and 0.1% ammonia in methanol over an elution gradient. Electrospray 
ionization-tadem mass spectrometry (ESI-MS/MS) was then used to quantify the 
analytes, which was carried out in the positive ionization mode (+) ESI. For increased 
selectivity, MS/MS with selected reaction monitoring (SRM) was used for detection of 
protonated propranolol ([M + H]
+
, 260.2 Da) and Xcalibur
TM
 software was used for data 
acquisition and processing. 
 
3.2.8 Hatchability trials 
In addition to examining the reproductive potential of fathead minnow pairs exposed to 
propranolol, batches of eggs were taken from each fish pair throughout the study to 
examine the effects of propranolol on egg hatchability and survivability. For each 
hatchability trial, 50 eggs were selected at random from the tile and transferred into an 
incubation cup; this was made of a wire mesh that allowed for the constant movement of 
water across the eggs. The oxygen supply was left to bubble rapidly into the hatchability 
tanks to ensure this movement of water. In some cases there were less than 50 viable eggs 
or there were not enough eggs laid on the tile, therefore hatchability trials were 
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performed on smaller batch sizes taken from the stainless steel mesh and tray, in order of 
preference, with appropriate adjustment of statistical analysis. 
 
Observations were made each day to assess the number of dead eggs (which were 
subsequently removed) and to score for abnormalities of stage development. Figure 39 
shows the scoring process as developed by Tamsin Runnalls (2005). Hatching success 
(%) was also recorded. Eggs were incubated on the hatching apparatus until all eggs had 
hatched or at least two days elapsed since the final hatching.  
 
Hatchability trials were undertaken during both the baseline and exposure period and 2 
hatchability trials were conducted for each pair during both periods. If the hatching 
success from both trials differed by more than 30% an additional trial was undertaken. 
Following the assessment of hatchability, all larvae were sacrificed with an overdose of 
tricane methane sulhponate (MS222) anaesthetic, adjusted to pH 7.5.  
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Figure 39. Photographs of the different stages of fathead minnow egg development (taken from the 
PhD thesis of Tamsin Runnalls, 2005). 
 115 
3.2.9 Sampling Fish 
On day 21 of the exposure period, adult fish were terminated by an overdose of pH-
adjusted MS222 anaesthetic. For propranolol analysis, blood was collected via a tail cut 
(through the caudal peduncle) into 75µl heparinised capillary tubes and then decanted 
into Eppendorf tubes and kept on ice. Due to volume size limitations, blood plasma from 
female fish were pooled together. The blood samples were subsequently spun in a 
centrifuge at 700 x g for 5 minutes to separate whole red blood cells and plasma, and the 
blood plasma was carefully collected. The plasma samples were subsequently stored at -
20
o
C before transportation on dry ice to AstraZeneca Brixham Environmental Laboratory 
for subsequent analysis. 
 
After blood collection, all fish were promptly measured for wet weight (g) and standard 
fork length (mm) and the CI was subsequently calculated (figure 38), which expressed 
the weight of the fish in relation to length. The liver was immediately extracted from each 
male fish for metabolomic analysis, promptly weighed and then snap frozen in liquid 
nitrogen before being stored at -80
o
C. The gonad was subsequently extracted from each 
fish and weighed to determine the GSI (figure 40), which expressed the size of the gonad 
in relation to body weight. The female gonads, liver, heart and brain were subsequently 
snap-frozen in liquid nitrogen for Real Time PCR β3-AR expression analysis. 
 
 
 
The fatpad from each male was subsequently weighed and the number of tubercles, and 
their prominence, assessed using the criteria outlined in table 19. Females were also 
examined for the presence of a fatpad and tubercles, which is indicative of androgenic or 
anti-oestrogenic effects. 
 
 
CI =     wet body weight (g) x 100   GSI = gonad weight (g) x 100 
 wet body weight (g)     fork length (mm) 
 
  
 
 
 Figure 40. Fish condition index (CI) and gonadosomatic index (GSI) calculations. 
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3.2.10 Plasma chemistry analysis 
All samples and standards were firstly prepared by protein precipitation (PPT) where 
50µL of plasma was added to acetonitrile (200µL) (Fisher Scientific, Cat # 14952-0010) 
containing metoprolol internal standard (0.25µgL
-1
) in a filtration vial (0.45µm). After 
vortexing, the filtrate was transferred to a vial and diluted with 100µL 30:70 
acetonitrile/water. Propranolol concentrations were then measured using online solid-
phase extraction/liquid chromatography (SPE/LC).  
 
3.2.11 The mammalian-fish plasma model 
To quantitatively use mammalian pharmacology data in ecotoxicology, a conceptual 
model has been developed using the human No Observed Effect Concentration (NOEC) 
based on the therapeutic plasma concentrations and predicted environmental 
concentrations to calculate a Plasma Exposure Ratio (PER) (Huggett et al, 2003b). The 
PER indicates the likelihood for a fish to bioaccumulate a particular pharmaceutical 
across the gills and therefore indicates the potential for a pharmacological response.  
 
A predicted fish stead state plasma concentration (FSSPC) was obtained for propranolol at 
each treatment concentration by multiplying the treatment concentration value by the 
blood: water partition coefficient (logP), which was derived from the ratio of the 
compound in a water solvent and a hydrophobic solvent such as octanol the logKow value 
(logKow = 3.48; logP = 45.7509) as logP is calculated from the ratio of solubility in water 
and in the hydrophobic solvent octanol (Leo et al, 1971). Propranolol PER was then 
Score Description 
0 No visible sign of tubercles 
+ Tubercles visible as white disks, not protruding above body surface 
++ Tubercles project above body surface 
+++ Tubercles are prominent, but not sharp 
++++ Tubercles are prominent and sharp 
Table 19. Fathead minnow tubercle scoring system (devised by Smith, 1978) used to assess tubercle 
prominence of male fathead minnows after exposure to propranolol for 21 days. 
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calculated by dividing the human therapeutic plasma NOEC (HTPC) (as derived by Wong 
et al, 1979) by the measured FSSPC. A PER <1 indicates that the FSSPC exceeds the 
HTPC and so there is a high likelihood for a pharmacological response in a fish; a PER>1 
indicates that the FSSPC is less than the HTPC and so a pharmacological response in a fish 
is unlikely. 
 
The aim was to examine how applicable the mammalian-fish plasma model was for 
predicting the potential pharmacological effects of propranolol.  
 
3.2.12 Statistical Analysis 
To compare water chemistry and blood plasma results from both exposures, a Mann-
Whitney rank sum test was used, which compared the mean propranolol concentrations 
from each designated concentration treatment group between experiments 1 and 2 and 
examined for significant difference between the experiments. The Mann-Whitney rank 
sum test is the non-parametric alternative to the commonly used t-test.  
 
To test the null hypothesis that there were no statistically significant differences between 
hatchability success between the baseline and exposure periods within each propranolol 
treatment group, the Mann-Whitney rank sum test was again adopted. To test the second 
null hypothesis that there was no significant difference in hatchability success between 
the different propranolol treatment groups, a Kruskal-Wallis One Way Analysis of 
Variance on Ranks (Kruskal-Wallis ANOVA) was performed. An ANOVA is a suitable 
alternative to running several t-tests and compares more than two data sets (Fowler et al, 
1998). However, as the hatchability data was not normally distributed, a Kruskal-Wallis 
ANOVA was performed. 
 
A parametric ANOVA was used to test the null hypothesis that there was no difference in 
egg production between the treatment groups. If a difference was found, a Holm-Sidak 
post-hoc test was used to identify which treatment groups were statistically significantly 
different to each other. Table 20 summarises the statistical tests used on the data collected 
on day 21 of the propranolol exposure.  
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Data set Null hypothesis Test used Post-hoc test used  
Wet Weight There are no differences in wet weight 
between treatment groups. 
 Parametric ANOVA Holm-Sidak 
Fork length There are no differences in fork length 
between treatment groups 
Parametric ANOVA N/A 
Fat pad weight There are no differences in fat pad 
weight between treatment groups 
Non-parametric Kruskal-Wallis One 
Way Analysis of Variance on Ranks 
Dunn‟s post hoc test 
Tubercle number There are no differences in tubercle 
number between treatment groups. 
Non-parametric Kruskal-Wallis One 
Way Analysis of Variance on Ranks 
Dunn‟s post hoc test 
Tubercle prominence There are no differences in tubercle 
prominence between treatment groups 
Non-parametric Kruskal-Wallis One 
Way Analysis of Variance on Ranks 
N/A 
Male gonad somatic index 
(GSI) 
 There are no differences in the GSI 
between treatment groups. 
Parametric ANOVA Holm-Sidak 
 
Female gonad somatic index 
(GSI) 
 There are no differences in the GSI 
between treatment groups. 
Parametric ANOVA Holm-Sidak 
 
Male Condition index (CI)  There are no differences in the CI 
between treatment groups. 
Parametric ANOVA Holm-Sidak 
 
Female Condition index (CI)  There are no differences in the CI 
between treatment groups. 
 
Parametric ANOVA N/A 
Table 20.  A summary of the null hypothesis for each parameter assessed, together with the statistical test that was applied, the post-hoc test used to accept 
or reject each null hypothesis. N/A indicates that there was not a statistical significant difference. Table amended from that used by Giltrow (2008). 
 119 
3.3 RESULTS 
 
3.3.1 Water Parameters 
Figures 41 to 44 show the results for measured water temperature (
o
C), dissolved oxygen 
(%), pH and water hardness (CaCO3 mgL
-1
). Water parameters for both pair-breeding 
assays (experimental tanks) and hatchability trials (progeny tanks) were routinely 
measured. For all figures the pink, filled green and orange boxes represent data collected 
in the baseline, transition and exposure periods, respectively. In some instances the water 
temperature dropped below the set limits. This was partly due to spells of hot weather 
which inadvertently activated the in-house chillers which in turn cooled the air 
temperature in the experiment rooms and as a result cooled the water temperature in the 
experimental tanks. Air bubbles also sometimes occurred in the in-flow tubes between the 
mixing chamber and an individual tank, thus preventing the flow of pre-heated water. 
Similarly to bubbles forming in water in-flow tubes, the pinching of oxygen inflow tubes 
occasionally prevented the flow of oxygen into individual tanks, which as a result caused 
levels of dissolved oxygen to drop below the set limit. However, these problems with 
tubing were quickly rectified and the set levels of both water temperature and DO2 were 
restored within 48 and 24hrs, respectively, and so the likelihood of the differences in 
these water parameters inducing a measurable response in the fathead minnow pairs was 
negligible. 
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With the exception of days 10 and 11 where the temperature in experiment 1 dropped 
below 24
o
C as the in-house chillers were activated, water temperature both between 
experiments and experimental periods (e.g. baseline and exposure period) did not vary 
considerably.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41. Water temperature in experiments 1 (blue) and 2 (green). Red lines represent temperature limits of 
25oC ± 1oC. Error bars represent maximum and minimum recorded temperatures.  
Figure 42. DO2 in experiments 1 (blue) and 2 (green). Red line represents the limit below which oxygen levels 
should not fall. Error bars represent maximum and minimum recorded DO levels.  
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The levels of DO2 did not vary significantly between both experiments and exposure 
periods. There were isolated instances where air inflows to individual tanks failed, 
however there was no relationship between propranolol exposure concentration and 
failure incidence of oxygen inflow.  
 
 
 
Although there was a notable difference between measured pH levels from exposure 1 
and exposure 2, all treatment tanks were measured in the range of 7.7 to 8.2 and so were 
all considered to be neutral. There was no relationship between pH levels and fish 
response to propranolol. One can observe that in both exposures pH levels increased 
during the propranolol exposure period (with the exception of day in exposure 2). This 
was most notable in the progeny tanks, as all progeny tanks held the maximum number of 
steel meshes. Steel is comprised from iron, which is alkalising. Therefore it is possible 
that the presence of steel over a 42-day period (including the baseline period) increased 
the pH, albeit minimally. 
 
The water hardness levels from both experiments ranged from 110 to 140mgL
-1
 CaCO3 
over both exposure periods. Water hardness levels were higher than those specified by 
Winter et al (2008), however this was due to location as CaCO3 levels in water from the 
Thames catchment are generally higher than those from the Dorset catchment (where 
Figure 43. pH levels in experiments 1 (blue) and 2 (green). Error bars represent maximum and minimum 
recorded pH levels.  
6.8
7
7.2
7.4
7.6
7.8
8
8.2
8.4
8.6
8.8
1 8 15 21 24 28 35 45
Date
p
H
 122 
Winter et al (2008) conducted the pair-breeding assay using the non-specific β-blocker 
atenolol). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.2 Exposure concentrations 
The mean propranolol levels for each concentration sampled on days 0, 4, 7, 14 and 21 of 
the exposure period are shown in tables 21 and 22. In total, 4 tanks out of 6 from each 
concentration were randomly selected and sampled.  In experiment 2, there was a high 
level of mortality in the 1.0mgL
-1
 treatment group and by day 13 all fish from this 
exposure had either died or were culled for ethical reasons. Therefore, water samples 
were taken both on day 13 and 14; the prepared 1mgL
-1
 stock ran out after day 14. In 
experiment 1, all fish had died within 48 hours of receiving 10mgL
-1
 propranolol and 
therefore, there was only a single water sample available. 
 
 
 
 
 
Figure 44. Levels of CaCO3 in experiments 1 (blue) and 2 (green). Error bars represent maximum and minimum 
recorded levels.  
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Water chemistry results from both propranolol experiments indicate that fish were 
exposed to propranolol and that the drug was absent from the dilution water control tanks 
indicating there was no contamination. With the exception of the 10mgL
-1
 tanks in 
experiment 1, the level of propranolol in each concentration was within the expected 
concentration range. Solubility issues and/or an unexpected uptake rate into fish were the 
Nominal 
Concentration 
(mg/L) 
 
 
Mean propranolol concentration of water samples  
Average result 
(mgL
-1
). % of 
nominal 
concentration in 
brackets 
0 
 
4 
 
7 
 
14 
 
21 
 
DWC <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 (100%) 
0.001 0.00014 0.000927 0.00063 0.000733 0.001567 0.00084 (84%) 
0.01 0.005867 0.003933 0.004 0.004933 0.009333 0.0053 (53%) 
0.1 0.092 0.083333 0.101 0.116667 0.128333 0.098 (98%) 
1.0 1.1 1.133333 1.0366667 1.166667 2.133333 1.16 (116%) 
10 3.4 - - - - 3.4 (34%) 
Nominal 
Concentration 
(mg/L) 
 
 
Mean propranolol concentration of water samples  Average result 
(mgL
-1
). % of 
nominal 
concentration 
in brackets 
0 
 
4 
 
7 
 
13 
 
14 
 
21 
 
DWC  - <0.0001 <0.0001 - <0.0001 <0.0001 <0.0001 (100%) 
0.001  0.00074 0.0011 0.002467 - 0.000957 0.001233 0.0013 (130%) 
0.01  0.006767 0.008867 0.010567 - 0.006633 0.007033 0.0080 (80%) 
0.1  0.038 0.065 0.065 - 0.113333 0.106667 0.078 (78%) 
1.0  0.476667 1.043333 0.983333 1.28 1.06 - 0.97 (97%) 
  Table 21. Summary of water chemistry results from propranolol experiment 1. 
  Table 22. Summary of water chemistry results from propranolol experiment 2. 
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most likely causes of such a low concentration of propranolol (34%) compared to the 
nominal concentration in the 10mgL
-1
 tanks. In all other treatments, concentrations 
ranged from 53 to 130% of the nominal concentration and, more importantly, there was 
no overlap of measured propranolol concentrations between treatments; there was at least 
a factor of x 6 between concentrations. Statistical analysis of the water chemistry results 
indicated that there were no significant differences in the mean levels of propranolol 
between the same concentrations from both experiments and so it was possible to pool 
the two sets of data together. 
 
3.3.3 Blood plasma results 
To ensure an accurate measurement could be taken, blood plasma from female fish from 
each treatment had to be pooled as there was very little plasma available for analysis. 
Blood plasma from individual male fish, however, could be analysed. The results, in table 
23, highlight that there was less than 0.00025mgL
-1
 of propranolol in the dilution water 
control fish plasma, which was the threshold of the mass spectrometry technique used to 
analyse the samples. Thus this can be interpreted as there was no propranolol in the fish 
plasma from the dilution water control treatment. As water propranolol concentration 
increased, the level of propranolol in blood plasma increased accordingly. It was evident 
that once the concentration of propranolol exceeded 0.1mgL
-1
, propranolol 
bioaccumulated in the plasma at a concentration that exceeded the environmental water 
concentration (exceeding 100%); this was also noted in female fathead minnows at the 
0.01mgL
-1
 treatment group. 
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3.3.3.1 Mammalian-fish plasma model 
Although the predicted FSSPC at 1mgL
-1
 was considerably higher than the mean 
measured FSSPC, the predicted and measured FSSPC values at each concentration, as 
shown in table 24, were all within one order of magnitude of each other and there was no 
overlap in predicted levels. This suggests the model was relatively accurate. The 
calculated PER values were less than 1 at both the 0.1mgL
-1
 and 1.0mgL
-1
 treatment 
concentrations, thus predicting a pharmacological response to propranolol.  
 
 
 
 
 
Nominal 
Concentration  
(mg/L) 
Actual mean  
water concentrations 
from both exposures  
(mg/L) 
Mean propranolol 
concentration 
in plasma (mgL
-1
) 
Plasma concentration as 
percentage of mean water 
concentration (%) 
Male Female Male   Female 
DWC <0.0001 <0.00025 <0.00025 <0.00025 <0.00025 
0.001 0.00107 0.000555 0.000690 51.87 64.5 
0.01 0.00665 0.00605 0.00855 90.98 128.57 
0.1 0.088 0.34 0.21 386.36 238.64 
1.0 1.065 15.00 5.75 1408.45 539.91 
Nominal 
Concentration 
(mg/L) 
Actual mean 
water 
propranolol 
concentration 
(mg/L) 
Mean measured 
FSSPC of 
propranolol (mg/L) 
Predicted 
FSSPC of 
propranolol 
(mg/L) 
HTPC 
(mg/L) 
 
PER 
Male Female Male Female 
DWC
a
 <0.0001 <0.00025 <0.00025 <0.00458 0.146 >584 >584 
0.001 0.00107 0.000555 0.000690 0.0595 263.06 211.59 
0.01 0.00665 0.00605 0.00855 0.3660 24.13 17.08 
0.1 0.088 0.34 0.21 3.5686 0.43 0.70 
1.0 1.065 15.00 5.75 44.3784 0.0097 0.025 
          Table 23. Mean concentration of propranolol in male and female blood plasma. Figures in bold represent where   
          plasma concentrations of propranolol exceeded water propranolol concentrations. 
Table 24. Comparison of mean measured FSSPC values based on measured plasma concentrations against predicted 
FSSPC values based on the mammalian-fish plasma model by Huggett et al (2003b). FSSPC = fish stead state plasma 
concentration; HTPC = human therapeutic plasma (as stipulated by Wong et al, 1979) NOEC; PER = Plasma Exposure 
Ratio. 
 126 
3.3.4 Physiological response to propranolol exposure 
 
3.3.4.1 Fish mortality 
By original design, there were four pairs of fish per treatment concentration and there was 
a sixth propranolol concentration of 10mgL
-1
. However, during the transition period in 
experiment 1 (when the drug was turned on and the fish were only observed and fed) all 
but 2 of the female fish died. The two remaining female fish showed signs of distress and 
an inability to orientate themselves in the tank and therefore, for ethical reasons, they 
were culled and their tissues collected. This suggested that at 10mgL
-1
, propranolol was 
acutely toxic to the fathead minnows. By day 5 of propranolol exposure in experiment 1, 
two of the males from the 1mgL
-1
 treatment group started to show similar signs of 
distress as the fish from the 10mgL
-1
 group and so they were culled and tissues collected. 
This suggested that propranolol at 1mgL
-1
 maybe chronically toxic to fathead minnows. 
 
In experiment 2, the 10mgL
-1
 treatment was not repeated. It was noted that by day 2 the 
fish from the 1mgL
-1
 group had a reduced appetite. By day 4, two of the males were 
showing the same signs of distress as the two males from the 1mgL
-1
 treatment from 
experiment 1. Therefore, these males were culled and their tissues were collected. The 
pairing females began showing signs of distress on day 5 and so were also culled and 
their tissues collected. The remaining fish from the 1mgL
-1
 group, though showing of 
reduced appetite, showed no further signs of distress. However, on day 11, one male was 
found dead outside the tank, which was unusual as there had been no signs of distress 
between day 5 and day 11. The one remaining pair of fish from this treatment were culled 
as they started to show signs of distress. Thus, there was no cumulative egg production 
data from the 1mgL
-1
 treatment group from experiment 2 after day 11. 
 
A further four female fish died during both experiments as they had become “egg bound”. 
This is where an egg becomes stuck in the female ovaries and hence the females can no 
longer spawn and thus swell. These incidences of egg-bound females were not related to 
propranolol exposure. A summary of the number of fish pairs used to collect both egg 
production and fish condition data is summarised in table 25.  
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Table 25.  Summary of fish pairs used for data collection. 
 
 
Since there was no egg production data collected from the 10mgL
-1
 group and the 
10mgL
-1
 exposure was not repeated for experiment 2, data analysis was only conducted 
on treatment groups DWC to 1.0mgL
-1
. 
 
3.3.4.2 Egg production 
The total number of eggs produced during the exposure period was less than during the 
baseline period for all treatments including dilution water control, as shown in figure 45. 
By the time the exposure period had started each fathead minnow pair had been together 
for at least 6 weeks, inclusive of acclimation period, and so the spawning rate naturally 
slowed down. It was not possible to statistically compare cumulative egg production data 
between propranolol treatments as different numbers of fish pairs were used to collect the 
data, therefore cumulative egg production data was compared between the same 
treatment groups between the baseline and exposure periods. There was a statistically 
significant difference (p<0.05) in cumulative egg production between the baseline and 
exposure period from the 1mgL
-1
 treatment group. 
 
 
 
Concentration 
(mg/L) 
Number of fish 
pairs used in 
experiment 1 
Number of fish 
pairs used in 
experiment 2 
Total 
number 
pairs  
Total number of 
fish for tissue 
collection 
  Male       Female 
DWC 3 5 8 9 8 
0.001 4 3 7 8 8 
0.01 4 4 8 8 8 
0.1 4 3 7 8 7 
1 3 3 for 11 days 6 (for 11 
days) 
4 6 
10 0 n/a 0 0 0 
Fish pairs used for egg production data 
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3.3.4.3 Hatchability success 
There was no apparent relationship between propranolol concentration and hatching 
success, as shown in figure 46, suggesting that propranolol did not have an affect on 
hatching success and initial survivability. 
 
 
 
 
 
 
 
 
 
 
Figure 45. Pooled cumulative egg production data from each treatment group during the 21-day baseline 
period and 21-day exposure period.   = DWC;  = 0.001mgL-1;  = 0.01mgL-1;  = 0.1mgL-1;  = 
1.0mgL-1.   denotes statistical significant difference (p<0.05) between baseline and exposure periods. 
 
0
200
400
600
800
1000
1200
-2
1
-1
9
-1
7
-1
5
-1
3
-1
1 -9 -7 -5 -3 -1 2 4 6 8 10 12 14 16 18 20
Day
N
u
m
b
e
r 
o
f 
e
g
g
s
BASELINE EXPOSURE
 
 
 129 
 
 
 
 
 
3.3.4.4 Fish condition endpoint 
Figures 47 to 52 show fish weight, fork length, male fatpad weight, male tubercle number 
and prominence, fish GSI and condition. Wet weight ranged from 2.43 to 5.68 and from 
0.81 to 2.49g in male (blue bars) and female (pink bars) fish, respectively. Male weight 
showed a dose-dependent decrease in weight as propranolol concentration increased and 
there was a statistically significant difference (p<0.05) in weight between the DWC and 
1.0mgL
-1
 treatment groups. Female wet weight, however, did not vary considerably and 
there was no relationship between propranolol concentration and weight.    
 
 
 
 
 
 
 
 
Figure 46. Mean hatching success from hatchability trials from all propranolol treatment groups. Error 
bars represent standard error of mean hatchability success. The blue and pinks bars represent baseline and 
exposure hatching success, respectivelyThere was no significant difference (p<0.05) between the DWC 
and propranolol treatment groups.  
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Fork lengths ranged from 52 to 71 mm and 42 to 65 mm in male (blue bars) and female 
(pink bars) fathead minnows, respectively. There was no significant relationship between 
fork length and propranolol concentration for both male and female fish; there was a 
slight trend between fork length decrease in male fathead minnows and increase in 
propranolol concentration, however this was not statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
Figure 47. Wet weight of male (blue) and female (pink) fathead minnows sampled on day 21 of propranolol 
exposure.  denotes statistical significant difference (p<0.05) between DWC and 1.0mgL-1 treatment groups. 
Error bars represent standard error of mean weight. 
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Fatpad index from 0.09 to 0.48g across all treatment groups and, once the propranolol 
concentration exceeded 0.01mgL
-1
, there was an inverse relationship between fatpad 
index and propranolol concentration; with a statistical significant difference (p<0.05) 
being observed between 0.01 and 1.0mgL
-1
. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48. Fork length of male (blue) and female (pink) fathead minnows sampled on day 21 of propranolol 
exposure. Error bars represent standard error of mean length. There was no significant difference (p<0.05) 
between the DWC and propranolol treatment groups.  
There was no difference between  
 
Figure 49. Fatpad index of male fathead minnows sampled on day 21 of propranolol exposure. Error bars 
represent standard error of mean fatpad index.  denotes statistical significant difference between treatment 
groups. There was no significant difference (p<0.05) between the DWC and propranolol treatment groups.  
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Figure 50, below, shows tubercle number (bar) and prominence (line) assessed using the 
qualitative scheme devised by Smith (1978). Tubercle numbers ranged from 12 to 16 and 
prominence score from 1 to 4. There was no relationship between propranolol 
concentration and tubercle number or prominence. No secondary sexual characteristics 
commonly associated with males were observed in any of the females. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gonad somatic index expresses gonad weight as a proportion of body weight and 
therefore serves as an additional indicator of reproductive status. Gonad weights in males 
(blue bars) ranged from 0.01 to 0.074 g and GSI ranged from 0.22 to 1.39 % and in 
females (pink bars) ranged from 0.01 to 0.357 g and GSI ranged from 1.32 to 17.14 %. In 
males there was an increase in GSI as propranolol increased from DWC to 0.01mgL
-1
, 
with a statistically significant difference observed between the two treatment groups, 
however this trend did not continue for the two higher propranolol concentration 
treatment groups. Female GSI exhibited a dose-related response, as propranolol 
concentration increased, GSI increased. Statistical significant differences (p<0.05) were 
noted between DWC and 0.1 mg/L, DWC and 1.0 mg/L, and between 0.001 and 1.0 
mg/L.   
 
 
Figure 50. Tubercle number (bar) and prominence (line) of male fathead minnows sampled on day 21 of 
propranolol exposure. Error bars represent standard error. There was no significant difference (p<0.05) 
between the DWC and propranolol treatment groups.  
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The condition index provides a useful overall assessment of general fish condition. CI 
ranged from 1.21 to 1.99 and 1.00 to 1.58 in male and female fish, respectively.  
Similarly to male fatpad index, male GSI showed an inverse relationship between 
propranolol concentration and index score once propranolol concentration exceeds 
0.01mgL
-1
 and a statistical significant difference (p<0.05) was found between 0.001mgL
-
1
 and 1.0mgL
-1
 and also between 0.01mgL
-1
 and 1.0mgL
-1
, indicating male fathead 
minnows from the highest dose group had the poorest condition. There was no treatment-
related effect on female CI.   
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Figure 51. Male (blue bar) and female (pink bar) GSI. Error bars represent standard error of mean GSI. 
denotes statistical significant difference between DWC and 0.01mgL-1 in male GSI;  denotes statistical 
significant difference between DWC and 0.1mgL-1 in female GSI;  denotes statistical significant difference 
between DWC and 1.0mgL-1 in female GSI;  denotes statistical significant difference (p<0.05) between 
0.001mgL-1 and 1.0mgL-1 in female GSI. 
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3.3.5 Conclusive physiological LOEC and NOEC from propranolol study 
Table 26 shows the LOEC and NOEC (non-observed effect concentration) for all 
physiological endpoints measured during the propranolol pair-breeding assay. There must 
have been a significant difference between a specified concentration and the DWC for the 
concentration to be deemed an LOEC. Propranolol concentrations expressed as their 
measured nominal concentration. 
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Figure 52. Male (blue bar) and female (pink bar) CI. Error bars represent standard error of mean CI. 
denotes statistical significant difference between 0.001mgL-1 and 1.0mgL-1 in male CI;  denotes 
statistical significant difference (p<0.05) between 0.01mgL-1 and 1.0mgL-1 in male CI. There was no 
significant difference (p<0.05) between the DWC and propranolol treatment groups.  
 
 
Propranolol concentration (mgL-1) 
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Endpoint LOEC nominal 
concentration (mg/L) 
NOEC nominal 
concentration (mg/L) 
Male Female Male Female 
Survival 1.0 10.0 0.1 1.0 
Egg production - 1.0 - 0.1 
Hatchability success >1.0 >1.0 >1.0 >1.0 
Wet weight 1.0 > 1.0 0.1 >1.0 
Fork length >1.0 >1.0 >1.0 >1.0 
Fatpad index >1.0 - >1.0 - 
Number of tubercles >1.0 - >1.0 - 
Prominence of tubercles >1.0 - >1.0 - 
GSI >1.0 0.1 >1.0 0.01 
Condition index >1.0 >1.0 >1.0 >1.0 
Table 26. LOEC and NOEC for physiological endpoints measured during propranolol pair-breeding. 
assay. 
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3.4 DISCUSSION 
 
3.4.1 Response of fathead minnow pairs to propranolol exposure 
The toxicity data obtained from the 21-day chronic exposure to propranolol study 
reported acute mortality for both sexes at 10mgL
-1
 and also male mortality at 1.0mgL
-1
 
after 11 days. To date, this is the first study to have reported acute toxicity of any β-
blocker on the fathead minnow and as such the observed affect of propranolol was 
unanticipated. Since the remit of the study was to examine for the chronic impacts of 
propranolol on reproduction in the fathead minnow, it was decided not to repeat the 
10mgL
-1
 treatment. 
 
Prior to euthanisation, the fish in the 10mgl
-1
 and 1.0mgL
-1
 treatments group (nominal 
concentration of 3.4 and 0.97mgL
-1
, respectively) were observed to be very disorientated 
and swimming on one side or nosing the bottom of the tanks, which suggested that 
propranolol, or possibly a metabolite derivative, may have been acting as a central 
nervous system (CNS) toxin. As propranolol is lipophilic, it can move across the blood-
brain barrier in organisms with relative ease (Olesen et al, 1978). Propranolol has been 
found in human brain tissue at concentrations ten to twenty six times higher than in 
plasma, compared to atenolol which has a brain: plasma ratio of 0.2 (Cruickshank & 
Neil-Dwyer, 1985). Therefore, it was possible that fathead minnows exposed to 10mgL
-1
 
and 1.0mgL
-1
 propranolol bioaccumulated the drug within the CNS, which induced the 
observed toxicological responses. The observed symptoms in the fish also mirrored those 
described upon fish exposure to ammonia (Arillo et al, 1981; Ronan et al, 2007). It has 
been well documented that drug-induced liver disease such as cirrhosis can lead to the 
production and accumulation of ammonia in humans, albeit the drug in question is most 
often alcohol (Zimmerman, 1995). The liver is the principal site of propranolol 
metabolism and studies have indicated that there was a non-linear relationship between 
dose and pharmacokinetic bioavailability of propranolol in human and rat livers and that 
the metabolic activity of propranolol in liver microsomes was higher than predicted from 
the plasma concentrations (Masubuchi et al, 1994; Kiriyama et al, 2007). The plasma 
concentrations of propranolol from fathead minnows exposed to 10mgL
-1
 and 1mgL
-1
 
exceeded the human therapeutic plasma concentration and therefore this combination of 
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propranolol overdose and elevated propranolol activity in the liver microsomes may have 
induced liver failure, resulting in hyperammonemia and thus caused the observed severe 
neurological dysfunction symptoms (Wong et al, 1979; Ronan et al, 2007). Overdoses of 
propranolol on the CNS in humans have induced similar symptoms to those observed in 
the fathead minnows including convulsions, drowsiness and in severe cases, coma 
(Frishman et al, 1979; Tynan et al, 1981; Das & Ferries, 1988). Male fathead minnows 
are larger than females and therefore there is an increased likelihood of rapid 
bioaccumulation of propranolol, which explains why males showed symptoms of 
propranolol toxicity earlier than females. 
 
Further propranolol-induced effects included a decrease in male wet weight (LOEC = 
0.97mgL
-1
; nominal concentration = 1.0mgL
-1
) and a decrease in GSI in females (LOEC 
= 0.078mgL
-1
; nominal concentration = 0.1mgL
-1
). It is difficult to determine whether 
propranolol toxicity was directly responsible for the loss of weight in the males from the 
1.0mgL
-1
 treatment group as the fish were not weighed prior to the study. However, in 
addition to showing symptoms of CNS toxicity and reduction in egg production, food 
accumulated in the bottom of the tanks suggesting the fish were not feeding. Egg 
production was severely impaired at the 10mgL
-1
 and 1mgL
-1
 treatment concentrations. 
However, because of the observed mortality at both concentrations, it is less likely that 
propranolol behaved as a reproductive toxin but rather as an acute toxin. 
 
3.4.2 Comparison with other aquatic β-blocker studies 
This toxicity data reported from this study provides a stark contrast to directly 
comparable data examining atenolol toxicity (Winter et al, 2008), where there was at 
least a 10-fold difference in the magnitude of response. Fathead minnows were able to 
tolerate high concentrations of atenolol (LOEC
survival
 = >10mgL
-1
). The most likely 
reason for this difference in observation was that atenolol has a much lower log Kow value 
than propranolol and is therefore less likely to readily bioaccumulate. Plasma 
concentrations of atenolol in relation to nominal water concentrations ranged from 1.8-
12.2%, whereas plasma concentrations of propranolol reached up to 1550% of the 
nominal water concentration. 
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When Huggett et al (2002) exposed Japanese medaka (Oryzas latipes) to propranolol for 
a chronic 28-day period, egg production and egg viability were found to be significantly 
lower at 0.0005mgL
-1
 and 0.0001mgL
-1
, indicating propranolol was acting as a 
reproductive toxin. The data from this study, however, indicated that propranolol 
inhibited reproduction at 1.0 mgL
-1
, which is a 1000 to 2000-fold higher concentration. 
This immediately suggests that the Japanese medaka is a potentially more sensitive 
species to propranolol exposure. However upon further inspection, there was not a dose-
response to propranolol exposure in the medaka, which was unusual considering the 
magnitude of difference between the control and aforementioned treatment groups. 
Secondly, the LOEC
survival
 values for the fathead minnow were 1.0mgL
-1
 and 10mgL
-1
 for 
males and females, respectively, which was much more sensitive than the recorded LC50 
of 24.3mgL
-1
 for the medaka, indicating that the fathead minnow was more acutely 
sensitive to propranolol. Thirdly, the work conducted in this study was repeated and the 
same result trends were recorded whilst the results from the medaka exposure have not 
been repeated.  
 
The pair-breeding assay primarily examined for mortality and a reproductive response to 
propranolol exposure. Arguably these are the most important endpoints in terms of 
species long-term survivability and, considering propranolol had been found to both 
inhibit reproduction and induce mortality in other fish species (Huggett et al, 2002), were 
particular relevant for this study.  
 
3.4.3 Plasma concentrations of propranolol in the fathead minnow 
It can be assumed that for a drug to elicit a pharmacological response in a human (target) 
system, the concentration of the drug must be sufficient enough to bind with the target 
site (e.g. receptor) in adequate numbers to trigger a measurable response. This desired 
concentration is most accurately reflected in the therapeutic plasma concentration. 
Therefore, it has been hypothesised that, assuming the species in question expresses the 
target site, the same concentration of drug would be required to affect another species. 
The mammalian-fish plasma model, proposed by Huggett et al (2003b) makes this 
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assumption and compares the predicted (or measured) plasma concentration, based on the 
physiochemical property of a drug, with the measured human therapeutic plasma 
concentration in order to predict whether the drug may induce a pharmacological effect in 
a different species.  
 
The predicted FSSPC was within one order of magnitude to the measured FSSPC and, as 
such, was relatively accurate in predicting the plasma concentration of propranolol. In the 
case of propranolol inducing a pharmacological effect on the fathead minnow, the 
mammalian-fish plasma model was relatively accurate. The model predicted that at both 
0.1mgL
-1
 and 1.0mgL
-1
 propranolol would induce a pharmacological effect. The plasma 
concentrations at these nominal water concentrations exceeded the water concentration 
dose demonstrating that propranolol was able to bioaccumulate because of its lipophilic 
nature. As a result female GSI was significantly lower in the 0.1mgL
-1
 group and male 
mortality was observed in the 1.0mgL
-1
 group. These data support the mammalian-fish 
plasma model and demonstrate that the read-across information from humans to fish is 
plausible, allowing for existing human pharmaco and toxicodynamic data coupled with 
the physicochemical property of a pharmaceutical to be used as a suitable starting point to 
predict the potential effects on organisms in the environment. 
 
In summary, the data suggests that propranolol was not acting as a reproductive toxin but 
as an acute toxin. Measured environmental concentrations of propranolol ranged from 
<0.000012 – 0.000255mgL-1 (approximately 1000-fold lower than the lowest 
pharmacological concentration in the current study)   and so it is extremely unlikely that 
propranolol will elicit a significant toxicological effect to fathead minnows in the aquatic 
environment. The data from the current study supports the use of the mammalian-fish 
plasma model and recommends this approach for future use. Ultimately, exposure to 
propranolol elicited both a strong acute-toxic and lesser physiological response in the 
fathead minnow. As such, the study provided tissues that were suitable for both subtle 
biomarker analysis using metabolomics and RT-PCR, as well as robust physiological 
endpoints for which any results from the biomarker analysis could be related to.  
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CHAPTER 4: IDENTIFYING A BIOMARKER OF 
PROPRANOLOL EXPOSURE USING 
1
H NMR 
METABOLOMICS 
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4.1 INTRODUCTION 
Any analytical technique used for metabolomics must be quantitatively interpretable and 
relatively unbiased in its interpretation. Additionally, it is most desirable that the results 
are easily reproducible and robust and that the analytical or technical variation introduced 
during data collection is less than the typical biological variation in the “normal” 
population of interest (Keun, 2006). With this in mind, there are two principal collection 
techniques used in metabolomics: mass spectrometry and nuclear magnetic resonance 
(NMR) spectroscopy.  
 
4.1.1 Mass spectrometry (MS) 
In brief, a mass spectrometer measures the characteristics of individual molecules by 
converting them into their constituent ions and manipulating them in external electric and 
magnetic fields. Individual ions (which represent different metabolites) are separated 
according to their mass-to-charge ratio and presented as signal peaks (Scoog et al, 1998). 
Because the signals are dispersed by the ion mass-to-charge ratio, considerable 
information is provided on the elemental composition of the metabolites. For example, 
the Fourier transform ion cyclotron resonance mass spectrometer (FT-ICR-MS) has a <1 
part per million mass accuracy, which allows for only one or a few elemental 
composition(s) to be assigned to each peak, thus aiding metabolite identification 
(Marshall et al, 1998). Furthermore, mass spectrometry is a sensitive method for 
detecting metabolites. Mass spectrometry is often combined with different initial sample 
separation techniques: the most commonly used are gas chromatography (GC), high-
performance liquid chromatography (HPLC) and capillary electrophoresis (CE).  
 
However, compared to NMR based metabolomics, the use of mass spectrometry is still 
relatively new and, as such, the studies are not as reproducible and the protocols are not 
as well developed as for NMR metabolomics. For these reasons, NMR was adopted for 
the current study. 
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4.1.2 Nuclear magnetic resonance spectroscopy (NMR) 
High resolution NMR spectroscopy is a quantitative technique that can measure hundreds 
of compounds (Viant, 2003). The principle of NMR is based on the behaviour of atoms 
placed in a strong electromagnetic field. The nuclei of some atoms possess a “spin” 
property. The “spinning” of these nuclei generates a magnetic moment along the axis of 
the spin, so that they act like tiny magnetic bars. Under normal conditions, the magnetic 
moments in a collection of nuclei in a metabolite sample will be randomly orientated (no 
net spin). However, when an external magnetic field (Bo) is applied, they can adopt 
different orientations with different energy levels (Engelke, 2007). Superconducting 
NMR magnets provide this strong, homogenous magnetic field. There are different types 
of NMR machines to interact with particular nuclei such as 
1
H, 
13
C and 
31
P, which 
interact with hydrogen, carbon and phosphorus nuclei, respectively. 
1
H-NMR, also 
referred to as proton-NMR, is used to examine samples for all metabolites (it is non-
targeted as all metabolites have hydrogen atoms), whereas 
13
C and 
31
P are used more 
specifically to examine samples that have carbon and phosphorus atoms, respectively 
(Skoog et al, 1998). 
 
On exposure to Bo in a proton-NMR, 
1
H nuclei can only adopt two orientations, either 
aligned with (parallel) or against (anti-parallel) the direction of the external magnetic 
field. In a given sample, a slight majority of 
1
H nuclei point in the direction of the 
magnetic field, termed bulk magnetisation or Mo. This net magnetisation will be aligned 
with the applied Bo, which is defined as the z-direction (Mz). In this equilibrium state, the 
net magnetisation vector does not produce a detectable signal. To acquire an NMR signal, 
a short radio-frequency radiation pulse is applied to the sample, as shown in figure 53. 
This causes the Mz to rotate 90
o
 (hence it is called a 90
o
 pulse) from the z-axis to the x,y 
plane. The resulting signal, called the free induction decay (FID) is subsequently 
detected, processed and then presented as a 
1
H-NMR spectrum. An NMR spectrum 
provides a characteristic “fingerprint” of the proton-containing metabolites (Engelke, 
2007). 
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One can differentiate between different metabolites according to their structure and 
chemical environment. For example, as shown in figure 54, the CH3 moiety has three 
hydrogen atoms, whilst the COH moiety only has one. The hydrogen atoms belonging to 
the CH3 moiety generate a stronger electron shield than the single hydrogen belonging to 
the COH moiety. Electron shielding is where the electrons within the hydrogen atoms 
shield the effect of Bo. Additionally, the oxygen atom will withdraw electron density 
away from the hydrogen atom and so the hydrogen atom will experience a higher level of 
Bo than the three hydrogen atoms. This effect is called the „chemical shift‟ and causes 
nuclei with different chemical environments to resonate at different frequencies, which 
therefore provides structural information and enables the user to differentiate between 
metabolites when examining the produced NMR spectrum (Harris, 1986; Engelke, 2007). 
 
 
 
 
 
 
x (90o pulse) 
y 
z 
Mz 
Mx,y 
 Bo 
Figure 53. A short radio-frequent radiation rotates Mz to Mx,y. The resulting 
signal is detected and presented on a 1H NMR spectrum. 
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There are two principal types of 
1
H-NMR spectroscopy: One dimensional (1D) and two-
dimensional (2D). Whilst 1D-NMR data presents the spectrum as a measure of frequency 
(x-axis) against intensity (y-axis), 2D-NMR data presents the data along the x and y 
(frequency) axes and z (intensity) axis, which provides additional information and 
resolution to solve overlap and problems in metabolite identification (Engelke, 2007). 
 
4.2 The use of NMR-metabolomics in pharmaceutical-based aquatic ecotoxicity 
studies 
To date, only two studies have examined the response of a fish, or any aquatic organism 
for that matter, to pharmaceutical exposure using metabolomics; both studies used 
1
H-
NMR spectroscopy and EE2 (the principal component of the contraceptive pill) as the 
NMR technique and test drug, respectively. Samuelsson and colleagues (2006) exposed 
  
  
  
 C 
 H 
 H 
 H 
  
 C 
 O 
 H 
Figure 54. A simplistic schematic representation of differentiating metabolites according to their structure. 
The CH3 molecule has considerable electron shielding (green circles around each H atom) from the external 
magnetic field (bold blue arrow) and therefore there is minimal energy change (red arrows) and loss of 
excitation energy (small blue arrow). The oxygen atom belonging to the COH molecule withdraws electrons 
away from the H atom and therefore upon excitation frequency, the hydrogen atom will experience a higher 
energy change (denoted by a bold red arrow). 
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rainbow trout (Oncorhynchus mykiss) to several concentrations of EE2 and observed 
elevated levels of vitellogenin in fish plasma in the highest treatment group (10ng/L), 
which was supported by enzyme-linked immunosorbant assay (ELISA) results. 
Vitellogenin (VTG) is a protein produced in the livers of female teleost fish and EE2-
exposed male fish (Tyler & Routledge, 1998). The use of VTG as a biomarker of EE2 
exposure is well characterised and routinely used. The study by Samuelsson and 
colleagues, therefore, demonstrated a proof of principle that a well-known protein, and 
associated metabolites, can be identified using metabolomics. More recently, Ekman and 
colleagues (2008) examined the liver metabolite profiles of adult fathead minnows 
exposed to EE2 and found that the metabolite profile of exposed male livers showed 
striking similarities to female livers. Furthermore, closer inspection of the exposed male 
liver metabolite spectra revealed that the most influential metabolites in feminization 
originated from increases in the amino acids glutamate and alanine. Alanine is one of the 
most abundant amino acids in a protein and it, along with glutamate, has been identified 
as a key amino acid in vitellogenin (Miles-Richardson et al, 1999) and so it is unlikely 
that glutamine and alanine were biomarkers of EE2 exposure but are indicative of 
vitellogenin production. 
 
4.3 Aim 
With the exception of EE2, metabolomics has not been used to understand the potential 
toxic mechanism of action and subsequent effects of pharmaceuticals on aquatic 
organisms. Following on from the pair-breeding assay, in which physiological endpoints 
were used, the aim of this study was to examine the effect of the non-specific β-blocker 
propranolol on the metabolite profiles of adult male fathead minnow livers and to 
determine whether it was possible to identify a robust and applicable biomarker of 
exposure. 
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4.2 METHODOLOGY 
 
4.2.1 General protocol for NMR-based metabolomics 
The general protocol for a NMR-based metabolomics experiment is tissue extraction, 
metabolite extraction, NMR data collection and finally data analysis using multivariate 
pattern recognition techniques and univariate statistics; and this process was applied to 
study the metabolic profiles of several fathead minnow (Pimephales promelas) tissues. 
 
4.2.2 Assessing the use of 
1
H-NMR-metabolomics to examine fathead minnow tissues 
Prior to running fish exposure studies, it was important to firstly examine whether it was 
viable to use 
1
H-NMR metabolomics to examine fathead minnow tissues (excluding 
urine); for example one would argue that if it was not possible to discriminate between 
different biological tissue samples using 
1
H-NMR, the technique may not be suitable for 
this type of ecotoxicological study. Therefore the aim of the preliminary study was to 
analyse a range of fathead minnow tissues and assess whether 
1
H-NMR metabolomics 
could differentiate between them. 
 
Ten stock adult (20 months old) male fathead minnows were culled via an overdose of 
MS222 anaesthetic at 40-100 ppm in dilution water, adjusted to pH 7.5 with 1M NaOH 
(Fisher Scientific, Cat # J/7620/15) to obtain complete anaesthesia (Kreiberg, 2000). The 
heart, brain, liver and adipose tissues were rapidly extracted and frozen.  
 
In any metabolomic study it is extremely important that the biological material should be 
as homogenous as possible, minimizing the level of analytical variation introduced at the 
sampling level, and ideally leaving the biological variation as the only inherited variation 
(Keun, 2006). Therefore the tissues were immediately snap-frozen in liquid nitrogen to 
prevent any metabolic degradation. The samples were subsequently stored at -80
o
C until 
starting the extraction procedure. 
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4.2.3 Metabolite extraction protocol 
The metabolite extraction protocol used in this study was based on the 
methanol/chloroform/water method adapted by Wu et al (2007) from that first described 
by Bligh and Dyer (1959) and considered to be the best in terms of reproducibility and 
metabolite recovery. Tissues were weighed (mg wet tissue) and the following solvent 
quantities determined: 
 
Solvent quantities for polar layer: 8μL/mg (wet tissue) HPLC-grade 100% methanol 
(MeOH) (Fisher Scientific, Cat # A456-1); 2.5μL/mg 100% deioinised water. 
 
Solvent quantities for non-polar layer: 8μL/mg pesticide-grade 100% chloroform 
(CHCl3) (Fisher Scientific, Cat # C/4920/08); 4.0μL/mg 100% deionised water. 
 
The heart tissues were considerably smaller than the other tissues and so had to be pooled 
together at a ratio of 3 tissues to form 1 sample. Tissue preparation was conducted in 
batches of eight and it was particularly important that tissue selection was randomized 
(i.e. in a given batch there were a mixture of tissue types). 
 
All solvents were pre-chilled to 4
o
 C and kept on ice. Firstly methanol and deionised 
water were pipetted into individually labeled Precellys vials, which contained ceramic 
beads, according to their calculated volumes and kept on ice. Each frozen tissue was 
added to its‟ respective Precellys vial, containing the methanol-water mix and 
subsequently homogenised by the Precellys-24 bead-based tissue homogeniser at 6400 
rpm for 2 cycles of 10 seconds, separated by a 5 second gap. Each mixture was then 
transferred to a 1.8ml glass vial using a glass Pasteur pipette. Calculated volumes of 
CHCl3 and deionised water were added to their respective glass vials via a Hamilton 
syringe (CHCl3 will cause leaching of plastics if transferred via a plastic pipette). Each 
solvent-tissue mixture was subsequently vortexed for 30 seconds before centrifugation at 
3000rpm for 10 minutes at 4
o
C. At this point, the mixture was bi-phasic (2 layers: polar 
and non-polar).  
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The upper, polar, layer was carefully removed using a Hamilton syringe so as not to 
extract any interphase layer (containing unwanted proteins and lipoproteins) and 
transferred into a clean 1.8ml glass vial. All vials were subsequently dried at room 
temperature using a Thermo Electron RVT4104 Refrigeration Vapor Trap speed vacuum 
concentrator. The dried pellets were subsequently stored at -80
o
C. 
 
4.2.4 1D 
1
H and 2D 
1
H J-resolved NMR spectroscopy 
The dried polar extracts were re-suspended in 640µL sodium phosphate buffer in 90% 
H2O and 10% D2O (100mM, pH 7.0) containing sodium 3-trimethylsilyl-1-2,2,3,3-d4-
propionate (TMSP), which served as an internal chemical shift standard. D2O served as 
the template signal for locking the magnetic radiofrequency onto a sample. Each glass 
vial was vortexed for 10 seconds to ensure the pellet was displaced before centrifugation 
at 12,000rpm for 10 minutes at room temperature. 600µL of the re-suspended sample was 
subsequently transferred to a clean NMR tube. All NMR spectra were measured at 500.18 
MHz using an advanced DRX-500 spectrometer (Bruker, Coventry, UK) equipped with a 
cryoprobe. One-dimensional 
1
H NMR spectra were collected at a temperature of 300 K 
using excitation sculpting to suppress the water resonance (Hwang & Shaka, 1995). 
Spectra were obtained using a 8.4-µs (60
o
) pulse, 6-kHz spectral width and 2.5 second 
relaxation delay with 80 transients collected per sample, requiring a total acquisition time 
of 6.5 minutes. Datasets were zero-filled to 32k points and exponential line-broadenings 
of 0.5Hz applied prior to Fourier transformation. All spectra were phased, manually 
baseline corrected using a quadratic function and calibrated (TMSP at 0.0ppm) using 
TopSpin (version 1.3, Bruker).    
 
A limitation of using 1D 
1
H-NMR is spectral congestion which limits the number of 
metabolites that can be uniquely identified and quantified. For this reason 2D 
1
H- 
predicted J-resolved (JRES) NMR spectra were also collected. A JRES spectrum 
separates the chemical shift and spin-spin coupling data onto different axis (termed F2 
and F1, respectively) thereby increasing proton signal dispersion and producing a less 
congested spectrum, thus aiding in biomarker identification (Viant, 2003). Spectra were 
obtained using a 90
o
 pulse; 16 transients per increment for 16 increments were collected 
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into 16k data points, with spectral widths of 6kHz in F2 and 50Hz in F1. A 4.0 second 
relaxation delay was employed, requiring a total acquisition time of 25 minutes per 
sample. Datasets were zero-filled in F1 and both dimensions multiplied by sine-bell 
window functions prior to Fourier transformation. JRES spectra were tilted by 45
o
, 
symmetrized about F1 and then calibrated, all using TopSpin (Bruker). Data were finally 
exported as the 1D skyline projections (along F2) of the JRES spectra (termed pJRES) 
(Parsons et al, 2009).  
 
4.2.5 Spectral pre-processing 
Both 1D and 2D pJRES
 1
H NMR data were converted to an appropriate format for 
multivariate analysis using custom-written ProMetab software in Matlab (version 7.1; 
The MathsWorks, Natick, MA, USA) (Viant, 2003). A single NMR data set can contain 
thousands of data points, which is too large to efficiently analyse and so a „binning 
technique‟ was used. In this approach, the predictors within a window of a defined width 
in ppm were replaced by a single value corresponding to the sum of the intensities in the 
window. This meant that tens of thousands of data points were conveniently reduced into 
approximately two thousand and yet the overall character of each spectrum was not 
affected (Purohit et al, 2004). For this study, each spectrum was segmented into 0.005 
ppm (2.5Hz) chemical shift „bins‟ between 0.6-10.0ppm with residual water bins 
excluded from all spectra. The total area of each spectrum (referred to as total spectrum 
area; TSA) was normalized to one which allowed for comparisons to be made between 
different spectra despite differences in original sample size and metabolite quantity. 
Additionally, bins containing pH sensitive peaks were compressed into a single bin. The 
binned data describing each spectrum were then compiled into a matrix, with each 
column containing binned NMR data and each row representing individual samples. The 
data was finally generalized log-transformed which tended to equalize the weightings of 
smaller and larger peaks. Spectral data were mean centered before multivariate statistical 
analysis (Viant, 2003; Purohit et al, 2004; Parsons et al, 2009).  
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4.2.6 Processing of data using multivariate statistical analysis 
To analyse both the 1D and 2D pJRES 
1
H NMR data, principal component analysis 
(PCA) was employed using PLS_Toolbox (version 3.53, Eigenvector Research, Manson, 
WA, USA). PCA is termed a “non-supervised” technique because no a priori knowledge 
(i.e. class) of the samples is required; it effectively reduces a great number of correlated 
variables into a smaller number of uncorrelated variables, called principal components 
(Nicholson et al, 2002). The first principal component explains the greatest variability in 
the data; the second principal component is orthogonal to the first component and is 
second best at explaining the variability of the data and so on. Each sample was plotted 
on a coordinate space, called a „scores plot‟, and samples of a similar metabolic nature 
clustered together. A corresponding „loadings plot‟ was then used to assess which 
variables were most responsible for the positioning/clustering of a sample/s. A PCA 
model can be used to quickly visualize which samples in a data set are similar or 
dissimilar to each other and which variables, ultimately corresponding to biomarkers, 
were the route causes of any separation (Keun, 2006). 
 
Similarly to PCA, partial least squares discriminate analysis (PLSDA) is a multivariate 
analytical technique used to classify samples. PLSDA is performed to enhance the 
potential separation between groups of samples by rotating PCA components such that 
maximum separation between sample groups is achieved. Unlike PCA, PLSDA is a 
„supervised‟ technique, whereby sample information (i.e. which treatment group/tissue 
type each sample belongs to) is input into the algorithm, thus enhancing the likelihood of 
achieving separation of sample groups. To evaluate a PLSDA model, a root mean square 
error of cross-validation (RMSECV) prediction value for each sample group ranging 
from zero to one is given. A value closer to zero indicates that a sample has been 
accurately assigned to a modeled group, whereas a value closer to one indicates that that 
a sample has been inaccurately assigned to a modeled group (Westerhuis et al, 2008). 
 
4.2.7 Metabolic analysis of liver tissues extracted from propranolol exposed fish 
One limitation of NMR is that tissues must exceed 30mg wet weight to be effectively 
analysed using both 1D and 2D pJRES spectrometry; for the preliminary assessment of 
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metabolomics as a suitable tool for analysis using the fathead minnow the hearts and 
brains were pooled together. Therefore the liver tissue was selected for NMR analysis; 
additionally the liver is also the primary site of propranolol metabolism (Huggett et al, 
2003). The protocols for tissue preparation and metabolite extraction, 1-D 
1
H and 2-D 
1
H 
pJRES NMR spectroscopy and both spectral pre- and post-processing (e.g. PCA) used to 
assess the suitability of 
1
H-NMR metabolomics to examine fathead minnow tissues were 
adopted for this study. Additionally relative standard deviation analysis was adopted to 
assess the quality of the data (Parsons et al 2009).  
 
4.2.8 Data processing – calculating Relative Standard Deviation (RSD) 
Relative Standard Deviation (RSD), also referred to as the coefficient of variance (CV), is 
a statistic that describes the level of variation within and between data sets. This is vital in 
metabolomics as one is ultimately trying to identify which variables are changing 
significantly under different conditions and without this understanding data can be, at 
worst, falsely interpreted (Keun et al, 2002; Teahan et al, 2006). 
 
To date, RSD has been predominantly used to establishing the stability of metabolite 
peaks and consequently used as an indicator of the strength of the results (Keun et al, 
2002; Teahan et al, 2006; Parsons et al, 2009). In this study, however, RSD analysis was 
used to examine the variability of tissue metabolite profiles within and between treatment 
groups and to assess the quality of the data. 
 
During exposure to propranolol, a number of male fish from all concentrations, including 
DWC, were culled prior to the 21-day termination date. One reason for this was that 
males in the highest concentration of 1.0mgL
-1
 showed signs of distress and, to abide 
with strict ethical guidelines, were culled. Another reason was that some female fish 
became “egg-bound”, which is where eggs get caught and therefore the female fish can 
no longer spawn yet they continue to produce eggs and so the females swell and become 
distressed and eventually die. There was no relationship between propranolol 
concentration and incidence of egg-bound females. In these cases both the females and 
males were culled as the pair-breeding assay could not continue. In addition to the liver 
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tissues collected on day 21 of the propranolol exposure, the dissected liver tissues from 
pre-21-day culled fish also underwent the metabolite extraction protocol. Therefore, by 
measuring the level of variation of liver metabolite profiles with and without the pre-21-
day culled tissues, RSD analysis was used to determine whether the pre-21-day extracted 
livers could be included in the data set. RSD analysis was conducted on both 1D and 2D 
pJRES data and also used to compare the liver metabolite profile variation between the 
different treatment groups. It should be noted that, unlike data prepared for PCA, data 
used for RSD analysis was not log transformed. 
 
The RSD protocol was adopted from that described by Parsons et al (2009). Before the 
data could be analysed using RSD, bins containing solely “noise” were removed from 
each NMR spectra. Noise refers to “signals” that are below a pre-defined signal-to-noise 
limit. They often give an artificially high amount of variation thereby heavily distorting 
the RSD distribution. To filter out this noise, the intensity of each bin in both the 1D and 
2D pJRES 
1
H NMR data was examined. Each spectrum was divided into 32 sections and 
the standard deviation of signal intensity for each section calculated. The noise threshold 
for the spectrum was then estimated as 3 times the smallest standard deviation of the 32 
sections. If the bin intensity was less than the corresponding noise threshold for each 
spectrum in the data set, the bin was deemed as “noise” and was removed. Only bins that 
had a signal greater than the noise threshold were included for RSD analysis. Finally, 
RSD was calculated for each bin (point) in the filtered spectrum as shown in figure 55. 
 
 
 
 
 
 
The distributions of the RSD were then compared using the Wilcoxon rank sum test for 
comparing two distributions (i.e. pre- and post-21-day exposure data) and the Krustal-
Wallis test for multiple distributions (i.e. comparing treatment groups) to establish if the 
RSD distributions differed significantly at p<0.05 (using the Matlab statistics toolbox). 
Figure 55. RSD calculation (according to Parsons et al, 2009). 
RSD = standard deviation of signal intensity     x     100 = % 
   mean signal intensity  
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4.2.9 Identification of biomarker metabolites using univariate statistics followed by 
False Discovery Rate (FDR) 
Both 1D and 2D pJRES 
1
H NMR data were analysed by one-way Analysis of Variance 
(ANOVA) using the Statistics Toolbox within Matlab (with treatment group as the factor; 
p = 0.05). To ensure a conservative assessment of significant bins was made, false 
discovery rate (FDR) was subsequently applied to the ANOVA output-data. Unlike the 
more commonly used Bonferroni technique that controls for the chance of any false 
positives (the proportion of inaccurately rejected null hypotheses), FDR controls for the 
expected proportion of false positives among a threshold, which is determined by the size 
of the observed p-value distribution, and hence is adaptive to the amount of signal in a 
data set (Nichols and Hayasaka, 2003). Therefore for a large and complex data set such as 
NMR data, the Bonferroni technique, which uses a fixed estimated error rate, is too 
conservative and prohibitive whilst FDR offers a more powerful statistical tool 
(Benjamini & Hochberg, 1995; Garcia, 2003). Through the use of ANOVA followed by 
FDR, bins whose intensities changed significantly between treatment groups were 
identified.  
 
Bins that were identified as “significantly different” by ANOVA and FDR were then 
identified as peaks on non-generalized log-transformed and non-normalized 1D 
1
H NMR 
spectra and quantified (measuring area under each peak, representing intensity levels) 
using Chenomx NMR Suite and associated libraries (version 4.5; Chenomx Inc, 
Edmonton, Canada). Intensity levels were divided by the TSA for each spectrum to 
ensure comparisons were accurately made between different spectra and treatment 
groups. Finally, average levels of metabolites were compared between different treatment 
groups as percentages (Ekman et al, 2007).  
 
 
 
 
 
 
 154 
4.2.10 Examining metabolic variation in fathead minnow livers 
 
4.2.10.1 Experimental design 
Metabolomic analysis of adult fathead minnow livers from the propranolol study revealed 
considerable variation between fish within individual treatment groups. Therefore the aim 
of the experiment was to address potential sources of this variation. 
 
During the propranolol exposure, fish were not starved prior to culling and so on the day 
of termination, it took several hours to cull all the fish and so it was possible that fish 
would have fed for different lengths of time depending on when they were culled. The 
liver is a principal site of food metabolism in the teleost body and, as such, a variation in 
diet and feeding regimes has a considerable influence on the metabolic activity of the 
liver (Cowley & Sargent, 1979; Sánchez-Muros et al, 1998; Pérez-Jiménez et al, 2007 
Enes et al, 2008). It is therefore likely that unregulated feeding in the propranolol study 
could have been a source of intra-fish variation. 
 
Another source of variation could be the result of “tank effects”. Each tank held only a 
single pair of fish, which in terms of metabolomic analysis (examining males only) 
effectively means a tank only held a single fish. It was also likely that tank posit ion 
within the room could be a source of variation. For example fish in the tank closest to the 
door may have experienced more stress than fish in tanks further away. In order to ensure 
that the room position had no bearing on the results for different propranolol exposures, 
the tank positions were randomized.  
 
Therefore, the aim of the experiment was two-fold: the first was to assess the effect of 
feeding on the metabolic profile of adult male fathead minnow livers and the second was 
to examine whether tank effects have any effect on the metabolic profile. This was 
achieved by setting up four tanks (working volume of 20L) each of which received 
dilution water (400ml min
-1
) only. Mature adult males, aged 26 months, were distributed 
into each tank (n = 16) and were fed twice per day for 6 days; on the 6
th
 day, fish were 
terminated by an overdose of MS222 anaesthetic, measured for wet weight (g) and 
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standard length (mm), and livers extracted for metabolomic analysis. Two of the tanks 
were fasted for 24 hours prior to termination whilst two of the tanks were fed for all 6 
days. Thus it was possible to examine for both metabolite differences of fish livers 
between feeding treatments and also between replicate tanks (“tank effects”).  
 
MS222 anaesthetic does not degrade rapidly in dilution water (Yuwiler & Samuel, 1974) 
and so it is common practice in ecotoxicological studies to prepare a “stock” of MS222 
and use the same stock throughout the culling procedure for entire fish experiments. 
However, MS222 is taken up via the gills and so as fish number increases, MS222 
concentration decreases due to removal, thereby increasing the time taken for fish 
anaesthetisation and consequently the stress a fish is likely to endure increases. Previous 
studies have suggested that stress can have a considerable effect on the metabolic activity 
of tissues (Morales et al, 1990; Kolanczyk et al, 2003) and so in the propranolol study, 
where a batch stock of MS222 was prepared, individual fish could have experienced 
varying levels of stress due to the time taken for complete anaesthetisation and so this 
could have been a source of variation. With this in mind, individual MS222 stocks were 
prepared for the feeding study.  A concentrated stock of MS222 was prepared and then 
aliquoted into individual beakers for each fish; dilution water was then added to each 
beaker to achieve a concentration of 0.5gL
-1
 (pH adjusted to 7.5). By preparing individual 
stocks of MS222, each fish was exposed to the same concentration of anaesthetic and 
therefore time taken for complete anaesthetisation was comparable between fish and as 
such stress endured by each fish should also be comparable.  
 
Metabolite extraction, 1D 
1
H NMR spectroscopy, spectral pre- and post-processing of 
data, RSD calculation and biomarker analysis protocols were followed as previously 
described. 
 
4.2.11 Analysis of data using Linear Discriminate Analysis (LDA) 
After analyzing the data using PCA, the “supervised” multivariate technique Fisher‟s 
LDA was applied to principal components 1 and 3 using Matlab version 7.1. LDA 
examines for linear combinations of variables so that the ratio of inter-group variation to 
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intra-group variation is maximized, thereby maximizing the separation of “decision 
regions” (or treatment groups) in the scores plot (Hines et al, 2007). Similarly to PLSDA, 
LDA was a “supervised” technique as the software was given information as to which 
treatment group each sample belonged to, unlike the “non-supervised” PCA technique, 
where no additional information of the data set was given. 
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4.3 RESULTS 
 
4.3.1 Preliminary metabolomic assessment 
Prior to assessing the effects of propranolol on the metabolic profile of male fathead 
minnow livers, 
1
H NMR metabolomics was employed to examine different fathead 
minnow tissues. As different tissues have very different metabolic profiles, this was a 
proof-of-principle assessment to determine whether metabolomics could be used to 
differentiate different tissues. As shown in figure 56, it was possible to separate fathead 
minnow according to tissue type on a PCA scores plots using 2D pJRES 
1
H NMR. This 
suggested that 
1
H NMR metabolomics could potentially be a viable technique for 
assessing the effects of propranolol exposure on the fathead minnow, where the 
metabolomic nature of a single tissue may vary according to the concentration of 
propranolol exposure. Fathead minnow adopise tissues had the greatest metabolic 
variation, as can be seen by the large ellipse and an outlying sample, whilst all other 
tissues fitted within the designated two standard deviation of the mean ellipses. 
 
 
 Figure 56. PCA scores plot of 
1H NMR metabolomics data showing adipose, brain, heart and liver 
plots. Ellipses drawn at two standard deviations (SD). 
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4.3.2 Propranolol exposure metabolomic results 
 
4.3.2.1 Liver tissues used for metabolomic analysis 
As discussed in chapter 3 section 3.4.1, 10mgL
-1
 propranolol was acutely toxic to male 
fathead minnows and therefore no liver data from this treatment group was available for 
analysis. Additionally several male liver tissues were extracted before the end of the 21-
day exposure period (termed pre 21-day liver data) from several treatment groups. Livers 
were collected from these fish and prepared for metabolomic analysis. The minimum 
amount of liver for a 
1
H NMR is 30mg and profiles produced by tissues under this size 
had a significant effect on the overall treatment metabolomic profiles and for this reason 
all metabolomic profiles from tissues under 30mg were excluded from both 1D and 2D 
pJRES data analysis. Table 27 summarises the number of suitable tissues used for 
metabolomic analysis. 
 
 
 
Propranolol treatment group (mgL
-1
) Number of tissues used for metabolite 
extraction 
DWC 8 
0.001 8 
0.01 8 
0.1 6 
1.0 4 
 
4.3.2.2 Relative standard deviation  
During both propranolol exposures, several male fish were culled (and their livers 
extracted) during the 21-day exposure period either because they were showing signs of 
distress (such as in the 1mgL
-1
 treatment group) or because the females had become “egg-
bound”, which is when an egg becomes trapped in the ovary duct and prevents the 
females from spawning; in these instances, the females were culled. Therefore, male fish 
were exposed to propranolol for different lengths of time, which may be a potential 
Table 27. Summary of number of male liver tissues extracted for metabolomic analysis. Tissues that were 
below 30mg were excluded from analysis. 
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source of metabolic variation within each treatment group. RSD was therefore used to 
examine the level of metabolic variation in each treatment group with and without the 
pre-21 liver data. Figures 57 and 58 show several box plots of median variation taken 
from 1D and 2D pJRES 
1
H NMR data with associated 10
th
, 25
th
, 75
th
 and 90
th
  percentile 
ranges, respectively. Each red cross represents the level of variation between all male 
livers within the same treatment group at a single outlying bin. There were over 2000 
bins per liver spectrum and therefore, although it appears that a significant quantity of 
data points are outside the 90
th
 percentile ranges, the box plots do accurately represent the 
data sets. The level of variation was significantly higher (p<0.05) in the 0.001mgL
-1
 and 
0.1mgL
-1
 treatment groups from the 1D data and significantly higher in all treatment 
groups from the 2D pJRES data. Therefore, the pre-21 liver metabolic data was excluded 
from further analysis. Table 28 summarises the number of tissues used for further 
metabolomic analysis at each propranolol concentration. 
 
One noticeable difference between the 1D and 2D pJRES data was that the level of 
median variation was considerably higher in the 2D pJRES data (median RSD variation 
ranged from 47.7-70.5%) than in the 1D data (median RSD variation ranged from 19.6-
30.2%). This is further highlighted in figure 59A and B. The variation in the 0.001mgL
-1
 
treatment group was significantly lower than the DWC and 0.1mgL
-1
 group in the 1D 
data (p<0.05), whereas in the 2D p JRES data the DWC and 0.01mgL
-1
 treatment groups 
had a significantly higher level of variation (p<0.05) compared to the other treatment 
groups. However, there was no relationship between propranolol concentration and 
observed level of variation between liver metabolite profiles. This data supports the 
findings of Parsons et al (2009), who suggested that because of the increased level of 
resolution and accuracy, 2D pJRES data has a higher level of variation.  
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Treatment 
group 
Pre 21-day vs. 21-day 
data (p <0.05) 
DWC No difference  
0.001mgL
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0.01mgL
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 No difference 
0.1mgL
-1
 Different  
1.0mgL
-1 No difference 
Figure 57. RSD box plots taken from 1D male liver data from all propranolol treatment groups. A = 
DWC; B = 0.001mgL-1; C = 0.01mgL-1; D = 0.1mgL-1; E = 1.0mgL-1. For each figure class 1 represents 
21-day data and class 2 represents pre 21-day and 21-day data. Table summarises significant statistical 
difference (p<0.05) between data sets. 
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Treatment 
group 
Pre 21-day vs. 21-day 
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Figure 58. RSD box plots taken from 2D pJRES male liver data from all propranolol treatment groups. A = 
DWC; B = 0.001mgL-1; C = 0.01mgL-1; D = 0.1mgL-1; E = 1.0mgL-1. For each figure class 1 represents 21-
day data and class 2 represents pre 21-day data. Table summarises significant statistical difference (p<0.05) 
between data sets.  
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To explore whether the observed level of metabolic variation in the DWC fathead 
minnow livers was inherent to fish species, RSD data from the control liver 1D data was 
compared with that from other fish test species (courtesy of Parsons et al, 2009) as shown 
Propranolol treatment group (mgL
-1
) Number of tissues used for multivariate 
and univariate statistical analysis 
DWC 7 
0.001 6 
0.01 7 
0.1 4 
1.0 3 
Figure 59. RSD box plots taken from 1D (A) and 2D pJRES (B) male liver data from all propranolol treatment 
groups. denotes statistical significant difference (p<0.05) between treatment groups exclusive for data set only.  
denotes statistical significant difference (p<0.05) between treatment groups exclusive for data set only. 
Propranolol concentration (mgL
-1
)        Propranolol concentration (mgL
-1
) 
Controls class 1 class 2 class 3 class4
0
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 Control   0.001      0.01        0.1         1.0 
Controls class 1 class 2 class 3 class4
-50
0
50
100
150
200
250
300
350
400
V
a
lu
e
s
 Control   0.001      0.01        0.1         1.0 
                         B        A 
Table 28. Summary of number of male liver tissues used for metabolomic analysis. Tissues smaller than 
30mg and also tissues extracted during the 21-day propranolol exposure were excluded from further 
analysis. 
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in figure 60. The three-spined stickleback (Gasterosteus aculeatus) and flounder 
(Platichthys flesus) lab samples were taken from fish bred under laboratory conditions, 
whereas the flounder Alde samples were taken from flounder living in the River Alde, 
Suffolk. The observed levels of metabolomic variation within each of these test species 
was similar to those observed in the fathead minnow. The median RSD values were 
28.8% for the fathead minnow, 26.8% for the three-spined stickleback, 27.3% for the 
flounder (from the laboratory) and 30.1% for the flounder taken from the river Alde.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.2.3 Multivariate analysis 
 
4.3.2.3.1 Principal component analysis  
PCA was used to group each propranolol data set according to the concentration of the 
two metabolites that showed the greatest variation in concentration between all liver 
tissues (termed principal components 1 and 2). However, the level of variation within 
each treatment group for both 1D (figure 61) and 2D pJRES (figure 62) data was such 
that it was not possible to separate the data according to propranolol treatment 
Figure 60. RSD box plots comparing control liver 1D data between different fish test species. 
Data taken from Parsons et al (2009). 
Fish test species 
    FHM           stickleback lab      stickleback Alde    Flounder lab 
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concentration, which was in stark contrast to the clear grouping of tissues achieved in the 
preliminary study (figure 56). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 61. PCA scores plot of PC1 vs. PC2 for 1D NMR fathead minnow 
liver data grouped according to classes. ▲ = control group; * = 0.001mg L-1; 
■ = 0.01mg L-1; + = 0.1mg L-1; ◊ = 1.0mg L-1.  
 
Figure 62. PCA scores plot of PC1 vs. PC2 for 2D pJRES NMR fathead 
minnow liver data grouped according to classes. ▲ = control group; * = 
0.001mg L-1; ■ = 0.01mg L-1; + = 0.1mg L-1; ◊ = 1.0mg L-1.  
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Figures 63 and 64 are examples of PCA plots that included both metabolic data from 
samples less than 30mg in weight and also metabolomic data taken from the two 
surviving females in the 10mgL
-1
 group (propranolol experiment 1). There was a clearer 
separation of the 1.0mgL
-1
 and 10mgL
-1
 groups. It was not clear whether this was as 
result of propranolol exposure, tissue size or, for the 10mgL
-1
 group, sex. Figure 64, also 
shows a pink highlighted male liver spectrum taken from a dying fish in the 1.0mgL
-1
 
treatment group. Note the metabolomic profile of this tissue was markedly different to 
other profiles, including those from the 1.0mgL
-1
 group. Also note that figure 64 
represents a PC1 vs. PC3 plot, indicating that there were at least 3 factors that influenced 
the variability in between tissues, besides the propranolol treatment, which further 
supports the variation-based observations made in figures 57-60. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.2.3.2 Partial least squares discriminate analysis 
Although there appears to be a clearer separation of treatment groups, as shown in figures 
65 and 66, the associated root mean square error of cross-validation (RMSECV), which is 
Figure 63. PCA scores plot of PC1 vs. PC2 for 2D 
pJRES NMR fathead minnow liver data grouped 
according to classes. ▲ = male control group; * = 
male 0.001mg L-1; ■ = male 0.01mg L-1; + = male 
0.1mg L-1; ◊ = maleb1.0mg L-1.        = 10mgL-1 female 
liver data. 
 
Figure 64. PCA scores plot of PC1 vs. PC3 for 2D 
pJRES NMR fathead minnow liver data grouped 
according to classes. ▲ = male control group; * = male 
0.001mg L-1; ■ = male 0.01mg L-1; + = male 0.1mg L-1; 
◊ = male 1.0mg L-1.  Highlighted pink diamond (♦) 
represents male fish that was dying. 
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the likelihood of the algorithm incorrectly placing a data point on the PLSDA plot for an 
individual treatment, ranged from 0.23 (1.0mgL
-1
 data points) to 0.68 (0.001mgL
-1
 data 
points) for the 1D data and 0.28 (DWC data points) to 0.70 (0.01mgL
-1
 data points). A 
statistically satisfactory RMSECV value should be <0.01.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Propranolol treatment 
group mgL
-1
 
RMSECV 
DWC 0.36 
0.001 0.37 
0.01 0.68 
0.1 0.53 
1.0 0.23 
Propranolol treatment 
group mgL
-1
 
RMSECV 
DWC 0.28 
0.001 0.49 
0.01 0.51 
0.1 0.70 
1.0 0.55 
 
Figure 65. PLSDA plot of LV1 vs. LV3 with associated RMSECV for 1D male fathead minnow liver data.  
▲ = control group; * = 0.001mg L-1; ■ = 0.01mg L-1; + = 0.1mg L-1; ◊ = 1.0mg L-1.  
 
Figure 66. PLSDA plot of LV1 vs. LV3 with associated RMSECV for 2D p JRES male fathead minnow liver data. 
▲ = control group; * = 0.001mg L-1; ■ = 0.01mg L-1; + = 0.1mg L-1; ◊ = 1.0mg L-1.  
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4.3.2.4 Identifying a biomarker of propranolol exposure using One-way ANOVA 
and FDR 
It was not possible to examine for a biomarker of propranolol exposure using multivariate 
statistics. Therefore, one-way ANOVA was used to examine for a difference in 
concentration at each „binned data‟ between different liver metabolic profiles from each 
propranolol treatment concentration. To ensure a conservative assessment of significant 
bins was made, FDR was subsequently applied to the ANOVA output-data. Figure 67 
shows the 1D data plot of all the fathead minnow liver spectra with highlighted bins that 
were significantly different to each other in terms of intensity/concentration between the 
different propranolol treatment groups. In total, 129 bins were significantly different, 17 
of which were identified as metabolites. The Chenomix software used to identify the 
metabolites is not a comprehensive library and so it is possible that a number of the 112 
bins that did not correspond to a metabolite were in fact representative of metabolites and 
some were “noise”, which would suggest that the noise-threshold was not set high 
enough. However, since the Chenomix suite is not complete, it is not possible to identify 
between the two possibilities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 67. Plot of fathead minnow liver spectrum with highlighted (red crosses) bins of statistical significant 
difference. Yellow = control; green = 0.001mg L-1; blue = 0.01mg L-1; cyan = 0.1mg L-1; black = 1.0mg L-1.  
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Using Chenomx
TM
 software, each fathead minnow male liver spectrum was analysed and 
metabolites that significantly differed between each treatment group were identified as 
glutamate, glucose and nicotinamide adenine dinucleotide (NAD+), as shown in figure 
68. Relative concentrations were calculated by measuring the area under each peak. To 
compare metabolite levels between fish livers between treatment groups, metabolite 
concentrations were normalized to the total spectrum area for each sample. The 
calculated concentrations indicated that there was an inverse dose relationship between 
propranolol concentration and glutamate levels (figure 69); as concentration increases, 
glutamate levels decreased. Glucose levels (figure 70) decreased as concentration 
increased from DWC to 0.01mgL
-1
, reaching a trough of 60.5% of DWC concentration, 
before increasing as propranolol levels increased. There was not a dose-dependent 
relationship between NAD+ levels and propranolol concentration (figure 71), though all 
NAD+ levels were lower in all propranolol exposed fish compared to control fish. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ? Plot of male fathead minnow liver spectrum with highlighted (red crosses) bins of 
statistical significant difference. Yellow = control; green = 0.001mg L-1; blue = 0.01mg L-1; cyan 
= 0.1mg L-1; black = 1.0mg L-1.  
 
Figure 68. One-dimensional 1H-NMR spectrum of a control fathead minnow liver sample analysed using 
ChenomXTM for assigning metabolite resonances. Glut = glutamate; Gluc = glucose; NAD+ = NAD+. 
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Figure 69. Concentrations of glutamate from propranolol-exposed livers as a percentage of 
measured glutamate levels in DWC livers.  
Figure 70. Concentrations of glucose from propranolol-exposed livers as a percentage of 
measured glucose levels in DWC livers. 
Figure 71. Concentrations of NAD+ from propranolol-exposed livers as a percentage of 
measured NAD+ levels in DWC livers. 
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An interesting point to note is that, following on from examining the metabolomic profile 
of the liver taken from the dying male fish from the 1.0mgL
-1
 propranolol treatment 
group on a PCA scores plot, the metabolic spectrum of this fish was markedly different 
from other fish from the same treatment group, as shown in figure 72. Levels of choline, 
lactate, formate and succinate were distinctly higher in the dying fish compared to other 
1.0mgL
-1
 fish.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 72. One-dimensional 1H-NMR spectrum of fathead minnow liver sample 45, which was culled early 
because of signs of distress. Ace = acetone; Cho = choline; Eth = ethanol;  For = formate; Lac = lactateSuc = 
succinate; UM = unidentified metabolite.  
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4.3.3 Examining sources of fathead minnow metabolic liver variation  
 
4.3.3.1 Summary of liver tissues used for metabolomic analysis 
Due to the cost of running the 
1
H NMR and based on the results from the propranolol 
exposure, it was deemed unnecessary to collect 2D pJRES data, thus only 1D data was 
collected from male livers. Fish in all four tanks were sexually mature adult males and 
during the 6-day experiment several males died. Many of the dead males showed signs of 
bruising and hemorrhaging, suggesting that the more dominant and aggressive males may 
have killed these less dominant smaller fish. During the 6-day period all four tanks were 
treated identically and so it was unlikely that there was an alternative source for the 
observed mortality. Table 29 summarises the total number of liver tissues used from each 
experimental tank.    
 
 
Propranolol treatment group (mgL
-1
) Number of tissues used for analysis 
Starved tank 1 9 
Starved tank 2 9 
Fed tank 1 10 
Fed tank 2 9 
 
4.3.3.2 Relative Standard Variation 
The level of variation did not significantly improve in the fasted tanks, as shown in figure 
73; on the contrary, compared to the level of variation observed in the fed tank 1, the 
level of variation was considerably higher.  
 
 
 
 
 
 
 
Table 29. Summary of number of male liver tissues used for metabolomic analysis. 
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4.3.3.3 Multivariate statistical analysis using PCA and LDA 
The PCA scores plot, as shown in figure 74, illustrated a degree of separation on the PC3 
scale between the two fasted 24 hrs prior to culling (blue and red circles) and the two fed 
for the entire experiment (green and cyan circles) treatment groups. The degree of 
separation was more apparent on the LDA plot as shown in figure 75. Similarly to figure 
56, outlying liver samples from the constructed ellipses were observed from both the 
starved and fed fish. The elipses represent one standard deviation of the mean and so at 
least two thirds of all samples will fit within the ellipses. Accordingly, samples that do 
not fit within the ellipse demonstrate the the considerable level of variation between liver 
tissues within treatment groups. 
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Figure 73. RSD box plots comparing male liver metabolomic variation 
between starved and fed fish up to and including day of culling. 
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Figure 74. PCA scores plot of PC1 vs. PC3 for 1D NMR fathead minnow liver data 
grouped according to classes. ▲ = starved group 1; ■ = starved group 2 * = fed group 1; + 
= fed group 2.Ellipses represent one standard deviation of the mean. 
 
Figure 75. LDA scores plot of PC1 vs. PC3 for 1D fathead minnow liver data grouped 
according to classes. = fasted 24hrs prior to culling; = fed for entire experiment. 
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4.3.3.4 Identifying a biomarker of feeding using One-way ANOVA and FDR 
Using One-way ANOVA followed by FDR correction, 53 bins were found to differ 
significantly between the fasted for 24hrs and fed treatment groups, as shown in figure 
76. Of the bins, 35 were deemed “noise” and 18 as identifiable metabolites. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As there was separation between treatment groups on the PCA and LDA along the PC3 
scale, it was possible to transpose the highlighted bins of significance onto the PC3 
loadings plot (figure 77) to examine whether the metabolites identified were markers of 
fasting or feeding. The bins highlighted by the red circle correspond to peaks arising from 
metabolites, whereas the other significant bins correspond to noise. The highlighted peaks 
were negative on the PC3 loadings plot which, when compared to the PCA and LDA 
scores plots, represented the starved fish liver metabolite profiles. Therefore, the 
metabolites that significantly differed between the two treatments were biomarkers of 
starved fish. 
 
Figure 76. Plot of fathead minnow liver NMR spectra with highlighted (red crosses) bins of statistical 
significant difference (p<0.05). Blue = starved fish livers; green = fed fish liver. 
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Analysis of the liver spectra using Chenomx
TM
 software was used to reveal which 
metabolites were found at significantly higher levels in starved fish (figure 78). Table 30 
indicates that glutamine levels in starved livers were 153% of those levels in fed male 
fathead minnow livers.  
 
 
 
 
 
 
 
 
 
 
Figure 77. PC3 loadings plot with highlighted bins of significant difference (p<0.05) between the two 
metabolite profiles. The peaks arising from metabolites that were significantly different between treatments 
are highlighted by the red circle. 
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Metabolite Fed fish livers up to and 
including day of culling 
Starved fish livers 24hrs 
prior to culling 
Glutamine 100% 153% 
 
 
 
 
 
 
 
 
 
 
Table 30. Comparison of glutamine levels between fed fish livers and starved livers. 
Figure 78. One-dimensional 1H-NMR spectrum of a liver sample taken from a male fathead minnow starevd for 
24hrs prior to culling. Glu = glutamine. 
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4.4 DISCUSSION 
 
 
4.4.1 Proof of principle 
The results from the preliminary study showed that 
1
H-NMR metabolomics was capable 
of examining and differentiating four different tissues from fathead minnow. Although 
this does not in itself provide new knowledge, it demonstrated the proof of principle that 
metabolomics could potentially be used in aquatic toxicity studies to examine the 
metabolic response of tissues to exposure to pharmaceuticals and other contaminants.  
The use of 
1
H NMR metabolomics to examine the metabolic response of fathead minnow 
livers to exposure to propranolol, however, was limited by metabolic variation between 
tissues from the same treatment groups (including control liver tissues). 
 
4.4.2 Addressing metabolic variation in fathead minnow livers 
Propranolol exerted an acute toxicological effect on male fathead minnows exposed to a 
concentration of 1.0mgL
-1
 and as the liver was the principal site of propranolol 
metabolism, it was anticipated that a metabolic response would be detected using 
1
H and 
2D pJRES NMR metabolomics (Masabuchi et al, 1994). However, the significant level of 
metabolic variation between liver tissues within the same treatment group was such that it 
was not possible to group them according to propranolol treatment concentration using 
both non-supervised PCA and supervised PLSDA. Therefore, it was not possible to 
identify a metabolic change in liver activity as a response to exposure to propranolol 
using multivariate analysis. One essential requirement of a metabolomic experiment is 
that the analytical variation introduced post-collection is less than the typical biological 
variation in the „normal‟ population of interest (Keun, 2006). Therefore to address the 
source of variation and determine whether it was „normal‟ or possibly introduced, RSD 
analysis was employed. Traditionally, RSD is used to examine the stability of metabolite 
peaks and consequently used as an indicator of the strength of results. In the current 
study, RSD was used to examine liver metabolomic variation levels within the same 
treatment group, according to the protocol described by Parsons et al (2009). The median 
RSD value for control male fathead minnow liver tissues was 28.8% and 55.6% for 1D 
and 2D p JRES data, respectively. Technical variation introduced by 
1
H NMR repeats 
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have been recorded at 3.07% and 12.5% for 1D and 2D pJRES data, respectively, 
indicating the variation observed in the fathead minnow tissues was most likely reflective 
of „normal‟ biological population variation, as opposed to „introduced‟ variation (Parsons 
et al, 2009). Furthermore, the median RSD levels in control stickleback, laboratory-
sampled flounder and wild flounder livers were closely comparable to that observed in 
the fathead minnow, suggesting further that this level of variation may be natural in 
teleost liver populations. There was no relationship between RSD liver variation and 
propranolol dose, indicating that any metabolic effect of propranolol on the livers did not 
override the natural variation in liver activity.  
 
4.4.2.1 Sources of metabolic variation 
 
4.4.2.1.1 Natural variation 
There are several potential reasons for the observed variation in the fathead minnow liver 
tissues. First and foremost, it could simply be natural. The metabolic phenotype can be 
described by the simple genetic relationship relating phenotype (observable physical or 
biochemical characteristics of an organism) to the variables that control it accordingly 
(German et al, 2003): 
 
Phenotype = (genotype + environment) + (genotype x environment)  
 
Considering the level of genetic variation between individuals and the sum of all external 
variables, there is the potential for considerable phenotypic variation within a single 
population. One method of minimizing metabolic phenotypic variation, which has been 
adopted for pharmacological studies, is to use inbred test species, which minimises 
genetic variation. For example, a typical median RSD level in the rat plasma (Ratus 
norvegicus) is 8.00% (Parsons et al, 2009), which is much lower than the median RSD 
levels in fathead minnow livers. The environmental relevance of using an inbred fish test 
species for an ecotoxicological experiment is questionable. However, the use of inbred 
fish may serve as a good starting point to understand toxicant mechanism of action before 
expanding upon the work with genetically diverse fish. 
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4.4.2.1.1 Introduced variation: technical variation 
The two-step tissue extraction protocol of methanol:chloroform:water optimized by Wu 
et al (2008) was unlikely to have contributed towards the observed level of variation as 
the recorded median RSD for technical replications (i.e. examining the same sample 
twice) was only 4.62%, as stated by Parsons et al (2009), although a technical replication 
median RSD was not recorded for the current study. 
 
4.4.2.1.2 Introduced variation: handling and anaesthetisation stress 
There are a handful of potential external sources of variation that may be introduced in all 
aquatic toxicology studies, including stress. In the propranolol exposure study, fish were 
culled by an overdose of MS222 and subsequent brain dislocation. It is possible that 
during the culling procedure, the fish may have experienced high levels of stress. Past 
studies have documented that handling and MS222 anaesthetisation stress can affect 
primary liver activity and biotransformation rates in the Arctic charr (Salvelinus alpinus) 
and rainbow trout (Oncorhynchus mykiss) (Morales et al, 1990 and Kolanczyk et al, 
2003, respectively), resulting in decreased cytochrome P450 levels, which can ultimately 
transform the liver metabolic profile. However, Hemre & Krogdahl (1996) suggested that 
handling and anaesthetisation stress had a minimal effect on secondary changes in 
carbohydrate metabolism in the Atlantic salmon (Salmo salar) and so possibly the 
magnitude and effect of stress may be species-specific. It was possible that different fish 
experienced different levels of stress and this variation in stress level may have had an 
effect on the overall variation in liver metabolite profiles.  
 
Regulated MS222 anaesthetisation for individual fish, used in the fish feeding 
experiment, did not improve the median level of RSD in each tank and so MS222 
anaesthetisation was also an unlikely source of introduced variation in the propranolol 
study. 
 
4.4.2.1.3 Introduced variation: Diet – feeding and fasting 
Another external source of variation could be feeding; in the propranolol exposure study, 
the fathead minnows were fed up to and including the day of culling; food was added 
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each morning. There were in total 40 fish (males and females) culled on both sampling 
days. Therefore, fish were culled at different times during each sampling day and so fish 
culled late on in the day may have had time to feed more than those culled earlier on. Diet 
has a huge influence on the hepatic metabolome (Griffin et al, 2007), and so it was 
possible that unregulated feeding may have contributed to the variation observed in the 
liver tissues.  
 
Fasting the fish 24 hours prior to culling did not reduce (improve) variation levels 
between liver metabolic profiles. The median RSD was indeed higher in livers taken from 
the „starved‟ tanks than in livers taken from the „fed‟ tanks. At the start of the 6 day 
feeding trial, 16 adult male fathead minnows were introduced into each tank and were fed 
for either 5 („fasted‟) or 6 days. It was very difficult to quantify the volume of food each 
fish consumed over this period as, naturally, fish hierarchy was established and thus some 
fish were likely to have consumed more food than others. It was apparent that there was 
an aggressive hierarchy in each tank as several smaller males died and showed signs of 
abdominal bruising, which is indicative of fighting between fish. When sexually mature, 
the male fathead minnow is a very territorial freshwater species (Cole and Smith, 1987). 
For the purpose of this study only adult male livers were suitable for 
1
H NMR 
metabolomic analysis because of their large size and so this hierarchal behaviour was 
anticipated. It has been suggested that to attempt to counter-balance this aggressive 
territorial behaviour, female fish should be introduced in sufficient numbers. However, 
previous studies have suggested that introducing several females into male tanks does not 
alter male fathead minnow behaviour (Pyron & Beitinger, 1989). As such, this observed 
hierarchal behaviour could have influenced feeding rates by individual fish in all tanks 
and possibly liver metabolomic profiles within the same tank and thus increase metabolic 
variation. Regardless, one can conclude that feeding up to and including the day of 
culling in the propranolol study was unlikely to be the principal source of introduced 
variation in the propranolol study.  
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4.4.2.1.4 Introduced variation: Tank effects 
It is possible that fish in different tanks can respond differently to exposure to the same 
concentration of a toxicant. For example, in the propranolol study each male fish was 
housed in an individual tank (6 tanks each with a different propranolol concentration) and 
so the fish in the tanks closest to the door may have experienced more stress than fish in 
tanks further away. However, the PCA scores plot from the feeding experiment suggested 
that there was little or no difference in liver metabolic profiles between both repeat tanks 
from the feeding and fasting treatments, suggesting there was no major tank effect. 
Therefore, different tank environments probably had a minimal contribution towards the 
observed variation between individual liver metabolic profiles within the same 
propranolol treatment groups. 
 
4.4.3 Identifying Biomarkers 
 
4.4.3.1 Propranolol exposure  
Univariate analysis was employed to identify a biomarker of propranolol exposure in 
male fathead minnow livers. Using one-way ANOVA (p<0.005) followed by FDR 
correction on the binned data, 17 bins that contained peaks from metabolites were 
identified as varying significantly between propranolol treatment groups; these 
metabolites were subsequently identified as glucose, nicotinamide adenine dinucleotide 
(NAD
+
) and glutamate. There was an observed decrease in all three metabolites upon 
exposure to propranolol, although glutamate was the only metabolite to show a dose-
dependent decrease. Glutamate is used in the tricarboxylic acid cycle and is therefore 
linked to energy production. There was an inverse dose-dependent response that as 
propranolol treatment concentration increased, glutamate levels decreased. Propranolol 
reduces energy metabolism and subsequent oxygen consumption in humans (Krag et al, 
2006) and so it is possible that this same effect was observed in propranolol-exposed 
fathead minnow. There is contradictory information regarding the effects of propranolol 
on glucose levels in humans and higher vertebrates. Hunt et al (2002) examined the 
effects of propranolol on glucose clearance and premature fatigue during exercise in the 
rat (Rattus norvegicus). They suggested that propranolol inhibited the epinephrine-
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mediated pathway of insulin-stimulated glucose uptake during muscle contraction and, as 
a result, plasma glucose levels were elevated. Allison et al (1969), however, found that 
propranolol slightly lowered plasma glucose levels and had no significant effect on 
insulin levels in humans and so the effect of propranolol on the insulin-stimulated glucose 
uptake is still unclear. There is little information which addresses the direct effects of 
propranolol on the metabolic profile of liver tissues. Epinephrine regulates 
glycogenolysis in muscle and liver tissues, which is the conversion of glucagon to 
glucose (McMurry, 1988). In the liver, glucose-6-phosphate is produced and is 
subsequently de-phosphorylated into glucose, which then diffuses into the bloodstream 
for uptake by other tissue cells (Berg & Tymoczko, 2002). It was not possible to 
differentiate between glucose and glucose-6-phosphate using the Chenomix software and, 
considering the rate at which glucose diffuses into the bloodstream, it is more likely that 
glucose-6-phosphate was detected. It was evident at all concentrations that fish were 
showing signs of stress and, as such, there would have been an increase in epinephrine 
levels (Bonga, 1997) and an increase in glyogenolysis. However, propranolol may have 
inhibited this pathway at the lower propranolol concentrations (0.001mgL
-1
 to 0.1mgL
-1
) 
and as a result the glycogenolysis rate was lowered and so there was a decrease in liver 
glucose-6-phosphate levels. Once blood plasma glucose levels fall below a threshold 
(hypoglycemia) in humans and higher vertebrates, glucagon is produced to stimulate the 
conversion of stored glycogen into glucose in the liver (Kieffer & Habener, 2000). 
Therefore, it is possible that glucose levels in fathead minnows exposed to 1mgL
-1
 
propranolol fell below the threshold, and in response glucagon induced the production of 
glucose-6-phosphate in the liver and by day 21 of the exposure period, glucose levels 
were almost restored to the same levels as measured in the DWC fish livers. However, if 
this did happen, one would have expected a corresponding decrease in glycogen levels in 
the 1mgL
-1
 fish livers, which was not detected. Metabolomics takes a “snap-shot” of 
tissue metabolic activity and so it is difficult to examine a metabolic response over time, 
as hypothesised. Secondly, as it was not possible to measure glucose levels in blood 
plasma because of limited sample sizes, it was not possible to examine whether glucose-
6-phosphate levels corresponded with glucose levels. 
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Due to the considerable variation observed between livers, it is possible that this response 
may have occurred but was not detected using 
1
H NMR metabolomics. NAD
+
 is a 
coenzyme involved in many redox reactions during metabolism. In higher vertebrates, 
NAD
+
 has been identified as an important cofactor of cytochrome P450 propranolol 
metabolism (Vu and Abramson, 1980) and so it is possible that upon exposure to 
propranolol, hepatic cytochrome P450 activity levels increased in the fathead minnow 
and there was a resultant decrease in NAD
+
 levels. There was not a dose-related response 
between NAD
+
 and propranolol concentration; this coupled with the fact that NAD
+
 
levels were not dramatically lower than the control levels suggests that perhaps what has 
been observed is an example of individual variation or that because NAD
+
 is involved in 
many critically important cellular pathways, levels  are maintained around a set point.  
 
A single liver tissue from a dying male from the 1.0 mgL
1
 propranolol treatment group 
was also analysed using univariate one-way ANOVA and FDR. The metabolomic profile 
from this single male liver suggested that there were several metabolites found at higher 
levels compared to DWC livers. Elevated levels of lactate, formate and succinate, which 
are all characteristic metabolites of liver failure, were observed (Oka & Sakai, 1969; 
Thompson, 1986; Sewell et al, 1997; Riordan & Williams, 2002). Elevated levels of 
choline were also observed. Choline is a constituent of cell membranes and so if there 
was a breakdown in the cell membranes, choline may have been released. This data 
supports the theory described in 3.4.1, that liver failure was potentially the cause of death 
observed in fathead minnows exposed to pharmacologically-relevant levels of 
propranolol and that the identified biomarkers were representative of dying.  
 
Two female tissues analysed from the 10mgl
-1
 treatment group, where acute toxicity was 
observed in both male and female fish, also demonstrated a significant different 
metabolite profile and were grouped accordingly. However, it was not possible to 
determine whether the differences were due to propranolol exposure, phenotype-related 
metabolic profile differences (Hines et al, 2007; Ekman et al, 2008) or because the 
tissues were smaller than 30mg and thus giving potential errors in NMR analysis. 
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Of the three identified “biomarkers” of propranolol exposure (excluding those indicative 
of dying), glutamate is perhaps the most suitable. Unlike glucose and NAD
+
, glutamate 
levels showed a dose-dependent response, with minimal variation and therefore may have 
served as an indicator of changes to energy production/metabolism. However, one cannot 
be sure that glutamate production (either decreased or increased) is specific to exposure 
to propranolol and therefore the use of glutamate as a biomarker must be validated 
against other pharmaceuticals. Additionally, considering the level of metabolic variation 
observed between liver tissues, the significance of glutamate as a biomarker remains 
questionable and also requires further validation. The use of univariate analysis has been 
frequently adopted to identify biomarkers of xenobiotic/contaminant exposure in aquatic 
organisms and therefore presents a suitable method of analysis, however the relevance 
and reliability of these identified biomarkers is still uncertain.  
 
4.4.3.2 Feeding/fasting 
Despite the levels of variation within each tank, it was possible to separate and group the 
liver metabolic profiles according to their feeding treatment using multivariate PCA and 
LDA. Combining this with univariate one-way ANOVA followed by FDR (p<0.05), 
glutamine was identified as a metabolite that varied significantly in concentration 
between livers from fish fed up to and including the day of culling and livers from fish 
starved 24 hours prior to culling; glutamine was therefore a potential biomarker of 
starving. Glutamine is a non-essential amino acid produced from muscles during 
gluconeogenesis, where glucose is generated from non-carbohydrate carbon substrates 
such as lactate, glycerol and glucogenic amino acids, during which nitrogen is converted 
to glutamine in the liver (Jungas et al, 1992). In higher vertebrates and teleosts, glutamine 
is an important substrate for red muscles and is an important fuel source when 
metabolism is increased and dietary sources of non-carbohydrate carbon substrates are 
low  (Chamerlin et al, 1991; Balzola & Boggio-Bertinet, 1996). Gluconeogensis typically 
occurs during periods of fasting, starvation or intense exercise (Nelson & Cox, 2000) and 
therefore it is likely that gluconeogensis activity in the livers of fish fasted for 24 hours 
increased which resulted in the increased production of glutamine. Surprisingly, 
1
H-NMR 
metabolomic analysis of the livers was not able to identify a decrease in glycogen levels 
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which has been observed in fasting rainbow trout (Oncorhynchus mykiss) and European 
sea bass (Dicentrchus labras) (Pottinger et al, 2003 and Pérez-Jiménez et al, 2007, 
respectively). However, the analytical techniques were used specifically for the 
determination of glucose-derivatives. 
 
The results from the feeding study demonstrated that there was not necessarily a direct 
relationship between RSD variation and the ability for unsupervised multivariate 
techniques to extract a biomarker of response. The median RSD levels were very 
comparable between livers from the feeding and propranolol exposure and yet it was 
possible to identify a biomarker of response using uni- and multivariate analysis from the 
feeding exposure whereas for the propranolol exposure, only univariate analysis was 
used. The trend in response to a „treatment‟ (i.e. the magnitude in change of specific 
metabolites) in addition to the level of metabolic variation is a crucial factor as to the 
likelihood of successful multivariate analytical interpretation (separation of „treatment‟ 
groups and identification of a biomarker) of data. 
  
4.4.4 Recommendations for future work 
Despite the considerable variation observed in both studies, it was possible to extract and 
identify potentially subtle biomarkers of propranolol exposure and fasting using 1D and 
2D pJRES 
1
H-NMR metabolomics. The use of RSD analysis for examining variation 
provided a clearer insight for understanding the multivariate analysis data. Additionally, 
RSD provided a valuable tool to determine whether data could be included for analysis. 
The use of RSD should be continued in this fashion for further aquatic toxicology based 
studies where genetic and phenotypic variation could potentially be very high and, with 
additional studies, it could possibly be used to determine benchmarks of variation. 
 
Efforts to minimise the level of variation could include using a larger fish test-species, 
such as the rainbow trout, and conduct time-dependent metabolomic analysis (i.e. 
sampling blood plasma every 24 hours) both before and during pharmaceutical exposure; 
each fish would thus serve as its own control. This approach is often used in human-
based pharmacological metabolomic studies as effectively each patient serves as their 
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own control, thus dramatically reducing variation levels (Clayton et al, 2006). There are 
however, ethical implications for such a study. The use of in-bred fish also presents 
problems in the interpretation and relevance to the environmental situation. 
 
Considering the physiological impact of propranolol on the adult male fathead minnows, 
it was surprising that it was not possible to extract a robust and sensitive biomarker of 
propranolol exposure. One principal limitation of using NMR is that it detects in the 
range of 50-100 metabolites (Skoog et al, 1998), whereas a fish metabolome contains 
probably more than 2000 metabolites, and so NMR is only able to examine 2.5-5% of all 
metabolites. As such, there is a high likelihood that the metabolic response of a particular 
tissue/sample may not be detected by NMR. Of the metabolites that NMR can detect, it is 
possible that NMR is too sensitive and so subtle changes in metabolites are masked by 
the large variations between individual tissues. 
 
Another potential limitation of this study was that only polar metabolites were extracted 
in the methanol stage. Assuming propranolol has a similar mode of action in fish as it 
does in humans and higher vertebrates, one may assume that propranolol interacts with 
the β3-AR in the fathead minnow, which is located in the adipose tissue, as well as other 
tissues. The β3-AR plays a key role in lipolysis and in response to interacting with 
propranolol, there may have been measurable changes in triglyceride and fatty acid 
concentrations (Rühling et al, 1980). It was not possible to measure these metabolites, 
and thus examine a potential direct mode-of-action of propranolol as they are non-polar 
and as such were extracted in the chloroform stage of metabolite extraction. Considering 
the level of variation observed in both metabolomic studies, it is difficult to postulate at 
this stage whether any significant changes would have been observed using multivariate 
analysis on non-polar metabolites. Regardless, it is important in the future to examine 
both polar and non-polar metabolites from samples to gain a better understanding of 
metabolic responses to pharmaceutical exposure. 
 
Perhaps the most realistic and long-term advantageous tactic for expanding our 
knowledge would be to firstly examine and understand the potential routes and causes of 
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natural biological variation and explore the possibility of using biofluids such as plasma, 
which is not as heavily influenced by sudden metabolic changes brought on by stressor 
factors (Polkowska et al, 2004). Ekman et al (2007) examined fathead minnow urine and 
plasma, however because of the small volumes analysed, the length of NMR analysis was 
considerably longer than for analyzing liver tissues and the subsequent measured RSD 
levels were 52.9% and 62.6%, respectively. This therefore provides an additional motive 
for using larger fish test-species. 
 
In conclusion, when considering firstly the limitations of NMR and secondly the possibly 
high inherent variation between tissues from a small fish test-species, 
1
H NMR 
metabolomics certainly offers promise for future studies in examining for a response of a 
fish test-species to an environmental stressor. This study has not only provided further 
proof-of-principle that it is possible to identify a biomarker of pharmaceutical exposure 
using 
1
H NMR and subsequent univariate statistical analysis, but it has (perhaps more 
importantly) also addressed current problems and made valuable recommendations for 
improvements to the use of metabolomics in ecotoxicological studies. 
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CHAPTER 5: EXAMINING CHANGES IN FATHEAD 
MINNOW β3bi-AR EXPRESSION IN RESPONSE TO 
PROPRANOLOL EXPOSURE 
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5.1 INTRODUCTION 
The polymerase chain reaction (PCR) allows the operator to amplify and subsequently 
identify a particular gene of interest from a complex sample and is widely used in 
molecular biological investigations (Lodish et al, 2005). Furthermore, the PCR is a 
robust, relatively cheap, sensitive technique and has therefore been utilised in a wide 
range of studies including those of an aquatic toxicology nature (Halm et al, 2002). The 
result from a PCR experiment, which is visualised on an agarose gel under U/V 
conditions illustrates whether the sample in question possesses and potentially expresses 
the gene of interest. There are, however, limitations to using a standard PCR reaction. For 
example, the whole process of extracting RNA (for reverse transcription PCR), reverse 
transcribing it to cDNA, running the PCR, collecting the samples and subsequently 
visualising them on an agarose gel is time consuming and cannot be achieved through an 
automated process. Secondly, results are entirely based on discriminating different sized 
products on an agarose gel, which can be very subjective and imprecise. Finally, and 
arguably most importantly, a standard PCR does not provide a quantitative measure of 
gene expression; it only tells the operator whether or not it is expressed. Therefore it is 
not possible to examine whether a particular gene is up- or down-regulated under 
different conditions. 
 
Real-time PCR (RT-PCR), also referred to as quantitative real time PCR (Q-PCR) is a 
technique based on PCR, which is used to detect, amplify and simultaneously quantify a 
target DNA molecule (Nolan et al, 2006). In brief, a fluorescent probe is added to a 
standard PCR reaction which binds with newly formed double-stranded DNA and, upon 
binding, emits a fluorescence signal which is detected and analysed. The greater the 
fluorescent signal, the greater the concentration of DNA and therefore the greater the 
starting expression level of the gene of interest. In addition to providing a reliable 
quantitative account of expression levels, real-time PCR also allows the user to measure 
the number of molecules during each exponential amplification stage, which represents a 
significant time-efficient advantage over a standard reverse transcription PCR 
(VanGuilder et al, 2008). 
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As such, RT-PCR represents a useful tool to identify gene expression changes in tissues 
exposed to a range of environmental conditions that may perhaps result in the elucidation 
of a potential biomarker(s) (Alberti et al, 2005).  
 
5.1.1 Types of RT-PCR 
There are two types of RT-PCR, the first is relative RT-PCR and the second is absolute 
RT-PCR. Both techniques allow for gene expression quantification using a small amount 
of RNA template and are equally sensitive. The difference between the techniques is how 
the measurements are quantified. Relative RT-PCR determines the changes in RNA 
levels of a gene and expresses it relative to the levels of an internal control 
“housekeeping” gene RNA. The theory behind this is that expression levels of 
housekeeping genes do not vary significantly between the same tissues taken from 
different treatment groups. Therefore, it is possible to directly compare the levels of the 
gene in question from different treatment groups with the internal housekeeping gene 
control (Thellin et al, 1999). As such, relative quantification does not require standards 
with known concentrations. A difficulty with using relative RT-PCR can arise if the 
treatment variable interacts with the housekeeping gene. For example Runnalls (2005) 
found that the pharmaceutical clofibric acid interacted with the housekeeping gene β-
actin in the fathead minnow and therefore β-actin was not a suitable internal control. 
 
Absolute RT-PCR uses an amplicon of the gene of interest as the control external 
standard. Once the number of molecules in the defined standard has been measured, a 
range of standard concentrations (for example 10
1
 to 10
7
 molecules) are run on each 
assay plate and their fluorescent levels measured, creating a standard curve. The standard 
curve is used as an indicator of RT-PCR efficiency. Using the standard curve, it is 
possible to calculate the number of molecules of a sample per µl. Absolute RT-PCR 
represents a more efficient and robust technique of quantifying expression levels as the 
standard RNA used to compare expression levels is the same as the gene RNA of interest 
and preparation of samples has been uniform. Hence, the standard and sample strands 
simultaneously undergo reverse transcription and amplification under the same conditions 
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at the same time, with the same primers, and therefore the experimental variables are the 
same, thus reducing the potential for errors in quantification. 
 
5.1.2 Use of mRNA in RT-PCR 
Traditionally, most RT-PCR studies use total RNA (tRNA) as the starting template as the 
isolation of mRNA from tRNA requires an additional step and can therefore result in the 
loss of starting material. However, for any RT-PCR, it is the mRNA that contains all the 
coded information stored in DNA and, thus, it is the mRNA expression level which is 
actually being measured (Lodish et al, 2005). Therefore, when measuring the expression 
of a potentially poorly expressed receptor in a tissue it is advantageous to use mRNA as 
the starting template as this will reduce potential background “noise”, which is imperative 
when using an extremely sensitive technique. 
 
5.1.3 Use of RT-PCR in aquatic ecotoxicological studies 
Like most techniques, the use of RT-PCR in aquatic ecotoxicological studies has, to date, 
been primarily used to examine the responses of aquatic organisms upon exposure to 
endocrine disrupting chemicals (EDCs) including EE2, testosterone, oestradiol (E2), 
polycylic aromatic hydrocarbons (PAHs) and dioxin pesticides (Hoffman & Oris, 2006). 
Accordingly, investigations have primarily focused on examining the responses of genes 
known to play a key role in reproduction, growth and development on exposure to EDCs. 
Kohno et al (2008), for example, observed differences in the expression of gonadal 
oestrogen receptors ESR1 and ESR2 belonging to wild juvenile American alligators 
caught in different Florida wetlands. Male juvenile alligators taken from a renowned 
pesticide-contaminated lake exhibited higher levels of testicular ESR1 and ESR2 mRNA 
than juvenile male alligators from different lakes, suggesting exposure to such 
contaminants up-regulated oestrogen receptor expression. Furthermore, male alligators 
demonstrated the same ESR1: ESR2 ratio as females from a reference site. Using RT-
PCR, this study began to address the underlying basis for the abnormalities that has been 
observed in testicular and ovarian biology in alligators from pesticide-contaminated 
wetlands, which up until then had not been possible. The up-regulation of P450 
aromatase mRNA expression in the liver and brain in response to environmental EDCs 
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have also been examined in the Atlantic salmon (Lyssimachou et al, 2006) as has the up-
regulation of vitellogenin mRNA expression in the so-iuy mullet (Mugil soiuy) (An et al, 
2006). Both absolute RT-PCR (Lyssimachou et al, 2006; Kohno et al, 2008) and relative 
RT-PCR (An et al, 2006) techniques were used, indicating that there is not a routinely 
prefered RT-PCR technique. 
 
Pharmaceuticals often exert their effect by up- or down-regulating mRNA expression 
and, as such, there have been a handful of laboratory studies that have examined for up- 
or down-regulation of gene mRNA expression in aquatic organisms exposed to 
pharmaceuticals. Lange et al (2008), for example, exposed roach to concentrations of EE2 
and observed that effects on gonadal development were associated with alterations in 
expression of estrogen receptor ESR 1 and aromatase CYP19a1b genes and demonstrated 
that both aromatase and estrogen receptors were associated with sexual differentiation in 
roach, and alteration in their expression can signal for disruptions in sexual development.  
 
5.1.4 Tissue selection for RT-PCR analysis 
The current study was part of a larger EU-collaborative study conducting a risk 
assessment on propranolol and one of the designated endpoints was the effect on β1- and 
β2-AR expression. As such, selected tissues for RT-PCR analysis had to express all three 
β-ARs. For this reason, the heart, liver, brain and gonad were selected. Although 
propranolol is a non-specific beta-blocker, the heart is the major target organ and 
therefore the heart was selected for RT-PCR analysis. Additionally, propranolol is a 
highly extracted drug in the liver (up to 95% removal) and so there is likely to be changes 
in β-AR expression in the liver (Ludden, 1991). In humans and higher vertebrates, β-ARs 
are found predominantly in smooth muscles around contracting hollow organs (i.e. heart 
and lungs) and their expression levels in skeletal muscle is, in comparison, minimal. 
Therefore, to examine for the same distribution pattern in the fathead minnow, the brains 
were also examined. Finally, Huggett et al (2002) demonstrated that propranolol 
exhibited an inhibitory effect upon the reproductive potential of Japanese medaka 
(Oryzias latipes) at concentrations as low as 0.5µgL
-1
. It was possible that propranolol 
may have interacted with and either up- or down-regulated β-AR mRNA expression in 
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the gonads, which may subsequently have induced the observed inhibitory reproductive 
effect. To examine this theory, β-AR expression was measured in fathead minnow 
gonads. 
 
The male liver and heart tissues were originally selected for metabolomic analysis. 
Therefore, female heart, liver, brain and gonad tissues were chosen for RT-PCR β-AR 
expression analysis. 
 
5.1.5 Aim 
The aim of the study was to examine the effects of propranolol exposure on β3-AR 
expression in selected female fathead minnow tissues using absolute RT-PCR, thereby 
providing a better understanding of the mode of action of propranolol. 
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5.2 METHODOLOGY 
 
5.2.1 Tissue acquisition 
Female fathead minnow tissues were analysed for β3-AR expression upon exposure to 
propranolol. Therefore female fathead minnow liver tisssues were used for the RT-PCR 
work. All tissue and subsequent mRNA extraction were acquired as described in sections 
2.2.1 and 2.2.4, respectively. The female fathead minnow hearts were too small for 
accurate and reliable mRNA extraction from individual tissues and therefore all the hearts 
from a single propranolol concentration were pooled together. The liver, brain and 
gonads were analysed individually. 
 
5.2.2 Exploring β-actin as a housekeeping gene for relative RT-PCR 
β-actin is a highly conserved protein in vertebrates including fish. Accordingly, it has 
previously been used in fathead minnow tissue RT-PCR studies as a housekeeping 
reference gene (Runnalls, 2005). Although it was not suitable for the study conducted by 
Runnalls (2005), it was examined whether β-actin could be used as a suitable 
housekeeping gene for this study as a different test substance was used. Several fathead 
minnow tissues from both male and female fathead minnows were examined by PCR for 
β-actin expression. All cDNA levels were diluted so that each PCR reaction contained the 
same quantity of starting mRNA material. The PCR reactions were finally visualised on a 
2% agarose gel under U/V conditions, as shown in figure 79. 
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Although β-actin was expressed in every tissue, it appeared to be expressed at different 
levels, which could present a problem when used for analysing and comparing different 
tissue expression of the β3bi-AR. For this reason, and taking into account the advantages 
of using absolute RT-PCR, it was decided not to use relative RT-PCR but instead use 
absolute RT-PCR.  
 
5.2.3 Absolute RT-PCR overview 
Absolute RT-PCR was used to quantitatively examine the levels of β3bi-AR expression in 
female fathead minnow tissues upon exposure to propranolol using the QuantiTect SYBR 
Green RT-PCR kit (Qiagen; Cat # 204243). During the assay, mRNA was firstly reverse 
transcribed to cDNA. Subsequently, during the primer annealing stage, DNA was formed 
at an exponential rate. During this step the SYBR green fluorescent dye bound to the 
newly-formed double-stranded DNA molecules and emitted a fluorescent signal. The 
Real Time PCR machine measured the level of green fluorescent signal and indicated the 
quantity of starting material. In terms of β3bi-AR expression: the higher the expression of 
β3bi-AR, the more DNA template formed and the more green fluorescence emitted. 
 
  1   2 3   4  5   6  7    8 9 10 
100bp 
200bp 
 1000bp 
Figure 79. UV photograph of a 2% agarose gel examining for beta-actin expression. 1 = male 
heart; 2 = male liver; 3 = male brain; 4 = male gill; 5 = male blood; 6 = female heart; 7 = female 
liver; 8 = female brain; 9 =female gill; 10 = female blood. β-actin was expressed in every tissue at 
the correct size of 100bp. 
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Effectively the SYBR green dye will bind to any DNA and therefore care was taken to 
remove any contaminant genomic DNA from the mRNA samples. Additionally, care had 
to be taken to ensure that non-specific primer annealing did not occur, as this would 
produce non-specific secondary DNA products that the SYBR green dye would have 
bound to, which would have thus produced a incorrectly high result.    
 
5.2.4 RT-PCR primer designing 
To minimise the potential for non-specific primer binding, primers were designed to the 
3‟ untranslated region (UTR). For a high efficiency RT-PCR, the amplicon (target DNA 
region that will be amplified) should be as short as possible, however it must be longer 
than 75 nucleotides so that it can be distinguished from primer dimers. The amplicon 
must not have any secondary structures and the guanine: cytosine (G: C) content should 
be between 40 and 60%.  
 
Both primers should be between 18 and 30 nucleotides in length (the longer the primer 
the less likelihood of non-specific binding) and have similar annealing temperatures of 
ideally 60
o
C. Each primer should also have a G: C content of between 50 and 60% and 
have no more than two guanine or cytosine nucleotides in the last five bases, yet end with 
either a guanine or cytosine nucleotide. Additionally, both primers should be significantly 
different from each other as to minimise the likelihood for primer dimers occurring. 
 
The Primer Express software, supplied by Applied Biosystems, was used to both locate a 
suitable amplicon region and find primers that met the outlined criteria. Figure 80 shows 
the entire β3bi-AR sequence with highlighted 3‟UTR, selected primers and anticipated 
amplicon region and table 31 gives details on the primers and amplicon region. The 
primers were manufactured by Applied Biosystems as the RT-PCR machine was 
calibrated to work optimally with these primers and also because the software used to 
generate the primers was developed by Applied Biosystems. 
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TGCTTGTGGATCGTTGTCGCTTACAGTCCTCTAGTCCTCGCCATCatgacactgcatgctgccgaaacag
aatcaaatgaccaggccaatgcaaggacaccttggtcttggatcaacatggcttagctaatttcatcaggattcgttcacatcccac
tactcatcatgattttgtctatgcacgcgtcttcctcgtcgcacaagacaggtacagctcattgcataccgtctaggttccaaacgag
tgcataggaaatcaggtccatggcacaacaacttgcttcgatgtgcaataacgtcggtgggatgacggcaaggcggaaaagttt
cccggaggcgaccgtccaaattaaccgctgtgaaggagcacaaggccctcaagacgctgggcatcatcatgggcatcttcaca
ctgtgctggctgcctttcttcgtggcgaacatcatcaatgttttcaatcgagatctgctaaccatgtatgtttttcgatatttaaactggtt
aggctacatcaactccagcctcaatcccatcatctactgccgcagcccagagtttcgtgcggccttcaagaaccttctcggctgtc
cctgggtatccccgctgagaatgaacttcctttacaaggagcttcggactcgatgcacttgcttcctgggttccgcagagtcggga
atgcctggatcgttcgagaagccccccacatccccaggggcactgcctggggaagggagcagccagagcagctacaggagc
gaggagccgtcgccgggaccaccgcactccaacggacgcacgttcttcagtgatttctccgagccggagacggagttctgtaa
cctataggagcaggatggctgagagtctctagcatggctgaaatgaaaggacgatgaggaagaagaaacagggaaaaggac
tgacttacatcacagttggcgggactttcccagcagagaccacaagggcccagcaaaaaacatccatgaaagccatcaggg
gagcctgctccaaaactgaaagacagaagagtgcaaagatataaccatagagaggcaagcactatgggaactttctcac
aaacagctcgtctatggaaagaacgactgaactggtactgttcatgaaggagtgtaacatggagtgatccgatactgctaacgttc
tattaagtactggagcaatccacttcagcccgg  
  
 
 
 
 
 
The primers were run in a PCR using control female fathead minnow liver cDNA to 
examine firstly whether the primers amplified the desired amplicon region, and secondly 
to examine for any non-specific amplified products. The PCR products were visually 
analysed on a 2% agarose gel under UV light, as shown in figure 81. The amplicon was 
distinguishable from the primer dimer. There was no indication of non-specific binding. 
 
 
 
 
Primer Sequence Length (bp) Melting temp GC (%) Conc (nM) 
Forward RT GGCCCAGCAAAAAACATCC 19 59 53 50 
Reverse RT TTCCCATAGTGCTTGCCTCTC 21 58 52 50 
Amplicon   105 79 47   
5‟ 
3‟ 
Figure 80. β3-AR nucleotide sequence. The 3‟ UTR is highlighted by the yellow region. The two primers are 
shown in bold red and the amplicon region in italics. The start and stop codon are shown by atg and tga, 
respectively. 
  Table 31. Summary of primer and amplicon nucleotide sequences. 
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The product was gel extracted and cloned, and the amplicon sequence was confirmed as 
shown in figure 82. In addition to sequence confirmation, the cloned amplicon was also 
used to generate the external standard. Thus it was important to determine the insert 
direction, which was found to be anti-sense and sense for clones 1 and 2, respectively. 
There was a 100% match between the sequence results and the original sequence. 
 
 
 
 
 
 
 
 
 
 
Figure 81. UV photograph of PCR product run on a 2% 
agarose gel. The white circle highlights the amplicon 
product, which is the correct size of 105 nucleotides; as 
compared with the 1Kb DNA ladder. The amplicon was 
distinguishable from the primer dimer, highlighted by the red 
circle. 
   100bp 
   200bp 
1,000bp 
 
>colony 1 
tcccatagtgcttgcctctctatggttatatctttgcactcttctgtctttcagttttggagcaggctcccctgatggctttcatggatgttttttgctgg
gcc 
 
>colony 2 
ggcccagcaaaaaacatccatgaaagccatcaggggagcctgctccaaaactgaaagacagaagagtgcaaagatataaccatagaga
ggcaagcactatgggaa 
 
Figure 82. Results from sequencing of amplicon product. Red highlights the primers and the italics highlights the 
amplicon. 
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5.2.5 Preparation of external standard 
The external standard was made from clone 1 with the amplicon inserted in the anti-sense 
direction. The standard was amplified in a PCR reaction using SP6 (5‟ ATT TAG GTG 
ACA CTA TAG 3‟) and M13R (5‟ CAG GAA ACA GCA TGA CCA TG 3‟) primers, 
which also amplified the T7 promoter region, as shown in figure 83. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The PCR products were run on a 2% agarose gel and DNA extracted, as detailed in 
section 2.2.9. The DNA sample was then cleaned using the QIAquick PCR purification 
kit (Qiagen; Cat # 28104). In brief, 50µl of lysis wash buffer was added to the 10µl of gel 
extracted PCR product and mixed by reverse pipetting. The mixture was then transferred 
onto a spin column in a 2ml collection tube and centrifuged at 17,900 x g for 1 minute at 
room temperature. The DNA product absorbed to the membrane whilst enzyme 
Amplicon 
T7 
M13R SP6 
Vector 
Figure 83.  Diagram of pDrive cloning vector that contains the 
amplicon. Using SP6 and M13R primers, the vector was essentially 
cut in half so that the transcript and T7 promoter were specifically 
amplified. 
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contaminants passed through. The flow-through was discarded and 750µl of a second 
wash buffer, containing ethanol, was added to the spin column and subsequently 
centrifuged at 17,900 x g for 1 minute at room temperature. The flow-through was 
discarded and the spin column was centrifuged again at 17,900 x g for 1 minute at room 
temperature to remove any residual ethanol. The spin column containing the absorbed 
DNA was transferred into a clean collection tube and 50µl of elution buffer was added to 
the spin column and left for 1min before centrifugation at 17,900 x g for 1 minute at 
room temperature. The absorbed DNA was released at subsequently collected in the flow 
through. The DNA was quantified on the NanoDrop-1000 Spectrophotometer (as detailed 
in section 2.2.3) and run on a 2% agarose gel for 45 minutes at 80 volts and subsequently 
visually examined under U/V conditions (see figure 84).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The cleaned DNA then underwent in-vitro transcription, creating RNA (to be used as the 
starting template for RT-PCR work) from DNA using the Riboprobe in vitro transcription 
systems (Promega; Cat # P1460). As the amplicon was inserted in the anti-sense 
direction, T7ase was used. 20µl of transcription-optimised buffer, 10µl 100mM DTT, 
200bp 
100bp 
300bp 
  1,000bp 
B  A 
Figure 84. Comparing non-purified (A) and purified (B) 
gel extracted external standard product. Note there are no 
additional bands in B. The Amplicon is larger than in 
figure 79 as it contains additional vector sequence. 
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2.5µl Recombinant RNasin ribonuclease inhibitor, 20µl of rNTP, 2.22µl of T7ase and 
43µl of nucleasefree water was added to 2µl of DNA sample and incubated at 37
o
C for 2 
hours. The newly made RNA was subsequently treated with 4µl DNAse I enzyme 
(Invitrogen; Cat # 18047019), to remove any contaminant DNA, and incubated at 37
o
C 
for 15 minutes. The sample was then cleaned to remove any salts and enzymes and 
precipitated to concentrate the RNA by adding 100µl T.E buffer, 10µl 4M lithium 
chloride and 300µl 100% ethanol to the sample and storing it at -20
o
C for 1 hour. The 
sample was subsequently centrifuged at 17,900 x g for 10 minutes at 4
o
C. This produced 
a concentrated RNA pellet. The supernatant was removed and discarded. To remove any 
residual enzyme contaminants, 500µl of 75% ethanol was added to the precipitate and the 
sample centrifuged at 17,900 x g for 10 minutes at 4
o
C. The supernatant was removed 
and the pellet left to air dry for approximately 5 minutes.  The pellet was subsequently 
reconstituted in 50µl of dH2O. The RNA sample was quantified on the NanoDrop-1000 
spectrophotometer and visually examined on a polyacrylamide gel. 
 
5.2.6 Examining RNA using a polyacrylamide silver staining procedure 
The problem with examining RNA on an agarose gel (which is usually used to visualise 
DNA) is that RNA forms extensive secondary structures via intra-molecule base pairing, 
which prevents it from migrating strictly according to nucleotide sequence size. One 
commonly used alternative method of visually examining RNA is to firstly treat the RNA 
with formaldehyde, which removes the secondary RNA structures and subsequently run 
the RNA on a formaldehyde agarose gel, which provides a better resolution. However, 
the problem with this is, firstly, formaldehyde is presents a health and safety hazard 
(when considering the large volumes) and, secondly the results are not always robust and 
reproducible (Southern, 1975).  
 
Therefore, a silver staining polyacrylamide gel technique modified from that first 
developed by Switzer et al (1979) was adopted for this study to visually inspect the RNA, 
as shown in figure 85. A polyacrylamide: urea gel was made from 4ml 10 x TBE buffer 
(see appendix 1), 19.2g urea (Fisher Scientific, Cat # BPE 169-212), 10ml 40% 
polyacrylamide gel (National Diagnostics, Cat # EC-850) and made up to 40ml with 
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dH2O. Glass plates were firstly cleaned with acetonitrile (Sigma, Cat # 34967), which is a 
powerful solvent that dissolves protein and nucleic matter. Between each plate, two strips 
of 4mm thick waterproof sheeting were laid at either end and the plates held together with 
bulldog clips. 20ml of the polyacrylamide: urea gel was aliquoted into a sterile falcon 
tube (Fisher Scientific, Cat # 661347) and 125µl 10% ammonium persulfate (APS) 
(Fisher Scientific, Cat # 7727-54-0) and 16µl tetramethylethylenediamine (TEMED) 
(Fisher Scientific, Cat # 110-18-9 was added to induce polymerisation of the gel. The gel 
was then pipetted into a gap between the plates and, through capillary action, dispersed 
between the plates. A comb was subsequently added to the top of the plates and the gel 
was left to set. One litre of 0.5 x TBE buffer was prepared and added to the positive and 
negative gel electrophoresis reservoirs. Once the gel had set, the comb was gently 
removed and each well rinsed with dH2O to remove any bubbles. The gel-containing 
plates were then clamped to the gel electrophoresis stand and buffer topped up so that 
there was contact between both the positive and negative buffer reserviors and the gel. An 
aluminium plate was placed across the plates to ensure that there was even distribution of 
electrical current across the gel. The electrophoresis set-up was connected to the anode 
and cathode on the power pack and the gel was pre-run at 700 volts.  
 
1µl of sample RNA was diluted in 50µl RNA buffer (8ml 100-% formamide (Fisher 
Scientific, Cat # 75-12-7)), 20µl 0.5M EDTA (annex), 0.5ml 1% Bromophenol Blue 
(Fisher Scientific, Cat # 62625-28-9), 0.2ml 2.5% xylene cyanol (Sigma, Cat # 220-167-
5) and 1.6ml dH2O to produce a working concentration of 0.06pmol. Two replicate RNA 
samples were examined. 1µl of DNA ladder was also added to 20µl RNA buffer. The 
RNA and DNA ladder samples were subsequently denatured at 85
o
C for 2 minutes.  
 
Urea dissociates in a gel and can therefore sit at the bottom of a loading well preventing 
the migration of a loaded RNA sample. Therefore prior to loading the RNA samples, 
each well was washed with TBE buffer. Each sample (including the DNA ladder) was 
loaded onto the gel at three different volumes: 2.5µl, 5µl and finally 10µl. The gel was 
run for 3 hours at 700 volts. During this time the first wash buffer (see table 32) was 
prepared. 
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After 3 hours, the top plate was gently removed and the polyacrylamide gel carefully 
transferred into an acetonitrile-washed glass dish. The gel was subsequently washed in 
several consecutive reagents, as shown in table 32. 
 
 
 
 
 
 
 
 
 
Figure 85. Schematic illustration of polyacrylamide: urea gel set-up. The red arrow indicates the 
movement of RNA down the gel from the negative cathode to the positive anode. 
   - 
  + 
Comb wells filled with 
TBE buffer 
Bulldog clip 
Aluminium 
plate 
Polyacrylamide: urea 
gel Waterproof 
sheeting 
Positive reservoir 
filled with TBE 
buffer 
 204 
 
 
  
 
After the final wash, the gel was scanned, as shown in figure 86. The RNA from each of 
the three loading concentrations was very clean and of the correct size. There was no 
DNA contamination and so it was decided that the RNA was suitable as an external 
standard for RT-PCR work. The RNA external standard was then separated into 3µl 
aliquots and immediately stored at -80
o
C to prevent any RNA degradation. A single 
aliquot was used for each RT-PCR assay. 
 
 
 
Wash stage Wash Buffer Time Reason 
1 40% methanol (v/v) 
10% acetic acid (v/v) 
30 minutes Wash off urea and fix RNA 
2 10% ethanol (v/v) 
5% acetic acid (v/v) 
15 minutes Wash off urea 
3 10% ethanol (v/v) 
5 % acetic acid (v/v) 
15 minutes Wash  
4 dH2O Quick wash Remove alcohol 
5 12mM silver nitrate (v/v) 
(Cat # S/1240/48) 
30 minutes Stain RNA 
6 dH2O Quick wash Removal residual silver 
7 0.28M Sodium carbonate (v/v) 
0.0185% formaldehyde (v/v) 
Quick wash Remove silver from surface 
of gel 
8 0.28M Sodium carbonate (v/v) 
0.0185% formaldehyde (v/v) 
Quick wash Develop RNA 
9 5% acetic acid (v/v) 15 minutes Fix RNA and stop reaction 
with sodium carbonate 
Table 32. Wash protocol for silver staining of polyacrylamide gel. The total volume for each wash stage was 
500ml. Fisher Scientific supplied all reagents: 95% methanol (Cat # A456-1), 99.9% acetic acid (Cat # A/0360/25), 
95% ethanol (Cat # E/0500/17), silver nitrate (Cat # S/1240/48), sodium carbonate 0.5M (Cat # J/7520/17), 10% 
formaldehyde (Cat # F/1451/25). 
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5.2.7 RT-PCR assay 
As the first stage of running the RT-PCR assay was to use a serial dilution of RNA 
standard and examine the efficiency of the assay, the number of molecules was calculated 
using the equation shown in figure 87.  
 
 
 
 
 
 
 
 
 
 
10µl 5µl 2µl 
 200bp 
1,000bp 
 300bp 
Figure 86. Scanned image from silver staining of polyacrylamide gel. The 
bands are of the correct size (~280 nucleotides) and were consistent across the 
different loading concentrations. There was no DNA contamination. 
 
       Xg/µl RNA 
                                                                      =    Y molecules/µl RNA 
[transcript length x 340] x 6.022 x 10
23 
Figure 87. Equation used to determine the number of RNA molecules per µl of sample in the 
external standard. Xg/µl refers to the concentration of RNA and transcript length is the inserted 
product from, and including, the SP6 to M13R promoters. There are 6.022 x 1023 molecules per 
mole of RNA. 
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Prior to examining the RNA samples, the RT-PCR assay conditions were optimised using 
the external standard. 
  
5.2.7.1 Optimising conditions using the external standard 
All surfaces, pipettes, microcentrifuge tube holders and the centrifuge were cleaned with 
75% IMS and wiped down with RNase way to remove any sources of DNA or RNA 
contamination. All components were thawed slowly on ice. The external standards were 
made by a serial dilution so that the working concentrations ranged from 10
7
 to 10
2
 
molecules. The stock standard of 10
9
 molecules was made by adding 2.4µl of sample to 
1ml of dH2O. The sample was mixed thoroughly by reverse pipetting and flicking, before 
being placed on ice for at least 5 minutes. The first standard of 10
7
 molecules was then 
made by adding 1µl of the stock standard to 100µl dH2O and subsequently mixing the 
sample thoroughly and placing on ice for 5 minutes. The subsequent serial dilutions were 
each made by adding 10µl of previous sample to 100µl dH2O, creating a 10 x serial 
dilution each time. Each standard was thoroughly mixed and placed on ice for 5 minutes.  
 
The external standards were run on every single plate, including those with RNA samples 
as they provided an indication of RT-PCR efficiency of RT-PCR. 
 
RT-PCR assays were made in 96-well plates. The master mix was made by adding the 
following components (final concentration in brackets); Quantitect SYBR green enzyme 
(1x), forward primer (0.5µM), reverse primer (0.5µM) (as described in section 5.2.4), 
RT-PCR mix (0.5µl per reaction), RNase-free water (make up to 20µl per well). The 
master mix was mixed thoroughly by reverse pipetting and briefly centrifuged at 17,900 x 
g at room temperature before adding 20µl of mix into each well. This was not conducted 
on ice as some methods suggest that making the master mix on ice can create primer-
dimers. Triplicate 5µl samples of RNA standard or sterile water (also referred to as the 
non-template control or NTC) were added to the designated well and a clear cover was 
stuck down onto the plate. The plate was then transferred to the RT-PCR machine on ice, 
centrifuged briefly at 13,000 x g at 4
o
C before being loaded onto the RT-PCR machine. 
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Figure 88 shows the original RT-PCR protocol used. The annealing temperature was set 
at 55
o
C. 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.7.2 Interpretation of results 
The NTC was firstly examined for any amplification. Any fluorescence seen in the NTC 
suggested that there was DNA contamination and so the RT-PCR assay would need to be 
repeated. Secondly, the wells were examined for any primer dimer formation. It was 
important to remove the potential for primer-dimers as these would produce an 
incorrectly high expression value. The efficiency of the RT-PCR assay was calculated 
from the serial dilution standard curve gradient and calculated according to figure 89. 
RT-PCR efficiency must be greater than 90% for each plate. All RT-PCR assay work was 
analysed using SDS 2.1 (Applied Biosystems), this had been previously configured to the 
RT-PCR machine. 
 
 
 
 
 
 
 
Figure 88. RT-PCR protocol for external standard.  
10mins 
 30mins 
40 cycles 1 cycle 1 cycle 
Holding 
temperature 
 30s 
Reverse 
transcription 
Elongation Amplification 
    ∞ 
 
15mins 30s 
30s 
  50.0
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C 
15.0
o
C 
 95.0
o
C 
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o
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o
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Figure 89. Equation used to determine efficiency of RT-PCR assay. 
 
1.       1 
                                           = a 
                     -(slope) 
 
 
2.                 [(10 x^y
a 
) – 1] x 100 = Efficiency (%) 
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Figures 90, 91 and 92 show the standard curve plot, amplification plot and dissociation 
curve, respectively, from the first RT-PCR assay. The calculated RT-PCR efficiency was 
90% and was therefore suitable for analysis. The amplification plot compares the number 
of cycles against fluorescence. As cycle number increases, fluorescence increases. The 
red CT line represents the cycle threshold, which is defined as the number of cycles 
required for the fluorescent signal to exceed background noise. Ct levels are inversely 
proportional to the amount of target nucleic acid in the sample. Once a sample exceeds 
the cycle threshold, it can be accurately measured (this is more applicable when running 
unknown samples as in the case of examining standards, the amount of RNA is already 
known).  
 
The red arrow highlights that there was fluorescence detected in one of the NTC wells, 
indicating DNA contamination, and so the assay was repeated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Slope = -3.593244 
Efficiency = 90% 
Figure 90. Standard plot for external standard for RT-PCR. Slope and calculated efficiency 
are also presented. Each triplicate value is shown. There was slight variation at 104 molecule 
concentration. 
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As SYBR green indescriminately amplifies any double-stranded DNA product, the 
dissociation curve, figure 91, is used to show what products were amplified. The large 
peak represents the desired amplicon. However, a primer-dimer (circled in yellow) has 
also been formed. In addition, the smaller peak (circled in red) shows the NTC 
amplification, supporting the amplification plot observation and further suggesting that 
there was DNA contamination in that single well. 
 
 
 
 
 
 
 
 
 
 
Figure 91. Amplification plot for external standard RT-PCR. Each standard plot molecule 
concentration is highlighted. The red arrow highlights amplification in the NTC, suggesting 
contamination. The red line is the automatically set CT threshold line. ΔRn is calculated from 
subtracting the signal baseline from the initial stages of PCR from the real time data and it 
represents the magnitude of the signal. 
102 103 104 105 106 107 
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A second RT-PCR assay was set up to explore minimising primer-dimer formation. 
Primer concentrations were diluted 1:1 (1µl primer to 1µl dH2O), 1:4, 1:9 and 1:19. Each 
primer concentration was examined at all serial dilution concentrations. Figure 93A to D 
shows the dissociation curve results from the 1:1, 1:4, 1:9 and 1:19 primer dilutions, 
respectively. The 1:19 and 1:9 dilutions produce far weaker amplicon peaks. The very 
small peaks are not DNA contamination of NTC but are the 10
2
 external standard peaks 
and 10
2
 to 10
4
 external standard peaks in figures C and D, respectively. The primer set 
had been diluted too much for the RT-PCR to work optimally, and this was reflected in 
the low RT-PCR efficiency values. Although the 1:1 primer dissociation curve (A) had a 
stronger amplicon peak, the level of baseline noise was higher compared to the 1:4 primer 
dissociation curve (B) and the 1:4 RT-PCR had a higher efficiency value of 94.3% 
compared to 92.9%. Therefore, a primer dilution of 1:4 was selected as the optimal 
concentration. 
Figure 92. Dissociation curve for external standard RT-PCR. Large peak represents the desired amplicon. 
Red highlighted circle peak represents NTC DNA contamination, yellow highlighted circle peak represents 
primer dimer. Double-ended arrow represents the level of baseline noise. 
Baseline 
 noise 
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To try and minimise baseline noise, the length of each step in the amplification cycle was 
reduced from 30 seconds to 15 seconds. Figure 94 shows that there was no improvement 
in level of baseline noise when the length of amplification cycles was lowered, however 
the efficiency of RT-PCR was below the acceptable threshold of 90%. Thus, the length of 
each step in the amplification cycle was maintained at 30 seconds. 
A B 
C D 
Figure 93. Dissociation curves for 1:1 (A), 1:4 (B), 1:9 (C) and 1:19 (D) primer dilutions. As dilution of 
primer increases, strength of amplicon peak decreases. The small peaks in figures C and D represent the 
lower external standard concentrations (as labelled). E values represent efficiency of each RT-PCR assay. 
102 
  102 
  103 
  104 
E = 61.3% 
E = 94.3% E = 92.9% 
E = 76.6% 
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The annealing temperature of the primers was also examined as a potential cause of 
baseline noise. The annealing temperature was originally set at 55
o
C, as stipulated by the 
Applied Biosystems manufacturer. However, the RT-PCR machine works optimally at an 
annealing temperature of 60
o
C. Therefore two RT-PCR assays were run, one with an 
annealing temperature of 57
o
C (figure 95A) and one with an annealing temperature of 
60
o
C (figure 95B). The level of baseline noise was marginally improved (~0.5 E-1 and 
1.0 E-1 for 57
o
C and 60
o
C, respectively); however the efficiency of both RT-PCR assays 
fell below the ideal threshold of 90%. Therefore, the annealing temperature was 
maintained at 55
o
C. 
 
 
 
E = 75.9% 
Figure 94. Dissociation for RT-PCR assay when length of each amplification cycle was reduced 
to 15 seconds. There was no improvement in the level of baseline noise. E value represents 
efficiency of the RT-PCR assay. 
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The RT-PCR assay conditions selected to examine β3bi-AR expression in female fathead 
minnows exposed to several concentrations of propranolol is summarised in figure 96. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 95. Dissociation curves for RT-PCR assay with an annealing temperature of 57oC (A) and 60oC (B). The 
baseline noise was marginally improved in both RT-PCR assays compared to the 55oC dissociation curve. 
However, the efficiency (E) of both assays fell below the threshold of 90%. 
E = 89.9% E = 86.1% A B 
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5.2.8 Preliminary examination of tissue profiles  
Prior to examining β3bi-AR expression of all propranolol-exposed tissues, it was firstly 
important to examine a handful of tissues to make sure there were no previously 
unforeseen problems. Therefore a small number of tissues were examined at 1, 3, 5 and 
10ng/µl to determine which concentration was optimal. It was found that the expression 
of the β3bi-AR in several tissues at the 1, 3 and 5ng/µl concentration did not fit within the 
external standard range. Therefore, the RT-PCR assay was repeated using external 
standards that ranged from 10
1
 to 10
5
 molecules. Figure 97 shows the standard plot taken 
from the latter experiment. The majority of the tissue β3-AR concentrations fitted within 
this external standard range, the exception to this was from some tissues at the 1ng/µl 
concentration. It was decided to use the tissue concentration of 5ng/µl as, firstly, β3-AR 
expression fitted within the external standard range at this concentration and, secondly, a 
previous study that examined β1-AR and β2-AR expression in the same female fathead 
minnow samples used a tissue concentration of 5ng/µl (Giltrow, 2008). Therefore, by 
Component Final concentration 
Quantitect SYBR green enzyme 1 x 
Forward primer 0.1µM 
Reverse primer 0.1µM 
RT-PCR mix 0.5µl per reaction 
RNase-free water Up to 20µl per well 
10mins 
 30mins 
40 cycles 1 cycle 1 cycle 
Holding 
temperature 
 30s 
Reverse 
transcription 
Elongation Amplification 
    ∞ 
 
15mins 30s 
30s 
  
50.0
o
C 
15.0
o
C 
 95.0
o
C 
 72.0
o
C 
  
95.0
o
C 
 55.0
o
C 
 72.0
o
C 
Figure 96. Summary of RT-PCR protocol and component concentration used to examine β3bi-AR expression 
in female fathead minnow tissues exposed to propranolol. 
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using this concentration it was possible to directly compare different β-AR expression 
levels. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.9 Examining internal standard 
In addition to running an external standard to assess the efficiency of each RT-PCR, an 
internal standard was also used. By analysing the same tissue sample on every plate, it is 
possible to get a measure of the inter-assay variation which is attributable to assays run 
on different plates at different times, and using different batches. The internal standard 
selected for the β1-AR and β2-AR expression study (Giltrow, 2008) was a liver sample at 
a concentration of 5ng/µl. Therefore, the same liver sample was examined for suitability 
as the internal standard in the current study. Figure 98 shows the standard plot from the 
RT-PCR assay and demonstrates that it was suitable for use as the internal standard. 
 
 
 
 
 
E = 91.3% 
Figure 97. Standard plot for examining β3bi-AR expression in several tissues. External 
standard concentration ranged from 101 to 105 molecules. All β3bi-AR expression profiles 
fitted within standard range (red), with the exception of two tissues highlighted in cyan. 
Each tissue was analysed in triplicate and is therefore represented by three crosses. 
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5.2.10 Statistical analysis 
To compare β3-AR expression levels between different treatment groups and between 
control tissues, a Kruskal-Wallis One-Way ANOVA was performed. This is a non-
parametric alternative to the commonly used ANOVA.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 98. Standard plot taken from RT-PCR assay exploring suitability of liver 
internal standard at 5ng/µl. The β3bi-AR expression levels fitted within the external 
standard range of 101 to 105 molecules. The efficiency of the RT-CPR assay was also 
above 90%. 
E = 93.8% 
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5.3 RESULTS 
 
5.3.1 Examining external standards 
The aim of the study was to examine β3-AR expression changes in the female fathead 
minnow brain, liver, heart and gonad tissues exposed to several concentrations of 
propranolol. It was not possible to examine every tissue on the same RT-PCR assay plate. 
Therefore it was important that the efficiency of each RT-PCR assay was comparable 
between each tissue assay plate. To examine the efficiency of each absolute RT-PCR 
assay, a series of external standards (prepared from a cloned amplicon) were run on every 
plate. External standard concentrations ranged from 10
1
 to 10
5
 molecules per μl and each 
concentration was run in triplicate. RT-PCR efficiency for each assay was calculated 
from the gradient of the slope on the standard plot, where molecule quantity was plotted 
against Ct value. There was no significant difference (p<0.05) between the Ct values at 
each external standard concentration between each assay plate, as shown in figure 99, 
which suggested that amplification efficiency across all assay plates was directly 
comparable.  
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Figure 99. External standard plot of measured Ct value at each designated concentration. ♦ =plate 1;  
= plate 2; ▲= plate 3; x = plate 4; ♦ = plate 5; + = plate 6; + = plate 7. There was no significant 
difference between Ct values at each concentration between the different assay plates (p<0.05).   
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5.3.2 Examining inter-assay variation 
The inter-assay variation was assessed using a standard liver sample at 5ng/μl, which was 
included on all plates. As can be seen from figure 100, the mean values obtained ranged 
from 2600 molecules/μl (plate 4) to 5500 molecules/μl (plate 2), giving a 2.1-fold 
difference. The levels of internal standard in plates 1, 3 and 4 were significantly lower 
than plates 2, 5, 6 and 7 (p<0.05). The RT-PCR was repeated for plates 1, 3 and 4, 
however there was only a marginal increase in molecule numbers. 
 
Two RT-PCR plates were used to analyse each tissue from both propranolol exposures 
(with the exception of the heart). Therefore to accurately compare changes in β3bi-AR 
expression within tissues, a 2.1-fold difference in molecule numbers must exist between 
the DWC group and propranolol treatment groups. Similarly, to determine differences in 
β3bi-AR expression between tissues, a 2.1-fold difference in molecule numbers must be 
present.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 100. Internal control results for each plate in the β3bi-AR RT-PCR assay. Each symbol denotes no 
significant difference, for example all plates that have a  are not different to each other. The brain samples 
were run on plates 1 and 2, the liver samples on plates 3 and 4, the gonad samples on plates 5 and 6 and the 
heart samples on plate 7. 
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5.3.3 β3bi-AR expression in response to propranolol exposure 
Figures 101 to 104 show the fold-changes in β3bi-AR expression at all propranolol 
concentrations, compared to DWC levels, in the brain, liver, gonad and heart tissues, 
respectively. There was no significant (p<0.05) difference in β3bi-AR expression between 
propranolol treatment groups and DWC up to and including 0.1mgL
-1
 in the brain (figure 
101). However, there was a significant decrease (p<0.05) in β3bi-AR expression between 
1mgL
-1
 and DWC, with an expression fold-difference of -2.2. 
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Similarly in the liver, a significant decrease (p<0.05) in β3bi-AR expression was observed 
between the 1mgL
-1
 and DWC treatment groups, with an expression fold-difference of 
 -3.2 (figure 102). 
 
 
Figure 101. β3bi-AR expression in female fathead minnow brain tissues upon exposure to propranolol. 
Symbols denote a statistically significant difference (p0.05 and fold-difference ≥ 2.1) between treatment 
and DWC groups.  
Propranolol concentration (mgL
-1
) 
 
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Although β3bi-AR expression in the gonad was 2.1-fold lower in the 0.1mgL
_1
 treatment 
group compared to the DWC group, it was not statistically significantly lower (p<0.05) 
because of considerable variation in β3bi-AR expression in the DWC group (figure 103). 
There was no significant effect of propranolol on β3bi-AR expression at any 
concentration, compared to DWC levels. 
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Figure 102. β3bi-AR expression in female fathead minnow liver tissues upon exposure to propranolol. 
Symbols denote a statistically significant difference (p0.05 and fold-difference ≥ 2.1) between treatment 
and DWC groups.  
Propranolol concentration (mgL
-1
) 
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β3bi-AR expression in the heart demonstrated a biphasic expression response. A shown in 
figure 104, as propranolol concentration increased from DWC to 0.mgL
-1
, there was a 
significant increase (p<0.05) in expression with a noted +2.4, +3.1 and +2.6-fold 
difference in β3bi-AR expression at 0.001mgL
-1
, 0.01mgL
-1
 and 0.1mgL
-1
, respectively, 
compared to DWC β3bi-AR expression. However, at 1.0mgL
-1
, there was a marked 
decrease in β3bi-AR expression compared to the other propranolol treatment groups and 
the expression levels were almost the same as those in the DWC group. 
 
 
 
 
 
 
 
 
 
Figure 103. β3bi-AR expression in female fathead minnow gonad tissues upon exposure to propranolol. 
There was no significant difference (p<0.05) in β3bi-AR expression between propranolol treatment 
groups and DWC.  
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Table 33 summarises the fold-induction of the β3bi-AR at each propranolol concentration 
for each tissue and highlights those that were both significantly different (p<0.05) to, and 
had a fold-induction difference of greater than 2.1 (± 2.1) to, DWC tissue β3bi-AR 
expression levels. Propranolol induced a down-regulation of the β3bi-AR at 1mgL
-1
 in 
both the brain and liver and yet had no significant (p<0.05) effect on β3bi-AR expression 
in the gonad. Whilst in the heart, exposure to lower concentrations of propranolol 
(1.001mgL
-1
 to 0.1mgL
-1
) exerted a significant (p<0.05) up-regulation of the β3bi-AR. 
Although there was a marked decrease in β3bi-AR expression at 1mgL
-1
, it was not 
significantly lower than that in the DWC heart. 
 
 
 
 
 
 
 
 
Figure 104. β3bi-AR expression in female fathead minnow heart tissues upon exposure to propranolol. 
Different symbols denote significant difference (p<0.05) between treatment groups. 
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5.3.4 β3bi-AR expression in control fathead minnow tissues 
β3bi-AR expression levels were compared between control female fathead minnow 
tissues, as shown in figure 105 and summarised in table 34. The β3bi-AR was expressed 
significantly highest (p<0.05) in the heart, at levels of 9800 molecules/μL, which 
corresponded to a +12.4, +2.5 and +11.7-fold (all of which exceeded 2.1-fold) difference 
to the brain, liver and gonad tissues respectively. The liver expressed the β3bi-AR at the 
second-highest levels of 3940 molecules/μL, and this was +5 and 4.7-fold, and 
significantly (p<0.05), higher than in the brain and gonad, respectively. Finally, the brain 
and gonad expressed the β3bi-AR at considerably lower levels of 840 and 790 
molecules/μL, respectively. As there was only a 1.1-fold difference (<2.1-fold) in β3bi-AR 
expression between the tissues, and as there was not a significant difference (p<0.05) in 
the number of β3bi-AR molecules, it was not possible to distinguish them in terms of 
preferential β3bi-AR expression. 
 
 
 
 
 
 
 
 
   PROPRANOLOL CONCENTRATION (mgL-1)    
TISSUE DWC 0.001 0.01 0.1 1 
brain 1 +1.1 +1.3 -1.3 -2.2 
liver 1 +1.2 -1.1 +1.2 -3.2 
gonad 1 +1.2 -1.5 -2.0 -1.4 
heart 1 +2.4 +3.1 +2.6 -1.2 
Table 33. Summary of fold-induction difference of the β3bi-AR at each propranolol concentration 
for each tissue.  Expression figures highlighted in red represent those that were both significantly 
different to β3bi-AR expression levels in, and were >2.1-fold different to, the respective DWC 
tissues. 
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  brain liver gonad heart 
brain   5 1.1 12.4 
liver 5   4.7 2.5 
gonad 1.1 4.7   11.7 
heart 12.4 2.5 11.7   
Figure 105. Comparison of β3bi-AR expression between examined DWC female fathead minnow 
tissues. Different symbols denote statistically similar values. 
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Table 34. Summary of β3bi-AR expression fold-difference between female fathead 
minnow control tissues. Figures highlighted in red represent both a significant 
difference (p<0.05) between tissues and a fold-difference >2.1. 
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5.4 DISCUSSION 
Analysis of the brain, liver, gonad and heart tissues taken from female fathead minnows 
exposed to propranolol showed that expression levels of β3bi-AR varied both between 
tissues and within the same tissues exposed to differing concentrations of propranolol. 
 
5.4.1 β3bi-AR expression in response to propranolol exposure – stress response 
As described in chapter 2, fathead minnows exposed to propranolol showed signs of 
elevated stress, especially at the highest concentration of 1.0mgL
-1
. The stress response in 
teleost fish is very similar to that of terrestrial vertebrates and involve the production of 
the catecholamines adrenaline and noradrenaline from the brain-sympathetic-chromaffin 
cell axis (equivalent to the brain-sympathetic-adrenal medulla) and the production of 
corticosteroid hormones such as cortisol (Bonga, 1997). Cortisol increases blood pressure 
and blood sugar and reduces the immune response (Weber, 1998). In fish, toxic stressors 
and pollutants have been found to directly increase catecholamine and cortisol 
production. This is mainly related to the fact that fish are exposed to aquatic pollutants 
via the extensive respiratory surface of the gills. The high bioavailability of many 
chemicals (including pharmaceuticals) in water is an additional factor (Bonga, 1997).  
 
In higher vertebrates (Spronsen et al, 1993) and the black bullhead fish (Dugan et al, 
2008), the β3bi-AR gene contains glucocorticoid-responsive element (GRE) sites and 
therefore glucocorticoids, such as cortisol, are able to modulate β3bi-AR density as well as 
β3bi-AR mRNA levels; in response to stress β3bi-AR mRNA expression increases. During 
the pair-breeding assay, fish from all treatment groups were likely to be stressed under 
the laboratory conditions and therefore β3bi-AR mRNA expression may have been 
elevated at all concentrations. Propranolol is a non-specific β-blocking pharmaceutical 
that binds to all β-AR subtypes and inhibits the response to adrenaline, noradrenaline and 
cortisol (Fent et al, 2006). Therefore, β3bi-AR activity in those fish receiving non-toxic 
doses of propranolol (0.001mgL
-1
 to 0.1mgL
-1
) may have had an inhibited response to 
elevated cortisol and catecholamine levels, compared to that in control fish. Although 
propranolol has a weaker binding affinity for β3bi-AR than adrenaline and noradrenaline 
(Strosberg & Pietri-Rouxel, 1996), there may have been an overall net “muffling” effect 
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of propranolol on β3-AR response to cortisol and catecholamine interaction. Therefore, to 
compensate for the reduced β3bi-AR activity, β3bi-AR mRNA expression may have been 
increased further in propranolol-exposed fish. It can be clearly seen in the heart that β3bi-
AR expression was significantly higher (p<0.05) in all propranolol treatment groups, with 
the exception of the 1mgL
-1
 treatment group (which may be due to a toxic desensitisation 
response as described in section 5.4.2), compared to DWC. There was also an increase in 
β3bi-AR mRNA expression at 0.001mgL
-1
 in the brain, liver and gonad tissues, compared 
to DWC levels, however they were not significantly (p<0.05) higher and they were not 
necessarily higher at each propranolol concentration. One possible reason for this is that 
β3bi-AR mRNA expression in the heart was 2.5 to 12 times higher than in the brain/gonad 
and liver, respectively, and so one is probably more likely to see a visible response to 
stress in the heart than in the respective tissues. 
 
5.4.2 β3bi-AR expression in response to propranolol exposure – desensitisation 
response 
There was a significant (p<0.05) decrease in β3bi-AR mRNA levels at 1mgL
-1
 in the brain 
and liver, compared to DWC levels and also the heart compared to the other propranolol 
treatment groups. It was unlikely that this response was directly related to the effects of 
increased stress levels as one would anticipate an increase in β3bi-AR mRNA expression 
compared to DWC levels. The response observed here is more likely due to propranolol 
toxicity. At 1mgL
-1
, male and female fathead minnows showed signs of acute toxicity 
(mortality) and therefore it was possible that propranolol was acting as a toxin. Under 
such circumstances, catechlolamine and cortisol levels were likely to be elevated to such 
an extent that, considering the β3bi-AR was a weaker binding affinity for propranolol than 
catecholamines and glucocorticoids, the net response would be the over-activation of the 
β3bi-AR.  
 
An important regulatory feature of G-protein signalling systems is that they are not 
constant but exhibit a memory of prior signalling and so the high activation of a receptor 
leads to a reduced ability to be stimulated in the future, termed desensitisation, and this 
leads to the down-regulation of the target receptor (Hausdorff et al, 1990). 
 227 
Desensitisation prevents over-stimulation of a receptor and thus serves to “safeguard” 
against over-stimulation of a cellular signal, which could potentially be harmful 
(Gainetdinov et al, 2004). As such, following activation by an exogenous agonist ligand, 
most GPCRs undergo regulation by a cascade of events that promote receptor 
densitisation and endocytosis. Following endocytosis, receptors are recycled to the 
plasma membrane, retained in an intracellular compartment or targeted for degradation 
(Martini & Whistler, 2007).  
 
There are two principal types of desensitisation; the first is homologous desensitisation, 
which is activation-dependent regulation and is commonly presented in the form of 
receptor sequestration. Sequestration is the rapid (within seconds to minutes of agonist 
interaction) movement of receptors from the cell surface by internalisation. Internalised 
receptors can be either recycled to the cell surface (resensitisation) or targeted for 
degradation in lysosomes (Gainetdinov et al, 2004). Prolonged stimulation generally 
leads to profound receptor loss from the cell surface. After long-term exposure, the net 
cellular expression of a receptor becomes decreased, termed down-regulated (Liggett et 
al, 1993; Bohm et al, 1997). An additional type of heterologous desensitisation is through 
the activation of GPCR protein kinases (GRKs), which discriminate between inactive and 
agonist-activated receptor states and, via phosphorylation, down-regulate the activated 
receptors. Once phosphorylated by a GRK, the activated receptor is bound by a member 
of another protein family, called the arrestins. Arrestins recognise both GRK 
phosphorylation sites on the receptor and the active conformation of the receptor and 
prohibit further G-protein activation by preventing the receptor from exchanging GTP to 
GDP on the G-protein α-subunit. GRKs, effectively promote receptor internalisation by 
virtue of helping to recruit arrestins to the activated receptor (Gainetdinov et al, 2004).  
 
The second type is heterologous desensitisation, which is receptor activation-independent 
regulation of receptors and regulates the G-proteins directly or by altering the signalling 
efficiency of downstream effectors (Gainetdinov et al, 2004). The most common 
mechanism for heterologous desensitisation is the feedback regulation of receptors by the 
second-messenger-regulated kinases they activate. For example, upon stimulation, β-ARs 
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activate several protein kinases including the β-AR kinase (βARK) and the cAMP-
dependent kinase protein kinase A (PKA). βARK and PKA in turn phosphorylate the β-
ARs which alters the responsiveness of the receptor and they become less able to mount a 
response to subsequent active agonist interactions (Liggett et al, 1993; Gainetdinov et al, 
2004).  
 
For both types of desensitisation to occur, the G-protein receptor complex must possess 
specific amino acid residues that serve as sites for phosphorylation. For example, in β-
ARs the sites of βARK phosphorylation reside in serine and threonine residues in the C-
terminal portion, whilst the two consecutive serine residues in the third intracellular loop 
are critically important for PKA mediated desensitization (Clark et al, 1989; Liggett et al, 
1993; Gainetdinov et al, 2004). The human β3-AR lacks most of the structural 
determinants that, in the β1- and β2-AR, allow for agonist-induced receptor 
desensitisation (Nantel et al, 1993). In contrast to the 11 serines and threonines in the 
distal portion of the cytoplasmic tail of the β2-AR, there are only three in the same region 
of the β3-AR. In addition the β3-AR lacks the consensus sequences in the third 
intracellular loop for PKA-mediated phosphorylation. Furthermore, the β3-AR lacks the 
critical 10-amino acid sequence motif in the cytoplasmic tail, which has been implicated 
as playing a role in β2-AR sequestration (Hausdorff et al, 1990). Finally, down-regulation 
response in the β2-AR is mediated via PKA phosphorylation sites, which the human β3-
AR lacks (Valiquette et al, 1990; Liggett et al, 1993). As such, the human β3-AR would 
appear to be resistant to receptor desensitisation.  
 
The fathead minnow β3bi-AR however, has 16 serine and threonine residues in the distal 
portion of the cytoplasmic tail and also expresses the consecutive serine residues in the 
third intracellular loop (at positions S
263
 and S
264
) and therefore possesses the necessary 
sites for receptor desensitisation via PKA and βARK phosphorylation and sequestration. 
Despite fish and humans evolving from the same vertebrate lineage, they are separated by 
450 million years of evolution and unlike humans which are diploid, fish have undergone 
tetraploidisation events, which in turn have led to functional divergence (Ruuskanen et al, 
2005; Froschauer et al, 2006). Therefore, despite being most similar to the human β3-AR 
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of all the β-ARs, the fathead minnow β3bi-AR has evolved to express the necessary motifs 
for agonist-desensitisation.  
 
A handful of studies have suggested that the β3-AR in adipocytes in humans and rats is 
poorly coupled to adenyl cyclase and is able to mediate receptor desensitisation through a 
cAMP-independent manner via other protein kinases (Jockers et al, 1998; Ikezu et al, 
1999). Considering the fathead minnow β3bi-AR does express the essential amino acid 
residues for phosphorylation, it is unlikely that desensitisation occurs via cAMP-
independent mechanisms, however further studies are required to examine this 
phenomenon of multiple potential desensitisation mechanisms further. Regardless, it was 
possible that upon prolonged exposure to elevated toxic levels of propranolol and 
elevated levels of cortisol and adrenaline/noradrenaline, β3-AR homologous and 
heterologous desensitisation events led to receptor down-regulation. 
 
As described in section 3.4.1, the two likely causes of mortality observed in fathead 
minnows exposed to 1mgL
-1
 propranolol were liver failure and/or CNS toxicity. As the 
brain and liver were the likely sites of propranolol toxicity, β3bi-AR expression in these 
tissues may have been more sensitive to propranolol toxicity and subsequent over-
stimulation and desensitisation events than β3bi-ARs located in the heart and gonad.  
 
5.4.3 β3bi-AR expression levels in female fathead minnow tissues 
The β3bi-AR was most highly expressed in the heart, followed by the liver and then the 
brain and gonad tissues taken from un-treated, control fish. There was a 2.5-fold 
difference in β3bi-AR expression levels between the heart and the liver and a 12-fold 
difference between the heart and the gonad and brain. This study supports the observation 
made by Nickerson et al (2003) that the β3-AR subtypes were most highly expressed in 
rainbow trout hearts, blood and the gills. It was not possible to examine for β3bi-AR 
expression in the blood as blood plasma was analysed for propranolol levels and the gills 
did not express the β1 or β2-AR (Giltrow, 2008) and were therefore not included for RT-
PCR analysis. Nickerson et al (2003) proposed that the β3-AR controlled red blood cell 
intracellular pH via Na
+
/H
+
 exchanger activity, which subsequently enhanced the affinity 
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of haemoglobin for oxygen and it is possible that it performs the same role in the fathead 
minnow. However, the rainbow trout did not express the β3-AR subtypes in any other 
tissue, whilst the β3bi-AR was found in all examined tissues, albeit at different 
concentrations. This suggests that the β3bi-AR could serve more than one function in the 
fathead minnow, much like it does in humans and higher terrestrial vertebrates (Manara 
& Bianchetti, 1990; Krief et al, 1993; Skeberdis, 2004; Rozec et al, 2005).  
 
5.4.4 Comparison of tissue distribution and response to propranolol between β1-, β2- 
and β3bi-AR in the fathead minnow 
Giltrow (2008) found that there was a relationship between the distribution of the β1- and 
β2-ARs in the fathead minnow and humans and higher vertebrates. The study found that 
the β1-AR was found at higher concentrations higher in the heart compared to the β2-AR, 
whilst the β2-AR was expressed approximatelty 100-fold higher than the β1-AR in the 
liver. This observed preference of tissue location is the same in the fathead minnow as in 
humans. Interestingly, this would suggest that the β3bi-AR should be preferentially 
located in the adipose tissue. It was not possible to quantitatively examine β3bi-AR 
expression in the adipose tissue. However results from chapter 2, supported by the 
expression levels in this study indicate that the β3bi-AR is located in many tissues and 
preferentially located in the heart, gill and red blood cells (though it needs to be 
confirmed by RT-PCR for the latter two tissues). Nickerson et al (2003) suggested that 
the β3-AR in the rainbow trout is preferentially located in the red blood cell and that its 
role is two regulate pH levels in, and facilitate oxygen binding to, haemoglobin, however 
this is still to be confirmed. Of all the β-ARs, the β3-AR is the least well understood and 
further studies are still required to examine β3-AR location in both higher vertebrates and 
fish. 
 
Interestingly, Giltrow (2008) suggested that at 1mgL
-1
, propranolol induced a 
desensitisation response in the β2-AR in the liver, which supports the observation made in 
this study. It also adds further support that as the liver is the prinicipal site of propranolol 
metabolism, β-AR expression in this tissue is the most sensitive to ligand-binding and 
thus desensitisation in response to over-activity. The β1-AR was poorly expressed in the 
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liver compared to the β2-and β3bi-AR and so was less likely to show a desensitisation 
response. 
 
5.4.5 Recommendations for future work 
The RT-PCR assay used in the current study provided an insight into potential stress and 
toxic mechanisms of propranolol exposure to female fathead minnow tissues and how 
this may have induced a change in β3bi-AR expression in all relevant tissues. 
Accordingly, it is recommended that RT-PCR is used in future studies to examine the 
response of a particular aquatic test organism to pharmaceutical exposure. However, 
conclusions made from this study were based on assumptions about corresponding 
protein, catecholamine and glucocorticoid levels. Therefore, it is important in future 
studies that one captures as much information as possible relating to either a known or 
unknown toxic mechanism of a particular pharmaceutical. For example, in this study, the 
toxic effects of propranolol could not have been predicted from the literature, especially 
since most of it was based on the responses of humans and terrestrial vertebrates. It is 
quite possible that other pharmaceuticals may also exert a toxic or stressful effect on 
aquatic organisms and so it is important that in addition to measuring expression levels of 
pharmaceutical-interacting receptors, one also measures the receptor protein, 
catecholamine and glucocorticoid levels so that a more complete picture as to the likely 
causes of response are understood.  
 
Additionally, variation of gene expression both between and within the same tissues can 
sometimes be considerable. Whitehead & Crawford (2005) examined the expression of 
192 genes in humans and found that 48% of them were differentially expressed among 
individuals within the same tissues. Therefore, when examining gene expression in 
tissues, one must interpret the data with an element of caution and, ideally, repeat the 
assays both in terms of technical and tissue replication to allow for a more robust and 
confident interpretation. 
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CHAPTER 6: GENERAL DISCUSSION 
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6.1 Pharmaceuticals in the aquatic environment: potential threat to environmental 
and human health 
Pharmaceuticals represent important and indispensable elements in modern society. It has 
been well established that after consumption and elimination from the human body, 
pharmaceuticals and their metabolites are not completely removed during conventional 
biological treatment and thus enter the aquatic environment via wastewater treatment 
plants. Accordingly, more than 50 pharmaceuticals have been detected, albeit at low 
concentrations, in waterways throughout Europe, the America‟s, Asia and Australasia. 
Since the majority of drugs are designed to affect specific protein targets at relatively low 
doses, pharmaceuticals represent a potential environmental hazard, even at such low 
concentrations (Williams, 2006). For example, the analgesic diclofenac fed to livestock in 
India and Pakistan caused a dramatic decline in populations of vulture as a result of acute 
renal failure (Oaks et al, 2004). Further aquatic-based examples include the synthetic 
oestrogen in the human contraceptive pill, 17 α-ethinyloestradiol (EE2), which induced 
fish feminisation downstream of sewage treatment works (Tyler & Routledge, 1998). To 
date, over 24 different pharmaceuticals have been found to elicit a toxicological effect on 
aquatic wildlife at environmentally relevant concentrations (see section 1.4). 
 
As well as representing a potential threat to aquatic organisms, pharmaceuticals also 
represent a threat to human health via environmental exposure. Drinking water is taken 
from the same waterways that treated wastewater is discharged into and despite recent 
advancement in drinking water purification treatment technologies; several 
pharmaceutical products resist removal from water, because of their physicochemical 
nature, and have therefore been found to pass directly into drinking water (Dorne et al, 
2007). Accordingly, pharmaceuticals have been detected in both the U.S and Europe in 
drinking and tap water (Loraine & Pettigrove, 2006; Donn et al, 2008) and it has been 
estimated that at least 41 million American homes receive pharmaceutical-contaminated 
drinking water (Donn et al, 2008). 
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Pharmaceuticals are designed to interact with protein targets in humans and so exposure 
to pharmaceuticals via drinking water is likely to induce an effect. Several studies have 
examined the impacts of endocrine disrupting, hormonally active chemicals on human 
infertility, testicular cancer, semen quality and subsequent male reproduction in adult 
males and breast cancer in adult females, and have suggested that at the detected low 
concentrations in drinking water, there is a weak association between exposure to 
endocrine disrupting drugs and endocrine-disruptive response (Saradha & Mathur, 2006; 
Foster et al, 2008; Garner et al, 2008; Phillips & Tanphaichitr, 2008). Johnson et al 
(2008) specifically examined the risk cytotoxic chemotherapy drugs pose to human health 
in the U.K and concluded that it was minimal to the adult population due to high removal 
rates during drinking water purification 
 
The embryonic in utero stage is a particularly sensitive period and so the exposure of the 
pregnant mother, or more specifically her foetus, to pharmaceuticals may pose a greater 
threat than to the adult human population. Collier (2007) suggested that over a 9-month 
gestation period, approximately 13% of a minimum dose of the contraceptive pill will be 
ingested via contaminated drinking water in the U.S and 5% of the minimum dose of 
diazepam, which is known to cause floppy infant syndrome at the latter stags of 
pregnancy, will also be ingested. Currently, there is not enough to data to understand the 
ramifications these low level pharmaceuticals have on the developing foetus.  
 
The drinking water directive (DWD) (Regulation 1882/2003/EC), which is supported by 
the European Union, has 48 parameters outlined within it; none however address 
pharmaceuticals. Recently, a cohort of pharmaceutical companies conducted a risk 
assessment on 26 pharmaceutical products based on their measured environmental 
concentrations using worldwide environmental monitoring data and used a similar ratio 
method to the current environmental risk assessment of medicinal products for human use 
guideline (EMEA/CHMP/SWP/4447/00 (2006)). By comparing the ratio between the 
measured concentration and the predicted no-effect concentration (PNEC) for children, a 
risk indicator was produced. None of the 26 pharmaceuticals examined posed a 
significant risk to human health. However, like the environmental risk assessment 
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guideline, there are several issues that require further assessment (Dorne et al, 2007). 
Regardless, there is currently no regulator guidance on pharmaceuticals in the 
environment and no safety limits set for pharmaceuticals in drinking water. 
 
6.2 Conclusions from study 
 
6.2.1 Propranolol toxicity on fish 
One of the biggest contributions from this study was identifying that the β-blocking 
pharmaceutical propranolol poses a potential threat to teleost fish via environmental 
exposure. On exposure to 10mgL
-1
, female and male fathead minnows showed signs of 
acute toxicity with 100% mortality being recorded in the latter sex over a 24 hour period 
and at 1mgL
-1
, there was an observed 25% and 80% mortality, respectively. At these 
nominal water concentrations, propranolol was measured in fish blood plasma at a level 
that exceeded the human therapeutic concentration (Wong et al, 1979) and so it is 
possible that at therapeutic dose, propranolol exerted an unanticipated toxic effect via two 
main mechanisms (which may have either acted independently or alongside of each 
other). Fish in the 10mgL
-1
 and 1mgL
-1
 showed signs of disorientation, which suggested 
that propranolol may have been acting as a central nervous system (CNS) toxin. As 
propranolol is highly lipophilic, it can move across the blood-brain barrier relatively 
easily (Vu & Beckwith, 2007); propranolol has been found in human brain tissue at 
concentrations ten to twenty six times higher than in plasma which, when compared to 
another β-blocker atenolol that has a brain: plasma ratio of 0.2, is considerably high 
(Cruickshank & Neil-Dwyer, 1985). This may also help to explain why propranolol was 
found to exert a toxicological effect, whilst a previous study by Winter et al (2008) found 
that atenolol had no effect upon fathead minnow survivability at the same test 
concentrations. Propranolol may have also been acting as a liver toxin. The liver is the 
principal site of propranolol metabolism and the observed physiological symptoms may 
have been the result of increased ammonia levels, which is produced as a result of drug-
induced liver disease (Arillo et al, 1981; Zimmerman, 1995).  
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Although it was not possible to accurately identify a robust metabolomic biomarker of 
propranolol exposure in fathead minnow livers using 
1
H NMR metabolomics, there was a 
dose-dependent relationship between propranolol and glutamate levels and glutamate 
levels were significantly (p<0.05) lower in the 1mgL
-1
 livers than in the control livers. 
Glutamate is reflective of the energy status of a particular tissue/organism and although it 
was not possible to directly relate glutamate levels to potential propranolol-induced liver 
failure, it is reasonable to expect energy levels to be significantly lower in a tissue that is 
the site of drug toxicity. Furthermore, a brief examination of the metabolomic profile of a 
fish liver taken from a dying male from the 1mgL
-1
 treatment group revealed significantly 
(p<0.05) elevated levels of lactate, formate, succinate and choline, all of which are 
potentially representative of liver failure. Therefore the data from the metabolomics study 
further suggested that propranolol exerted its toxicity on the liver. This does not 
necessarily mean that propranolol did not exert toxicity on the CNS; it was not possible to 
analyse brain tissues using 
1
H NMR metabolomics because of tissue size limitations. In 
response to exposure to 1mgL
-1
 propranolol, the β3-AR was found to be significantly 
lower in the brain and liver, which was most likely due to desensitisation in response to 
continuously elevated levels of corticosteroids and catecholamines as a result of increased 
stress which was the consequence of propranolol toxicity. This further supports the notion 
that the brain and liver were both sites of propranolol toxicity as β3bi-AR expression in 
these tissues may have been more sensitive to propranolol toxicity and subsequent over-
stimulation and desensitisation events than β3bi-ARs located in other tissues that were not 
sites of propranolol toxicity.  
 
The current study demonstrated that through bioaccumulation, propranolol acted as both 
a CNS- and hepatic-toxin. It is unlikely that propranolol represents an acute threat to the 
aquatic environment as the concentrations at which it acted as a toxin were approximately 
1000-fold higher than what has been measured in the environment. Nevertheless, it has 
been demonstrated that, due to its physical and chemical characteristics, propranolol has 
the potential to bioaccumulate in fish tissues and may therefore pose as a threat through 
chronic environmental exposure at environmentally relevant concentrations.  
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One of the most interesting results from the study was that the β3bi-AR was found to be 
expressed at significantly higher levels than in other examined tissues. There was also a 
statistically significant response to propranolol at environmentally relevant 
concentrations (0.001mgL
-1
 to 0.01mgL
-1); as propranolol concentration increased, β3bi-
AR expression increased. This was the only significant expression response to 
propranolol at environmentally relevant concentrations and suggests that fish exposed to 
these concentrations in the aquatic environment may experience inhibited β3bi-AR 
activity, which may have further ramifications at the physiological level. The function of 
the β3bi-AR, however, has not been identified and so it is important to establish its 
function, so that the potential effects of propranolol in the aquatic environment are mopre 
comprehensively understood. This finding also gives further support as to developing in 
vivo assays that have specific pharmaceutical mode-of-action endpoints. In this study, 
cardio-specific physiological endpoints perhaps could have been adopted, such as heart 
rate and blood pressure. Larsson et al (2006) examined heart rate in the rainbow trout and 
found that at 1.5mgL
-1
, there was a significant decrease in heart rate. The fathead 
minnow, however, is considerably smaller than a rainbow trout and it would be extremely 
challenging to include this cardio-specific endpoints. Bearing in mind the tissue and 
sample size limitations of the metabolomics study and difficulty in obtaining large 
enough tissue samples for molecular analysis, perhaps the most advantageous step would 
be to use larger fish test species, such as the rainbow trout. 
 
6.2.2 Use of current techniques in environmental risk assessments of pharmaceutical 
toxicity 
The current pharmaceutical environmental risk assessment for pharmaceuticals 
(EMEA/CHMP/SWP/4447/00 (2006)) uses a step-wise, phased procedure. The first pre-
screening phase examines the likelihood of a drug bioaccumulating in the environment 
and also determines the predicted environmental concentration (PEC). The second phase 
uses standard chronic-toxicity endpoints of immobilisation in the invertebrate Daphnia 
magna, inhibition of growth in algae and mortality in early life stage fish to calculate a 
predicted no-effect concentration and the third and final phase evaluates the fate of the 
drug and/or its metabolites in the aquatic environment. Although the ERA represents a 
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marked improvement over pervious risk assessments, it examines for a limited general 
toxicity response to predict the effects of low-level pharmaceuticals that have specific 
modes of action and are therefore likely to induce protein-target-specific responses that 
may not be detected using generalised endpoints. For example, using the current ERA 
risk assessment, the environmental effects of EE2 would not have been predicted 
(Sumpter, 2007). This suggests that prospective testing could be made more powerful by 
including targeted test strategies, i.e. selection of species, tests and endpoints by 
transferring known information on pharmaceutical properties from mammalian studies. 
 
The aim of the current study, therefore, was to develop an intelligent testing strategy that 
both examined pharmaceuticals based on known properties elucidated from mammalian 
pharmacology studies and also for subtle, perhaps more realistic, responses to 
pharmaceutical exposure (as opposed to just physiological responses). With this in mind, 
a proposed intelligent targeted testing strategy was developed (as shown in table 35). 
 
 
Prior to conducting an in vivo exposure, the first phase established whether the test-
species (fathead minnow) expressed the specific pharmaceutical protein-target, which in 
this study were the β-AR subtypes. It was assumed that as propranolol, like all 
pharmaceuticals, is found at low concentrations in the aquatic environment, any 
measurable adverse effects in non-target species are most likely to occur as a 
consequence of specific drug-target interactions rather than via an unspecific mode of 
action, such as narcosis. Thus evolutionary, well conserved targets in a given species are 
associated with an increased risk (Gunnarsson et al, 2008). Along with another study, the 
Phase Description 
I Establishment of pharmaceutical protein-receptor target 
II In vivo exposure 
III Metabolomic analysis for subtle response to pharmaceutical exposure 
IV Expression analysis of pharmaceutical protein-target receptor upon exposure 
to pharmaceutical 
Table 35. Proposed intelligent targeted testing protocol for assessment of pharmaceuticals in the aquatic 
environment 
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β1- and β2i- and β2ii- (Giltrow et al, 2008) and β3bi-ARs were identified in the fathead 
minnow, which suggested that propranolol had the potential to bind and induce a 
response in its target receptors in the fathead minnow. As discussed in 6.2.1, an 
unanticipated toxic response to propranolol was observed in the fathead minnow and it 
was not possible to determine whether this was mediated via β-AR interactions. 
Nevertheless, phase I represents a good starting point for understanding potential 
pharmaceutical toxicity in an aquatic test-species, however the results from this study 
suggest that even if the test-species in question does not express the pharmaceutical 
protein-target receptor, an in vivo exposure should still be implemented and as such, 
phase II should not be dependent on phase I.  
 
A pair-breeding assay was implemented for phase II, whereby pairs of fathead minnows 
were examined for their reproductive potential over two concurrent 21-day periods: the 
first prior to- and the second upon exposure to propranolol. The advantages of employing 
this assay were firstly, it examined for both acute and reproductive toxicity, which are 
arguably most important with regards to propagation and survivability of a species and 
secondly, each fish pair served as their own control, which thus allowed for a statistically 
robust comparison of breeding ability before and during pharmaceutical exposure. As 
discussed in section 6.2.1, results from the pair-breeding assay suggested that propranolol 
acted as a toxin at concentrations >1mgL
-1
 and the most likely causes of toxicity were 
liver failure and CNS toxicity. Although one could not confidently identify the cause of 
mortality at this stage; by working with smaller tanks and individual fish pairs and also 
by nature of each pair serving as its own control, it was easier to observe and understand 
the physiological responses of fish to propranolol, which may not have been possible if 
tank sizes and fish-group sizes were larger and more complex. 
 
Phase III used metabolomics in an attempt to identify a robust and reliable biomarker of 
pharmaceutical exposure. Metabolomics is the quantitative and comprehensive analysis 
of all metabolites in a biological sample. Metabolites are bi-products of metabolism and 
the metabolome represents the final “omic” level in a biological system. Therefore, 
unlike genomics and transcriptomics, metabolomics reveals „actual‟ functional changes in 
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a study organism, as opposed to potential changes (Nicholson et al, 2002; Nicholson & 
Wilson, 2003; Goodacre et al, 2004). Since the liver is the principal site of propranolol 
metabolism and considering the physiological impact of propranolol on the fathead 
minnow, it was anticipated that a significant response would be observed in propranolol-
exposed fish livers. As mentioned in section 6.2.1, 
1
H NMR metabolomic analysis of 
male fathead minnow livers provided more information as to the potential toxic actions of 
propranolol on the liver, however there were several difficulties encountered during 
metabolomic analysis (as mentioned in section 6.2.3) which still need to be addressed if it 
is to be reliably used as a diagnostic tool in future environmental-based pharmaceutical 
toxicity studies. 
 
The fourth and final phase of the intelligent-testing protocol was to examine the response 
of the target receptor to pharmaceutical exposure using the highly sensitive real time 
polymerase chain reaction (RT-PCR). In response to exposure to 1mgL
-1
 propranolol, 
there was a significant decrease in β3bi-AR expression in the liver and brain, which could 
possibly be the result of focused propranolol toxicity on these tissues and resultant 
desensitisation events in response to elevated levels of cortisol and catecholamines. By 
using RT-PCR, it is possible to examine expression level changes of a particular target 
receptor in response to pharmaceutical exposure and, in the context of this study, helps to 
build a more complete picture of pharmaceutical toxicity. However, as discussed in 
section 6.2.3, there are several limitations of interpreting expression study results that 
must be addressed for it to be more efficiently implemented in future pharmaceutical 
ecotoxicity studies. 
 
In conclusion, the proposed testing strategy adopted in this study represents several 
advantages over the current ERA. First and foremost, it is a bespoke study that addresses 
individual pharmaceuticals according to their individual properties and mode of actions; 
secondly it is not limited by examining solely for physiological responses but analyses 
pharmaceutical interactions at the molecular (predictive toxicity), metabolomic (subtle 
measurable toxicity) and physiological (observable toxicity) level. Measuring the 
response of the fathead minnow to propranolol served as a good case study as there was 
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an unanticipated response to the drug which could not have been predicted from 
mammalian pharmacological data. It also revealed the limitations of the current study and 
allowed for recommendations to be made both to the proposed testing strategy and the 
current ERA testing strategy for examining pharmaceutical toxicity in the future, some of 
which may share similar characteristics with propranolol (such as its lipophilic nature and 
affinity to bioaccumulate). 
 
6.2.3 Limitations of study 
 
6.2.3.1 Variation 
Considerable variation was observed at the molecular and, in particular, the metabolomic 
level. With regards to metabolomics, the principal problem was that inherent 
metabolomic variation between individual fish livers both within and between treatment 
groups was such that it was not possible to accurately and confidently identify a 
metabolomic biomarker of propranolol exposure. The measured variation was not 
significantly higher than other fish test-species and was therefore most likely indicative 
of “natural variation”. Additionally the source of variation was not feeding, tank effects 
or MS222 anaesthetisation and was therefore unlikely to have been introduced. In human 
and higher vertebrate pharmacology studies, time-dependent studies (termed 
metabonomics) are used so that each test-organism serves as its own control, or 
genetically inbred animals are used to thus minimise variation. However, in 
ecotoxicological studies using small test-species (such as the fathead minnow), it is not 
particularly easy to conduct time-dependent studies (especially with regards to ethical 
guidelines) and the use of inbred fish strains has no environmental relevance.   
 
Similarly with the RT-PCR study, there was considerable variation in β3bi-AR expression 
both between the same tissues and between internal standard controls between plates 
(where there should be little variation as it is the same sample on every plate). In 
circumstances where β3bi-AR expression levels were different between plates, the assay 
was repeated, however due to cost and time constraints it was not possible to fully 
understand the reasons for variations in internal standard expression between plates. Gene 
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expression levels can vary considerably between individuals (Whitehead & Crawford, 
2005) and this is something that must be considered when conducting, and more 
importantly concluding from, RT-PCR expression studies.  
 
6.2.3.2 Test species 
The fathead minnow, Pimephales promelas, was the selected test species as it is a model 
test species used by a multitude of agencies including the Environmental Protection 
Agency (EPA), the Environment Agency (EA) and the Organisation for Economic 
Cooperation and Development (OECD). With developments in genomic, proteomic and 
histological techniques, the fathead minnow has become an established biomarker test 
species, with several physiological and biochemical endpoints, for a diverse number of 
contaminants including several pharmaceuticals; arguably the most extensively studied of 
which has been EE2 (Harries et al, 1998; Harries et al, 2000; Halm et al, 2002; Zerulla et 
al, 2002; Leino et al, 2005; Ankley & Villeneuve, 2006; Miracle et al, 2006). 
 
However, one major limitation of the fathead minnow is its size. The fathead minnow 
reaches a maximum length of 50mm and 1g in weight. Therefore, for metabolomic-based 
studies, the only viable tissue for analysis is the liver. For the purpose of this study, the 
liver was an ideal tissue because of its involvement in propranolol metabolism and being 
a potential site of propranolol toxicity. However, it was not possible to use 
1
H NMR to 
analyse other tissues such as the brain, which would have been particularly useful to 
examine as it was the other proposed site of propranolol toxicity. Only liver tissues from 
male fathead minnows were suitable for analysis as female livers fell below the tissue 
threshold size. Furthermore, several liver tissues from males were excluded as they were 
too small.  
 
6.3 Recommendations for future work 
Although one cannot be entirely certain that propranolol did not induce toxicity via β-AR 
binding as only a handful of tissues were examined for β-AR expression changes, it 
appears that propranolol did not induce a toxicological response through interactions with 
the β-AR subtypes. Therefore it is perhaps essential that a robust in vivo assay is adopted 
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for pharmaceutical screening, regardless as to whether the aquatic organism possesses the 
drug target, such as the pair-breeding assay used in this study. The pair-breeding assay 
represented a robust, repeatable assay that examined for mortality and reproductive 
endpoints, which when considering the ramifications on the population level are arguably 
the most important. However, ideally a bespoke in vivo assay is required that will address 
both population-level endpoints and pharmaceutical-specific physiological endpoints; it is 
important to use mammalian pharmacology data to address the latter.  
 
An alternative in vivo pharmaceutical examination is to use an embryo-larval bioassay, 
which addresses both lethal and sublethal effects and can be tailored for a specific drug 
mode of action. The problems with a standard adult toxicity assay include genetic 
variation, differences in the condition of individual animals, the missing knowledge about 
possible interaction effects between individuals and especially with micropathogens and 
also statistical problems such as sample sizes and pseudoreplication. Multi-factorial 
embryo tests on ecologically relevant test species can solve many of these issues 
(Wedekind et al, 2007). The use of in-bred embryos to minimise genetic variation may 
prove to be potentially hugely advantageous with regards to subsequent metabolomic 
analysis. For example Fraysse et al (2006) examined zebrafish (Danio rerio) embryo-
larval development upon exposure to propranolol by measuring heart rate, spontaneous 
movement and hatching rate, thus collecting drug-specific and population-reflective data. 
This type of bioassay represents both ethical and financial advantages over the pair-
breeding assay used in the present study; however it is difficult to collect suitable 
material for further metabolomic or genomic studies and so perhaps serves as an addition, 
rather than alternative, assay.  
 
The use of larger in-bred fish to minimise genetic and metabolic variation presents 
several advantages. Firstly, it could be possible to conduct time-dependent studies, where 
each fish would serve as its own control, thus minimising variation further. Secondly, 
tissue size would not be a limiting factor and so it could be possible to extract samples for 
both metabolomic and genetic analysis from the same tissue, thus allowing for a direct 
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comparison to be made between gene expression and metabolic changes within an 
individual fish.   
 
Although this study addressed pharmaceutical toxicity in the aquatic environment more 
comprehensively than current ERA assessments, informed assumptions were still made to 
piece together the overall picture of understanding propranolol toxicity. For example, it 
has been assumed that an increase/decrease in β3bi-AR mRNA expression is directly 
related to β3bi-AR activity, which may not necessarily have been the case. Likewise, it 
was not clearly evident whether the metabolic response to propranolol was linked to β3bi-
AR activity and changes in β3bi-AR expression. When addressing pharmaceutical toxicity, 
it is hugely important to build a complete picture of understanding and, as such, future 
studies should also include proteomic and transcriptomic studies to confidently link 
together genomic and metabolomic responses. Additionally, laboratory-based studies 
should routinely measure cortisol and catecholamine levels to understand and potentially 
differentiate between a toxicological response directly related to the test pharmaceutical, 
and a stress response related to laboratory test-conditions and exposure to a 
pharmaceutical.  
 
With regards to environmental relevance, the issue of mixture-toxicity should be 
addressed long-term. Pharmaceuticals are seldom found as single substances in the 
aquatic environment, but more commonly as complex mixtures. In mixtures, 
pharmaceuticals can either behave as concentration addition (toxicity exerted is greater 
than as individual substances) or independent action (toxicity exerted by each substance 
is independent of others, i.e. no greater toxicity) (Cleuvers, 2004; Brian et al, 2007; 
Johnson et al, 2008). Accordingly, both the proposed intelligent testing strategy and ERA 
require further modifications to allow for the examination of mixture-toxicity; this 
however may be location-specific, which in turn presents problems such as 
environmental (i.e. seasonal) and global change (Brian, 2008 et al; Wingfield, 2008) 
effects. 
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Pharmaceutical toxicity is a multi-faceted problem and, as such, requires an integrated 
scientific approach of understanding from the manufacturing, distributing and 
consumption of pharmaceuticals, to sewage treatment works, and finally to interactions 
with environmental receptors in exposed animals (Cotsier et al, 2007). As such, a 
comprehensive integrated programme of research is required to enable use to act 
efficiently to reduce the impact of pharmaceuticals in the aquatic environment. 
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APPENDIX 
 
APPENDIX 1: 10 x TRIS BORATE EDTA BUFFER REAGENTS 
 
Add the following components to a 1L flask: 
 
109g Tris Base 
7.3g EDTA 
55g Boric acid 
 
 Make up to 1L with dH2O. 
 Autoclave for sterilisation and to ensure complete dissolution of components 
 
To make 1 x TBE, dilute 10 x TBE ten-fold in dH2O. 
 
 
APPENDIX 2: AGAR REAGENTS 
 
Add the following components to a 1L flask: 
 
10g tryptone 
5g yeast extract 
10g NaCl 
15g Bacto agar 
 
 Make up to 1L with deionised dH2O 
 Autoclave for sterilisation and to ensure complete dissolution of components 
 
 
APPENDIX 3: LURIA BROTH (L-BROTH) REAGENTS 
 
Add the following components to a 1L flask: 
 
10g tryptone 
5g yeast extract 
10g NaCl 
 
 Make up to 1L with deionised dH2O 
 Autoclave for sterilisation and to ensure complete dissolution of components 
 
 
